i 
 To: CTEP Protocol and Information Office  
From:  Alice Chen , MD , DTC, NCI  
Date:  January 7, 2019  
Re: Amendment to Protocol 9149 : Molecular Profiling -based Assignment of Cancer 
Therapy for Patients With Advanced Solid Tumors  
With this amendment, we are incorporating recommendations from CTEP’s review of protocol 
version 02/06/2019, and making some administrative changes.  
 
We would also like to update the protocol to allow the sole patient who continues to receive 
randomized Trametinib D MSO treatment (22+ cycles) to consent to having her mutational status 
and arm assignment (i.e., experimental or control) disclosed to herself and/or her treating 
physician now , rather than wait until disease progression , given the new non -randomized study 
design and statistical analysis plan .  We would also like to allow this patient to consent to  sample 
unlinking while she remains on study, in order to enable research -use analysis of her sample in 
parallel with the other results from the randomized portion  of the study.   Thank you for your 
consideration.  
 
I. Recommendations from CTEP review of Amendment #37 (pv 02/06/2019)  
# Section  Comments  
1.  12.[ADDRESS_1005299] is granted through the iMedidata application to all 
persons with the appropriate roles assigned in the Regulatory Support System 
(RSS).  To access R ave via iMedidata, the site user must have an active CTEP 
IAM account (check at https:// ctepcore.nci.nih.gov/iam ) and the appropriate Rave 
role (Rave CRA, Rav e Read -Only, Rave CRA (Lab Admin), Rave SLA, or Rave 
Investigator)  (Rave CRA, Read -Only, CRA, Lab Admin, SLA, or Site 
Investigator)  on either the LPO or participating organization roster at the enrolling 
site. To hold the Rave CRA role or Rave CRA (Lab Adm in) Rave CRA role or 
CRA Lab Admin  role, the user must hold a minimum of an AP registration type.  
To hold the Rave Site Investigator role, the individual must be registered as an 
NPI[INVESTIGATOR_6735].  Associates can hold read -only roles in Rave.   
PI [INVESTIGATOR_28516]:   We have revised the paragraph as indicated.  
 
II. Other Protocol Changes  
# Section  Comments  
2.  Cover Page  Updated the protocol version date and letters.  
ii 
 # Section  Comments  
3.  Cover Page  Updated the list of Associate Investigators.  
4.  2 
5.2 Given the new non -randomized study design and statistical analysis 
plan, we would like to revise  and update  the protocol to allow the sole 
patient who continues to receive randomized Trametinib DMSO 
treatment (22+ cycles) to consent to having her mutational status and 
arm assignment (i.e., experimental or control) disclosed to herself and/or 
her treating physic ian now , rather than wait until disease progression  to 
find out per the original study plan .  The patient, in discussion with the 
treating physician, will have the same on -study treatment options at 
progression as before, but because she is unblinded we think she will 
have better information sooner about her future treatment options.   
5.  9.4.1  Revised the  sample unlinking procedure to allow sample unlinking for 
the sole remaining randomized patient to o ccur while the patient remains 
on study,  in order to enable research -use analysis  of her sample in 
parallel with the other results from the randomized portion  of the study.  
6.  Appendix F  Replaced the Biopsy Seq uencing Results and Analysis Form with an 
updated form  supplied by [CONTACT_735862].  . 
CTEP #9149 (01 -07-2020 ) 
 
1 
 Molecular Profiling -based Assignment of Cancer Therapy for Patients With Advanced 
Solid Tumors  
 
Abbreviated Title : MPACT  
 
Coordinating Center : LAO -NCI/National Cancer Institute LAO  
  National Cancer Institute  
  [ADDRESS_1005300], 12N226  
  Bethesda, MD [ZIP_CODE]  
 
 
Principal Investigator:  A. P. Chen, MDA-E 
  Developmental Therapeutics Clinic  (NCI DTC MM)  
  [ADDRESS_1005301], Bldg 31, Room 3A44     
  Bethesda, MD [ZIP_CODE]  
  Phone: (240 ) 781-3320  
  Fax: (240)  541-4515  
            [EMAIL_975]  
 
NCI Co-Investigators:  James H. Doroshow, MD, DCTDA-E 
 Richard Pi[INVESTIGATOR_79577], MD, PhD, DCTDA-E 
 Geraldine O’Sullivan Coyne, MD, PhD , DCTDA-E 
 Howard Streicher, MD, DCTDA-E 
 Naoko Takebe, MD, PhD, DCTDA-E 
 Arjun Mittra, MD, DCTDA-E 
Sheila Prindiville, MD, MPH, DCTDA-E 
Rafeh Naqash, MD, DCTD/ NCIA-E 
Jessica Mukherjee, MS, CRNP, DCTD/NCIA,B,E 
 
Non-NCI Co-Investigators:  Lamin Juwara CRNP , Leidos Biomed., FNLCRA,B,E 
 P. Mickey Williams, PhD , Leidos Biomed., FNLCRF  
 
Referral Contact:   
[CONTACT_735863], RN, DCTDA,B,E  
Bldg 10/Rm 13N -214  
(240) 760 -6045  
Fax: ([PHONE_930]  
[EMAIL_14046]  
 
 
Roles: Aobtains information by [CONTACT_52360]; 
Bobtains identifiable private information about living individuals; Cobtains  the voluntary informed 
consent of individuals to be subjects; Dmakes decisions about subject eligibility; Estudies, interprets, or 
analyzes identifiable private information or data/specimens for research purposes ; Freviews patient 
genetic sequencing data but is not involved in clinical care    
CTEP #9149 (01 -07-2020 ) 
 
2 
 Participating Organizations:  
LAO -[ZIP_CODE]  / University Health Network Princess Margaret Cancer Center LAO  
LAO -CA043 / City of Hope Comprehensive Cancer Center LAO  
LAO -CT018 / Yale University Cancer Center LAO  
LAO -MA036 / Dana -Farber - Harvard Cancer Center LAO  
LAO -MD017 / JHU Sidney Kimmel Comprehensive Cancer Center LAO  
LAO -MN026 / Mayo Clinic Cancer Center LAO  
LAO -NC010 / Duke University - Duke Cancer Institute LAO  
LAO -NJ066 / Rutgers University - Cancer Institute of New Jersey LAO  
LAO -OH007 / Ohio State University Comprehensive Cancer Center LAO  
LAO -PA015 / University of Pi[INVESTIGATOR_25449] -TX035 / University of [LOCATION_007] MD Anderson Cancer Center LAO  
 
Statistician s:  Larry Rubinstein , PhDE  
[ADDRESS_1005302].  
Rockville, MD  [ZIP_CODE]  
Phone: ([PHONE_15294]   
[EMAIL_14047]  
 
Jared Foster, PhD  
[ADDRESS_1005303].  
Rockville, MD  [ZIP_CODE]  
Phone: ([PHONE_15295]   
[EMAIL_14048]  
 
NCI-supplied Agent s: AZD1775 (NSC 751084)  
 Veliparib  (NSC 737664 ) 
 Trametinib DMSO (NSC 763093)  
 Everolimus  (NSC 733504)  
Temozolomide  (NSC 362856)  
Carboplatin  (NSC  241240)  
 
   
IND Number:   116976  
 
Version Date:   January 7, 2020  (Amendment Y, iRIS V)  
CTEP #9149 (01 -07-2020 ) 
 
3 
 PRÉCIS  
Background:  
• Targeted therapy based on identifying underlying genetic aberrations within the tumor is the 
goal of personalized medicine.  This pi[INVESTIGATOR_735806],  and with tumor muta tions in one 
of [ADDRESS_1005304] s (DNA repair, PI3K , or RAS /RAF /MEK ) are more likely to derive 
clinical benefit if treated with agents targeting  that pathway th an if treated with agents that do 
not.  Each patient  will be randomly assigned to receive the recommended Phase II dose  of 
either a study drug  identified to work on their tumor’s mutation/aberrant pathway , or an agent 
from the complementary set not identified to work on the mutations  of interest.   As of 
Amendment U, only the DNA repair arm remains open  to accrual .  
Objectives:  
• Evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in 
patients with advanced refractory cancers.  
Eligibility:  
• Adult patients with histologically documented solid tumors whose disease has progressed 
following at least one line of standard therapy  and/or for which no standard treatment is 
available that has been shown to improve survival.  
• Tumor amenable to percutaneous  biopsy, and will ingness to undergo tumor biopsy .  
Study Design:  
• Patients  enrolled on study will have a tumor biopsy  sequenced in a CLIA -certified lab for 
specific mutations of interest  in DNA repair pathways.   If such mutations are not detected , the 
patient will be taken  off study .  Eligibility may also  be determined from existing CLIA 
genetic testing reports  from a MATCH -designated CLIA lab .  
•  Patients who have received PARPi  [INVESTIGATOR_735807].  
• Patient s in whom a mutati on of interest is detected will receive an agent prospectively 
identified to target that mutation/pathway   
• Targeted d rugs will be administered at recommended Phase II doses  and schedules : (1) 
Veliparib  (PARP inhibitor) with t emozolomide for defects in the DNA repair pathway ; (2) 
AZD1775 (Wee1 inhibitor ) plus carboplatin for defects i n DNA repair pathway ; (3) 
Everolimus (mTOR inhibitor ) for mutations in the PI3K pathway; or (4) Trametinib DMSO 
(MEK i nhibitor) for mutations in the RAS /RAF/MEK  pathway .  As of Amendment U , only the 
Veliparib with temozolomide arm remains open to accrual.  
• Given the relative frequencies of the mutations, up to  100 patients will need to be enrolled to 
acquire 30 evaluable patients  per open arm. 
 
 
  
CTEP #9149 (01 -07-2020 ) 
 
4 
 SCHEMA  
 
 
 
 
 
  a Tumor biopsy (mandatory) will be performed on all patients enrolled on study; tissue will be 
sequenced for the  presence of specific mutations  of interest.   Patients with qualifying MATCH -
designated lab genetic testing reports may also be eligible.  
 
b Only pa tients with specified mutations of interest will be administered targeted drug at recommended 
Phase II doses and schedules (see page 5).  
 
One additional optional tumor biopsy may be performed at time of d isease progression on study to 
assess for new mutations .  (This biopsy may instead be collected on day 1 (± 2 days) of the cycle 
following any restaging at which a 10 -19% increase in tumor volume is observed (per RECIST criteria) 
if the patient has been on study for at least 4 cycles).   Tumor  
biopsy  
from all 
patients for 
sequencing 
or qualifying 
mutation a Mutation  
not detected  Assign treatment  
identified to target 
mutation  
OR Mutation 
detectedb 
Off Study  
Patients with specified mutations of interest will be assigned to receive the following study drug  
combination  at the assigned dose.  Cycle length is +/ - 1 day for scheduling:  
 
• Veliparib  40 mg orally BID qd days 1 -7 plus temozolomide  150 mg/m2 orally qd 
days 1 -5 (no food restrictions) in 28 -day cycles  Temozolomide  Veliparib  D1     D5 D7   D21 D28 Cycle 1 and Subsequent Cycles  
Veliparib  plus 
Temozolomide  
CTEP #9149 (01 -07-2020 ) 
 
5 
 TABLE OF CONTENTS  
 
PRÉCIS  ................................ ................................ ................................ ................................ ... 3 
SCHEMA  ................................ ................................ ................................ ................................ . 4 
TABLE OF CONTENTS  ................................ ................................ ................................ ............  5 
1. OBJECTIVES  ................................ ................................ ................................ .......  7 
1.1 Primary  ................................ ................................ ................................ ................. 7 
2. BACKGROUND  ................................ ................................ ................................ ... 7 
2.1 Targeted Mutations and Pathways ................................ ................................ .............. 9 
2.2 Targeted Genes/Locus Selection ................................ ................................ ..............  14 
2.3 Study Agents  ................................ ................................ ................................ ........  17 
2.4 Study Disease  ................................ ................................ ................................ .......  18 
2.5 Genetic Sequencing Research Ethics and NIH Genomic Data Sharing Policy  .................  18 
2.6 Rationale for the Study  ................................ ................................ ..........................  20 
3. PATIENT SELECTION (TUMOR SEQUENCING/DRUG TREATMENT) .................. 20 
3.1 Eligibility Criteria: Tumor Biopsy Sequencing  ................................ ..........................  21 
3.2 Exclusion Criteria: Tumor Biopsy Sequencing ................................ ...........................  22 
3.3 Eligibility Criteria: Targeted Treatment  ................................ ................................ .... 23 
3.4 Exclusion Criteria: Targeted Treatment  ................................ ................................ .... 25 
3.5 Evaluation for Enrollment for Tumor Biopsy Screening  ................................ ..............  26 
3.6 Evaluation for Treatment on Study  ................................ ................................ ..........  26 
4. REGISTRATION PROCEDURES  ................................ ................................ .......... 27 
4.1 Investigator and Research Associate Registration with CTEP ................................ .......  27 
4.2 Site Registration  ................................ ................................ ................................ ... 27 
4.3 General Guid elines ................................ ................................ ................................  30 
4.4 Randomization Procedures (N/A)  ................................ ................................ ............  30 
5. TREATMENT PLAN ................................ ................................ ............................ 30 
5.1 Study Design  ................................ ................................ ................................ ........  30 
5.2 Targeted Therapy Arms  ................................ ................................ .........................  31 
5.3 Agent Administration  ................................ ................................ ............................  33 
5.4 General Concomitant Medication and Supportive Care Guidelines: ...............................  34 
5.5 Definition of Off -Study Parameters ................................ ................................ ..........  35 
5.6 Duration of Follow -Up ................................ ................................ ..........................  36 
5.7 Criteria for Removal From Study ................................ ................................ .............  36 
6. DOSING DELAYS/DOSE MODIFICATIONS  ................................ ......................... 36 
6.1 Dose Modifications  ................................ ................................ ...............................  36 
6.2 Agent -specific Dose Modifications: Trametinib DMSO  ................................ ..............  37 
6.3 Agent -specific Dose Modifications: Everolimus  ................................ ........................  47 
6.4 Agent -specific Dose Modifications: Veliparib  ................................ ...........................  51 
7. ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS ............................ 52 
7.1 Comprehensive Adverse Events and Potential Risks  Lists (CAEPRs)  ............................  53 
7.2 Adverse Event Characteristics  ................................ ................................ .................  66 
7.3 Expedited Adverse Event Reporting ................................ ................................ .........  66 
7.4 Routine Adverse Event Reporting ................................ ................................ ............  68 
7.5 Secondary Malignancy ................................ ................................ ...........................  69 
7.6 Second Malignancy  ................................ ................................ ...............................  69 
8. PHARMACEUTICAL INFORMATION  ................................ ................................ ..69 
8.1 Temo zolomide (NSC 362856) ................................ ................................ .................  69 
8.2 Carboplatin (NSC 241240)  ................................ ................................ .....................  70 
CTEP #9149 (01 -07-2020 ) 
 
6 
 8.3 Everolimus (NSC 733504) ................................ ................................ ......................  72 
8.4 Velipa rib (NSC 737664)  ................................ ................................ ........................  73 
8.5 AZD1775 (NSC 751084)  ................................ ................................ .......................  74 
8.6 Trametinib dimethyl sulfoxide ([COMPANY_004]1120212B) (NSC 763093)  ................................ ... 76 
8.7 Agent Ordering ................................ ................................ ................................ ..... 77 
9. GENETIC ANALYSIS  ................................ ................................ .......................... 78 
9.1 Tumor Biopsies  ................................ ................................ ................................ .... 78 
9.2 Screening Eligibility Sample Collection and Processing  ................................ ..............  80 
9.3 Shippi[INVESTIGATOR_735808] ................................ ................................ .................  81 
9.4 Sample Handling and Unlinking Procedures ................................ ..............................  82 
10. STUDY CALENDAR:  ................................ ................................ .......................... [ADDRESS_1005305] – Solid Tumors ................................ ................................ .............  86 
12. STUDY OVERSIGHT AND D ATA REPORTING / REGULATORY REQUIREMENTS
 92 
12.1  Data Reporting  ................................ ................................ ................................ ..... 92 
12.2  Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement 
(CTA)  ................................ ................................ ................................ .................  94 
12.3  Publication Policy  ................................ ................................ ................................ . 96 
13. STATISTICAL CONSIDERATIONS  ................................ ................................ ......97 
13.1  Sample Size/Accrual Rate  ................................ ................................ ......................  [ADDRESS_1005306] Selection ................................ ................................ ................  98 
14.2  Justification for Exclusions  ................................ ................................ .....................  99 
14.3  Evaluation of Benefits and Risks/Discomforts  ................................ ...........................  [ADDRESS_1005307] or Minimizing Any Potential Risks  ..........................  100 
15. REFERENCES  ................................ ................................ ................................ ... 101 
APPENDIX A: Performance Status Criteria  ................................ ................................ ................  106 
APPENDIX B: Potential Drug Interactions and Drug Information Handouts  ................................ .... 107 
APPENDIX C: Medications That May Cause QTc Prolongation  ................................ ....................  116 
APPENDIX D: Patient Study Diaries  ................................ ................................ .........................  118 
APPE NDIX E: MPACT (9149) Sample Shippi[INVESTIGATOR_735809]  ................................ .... 131 
APPENDIX F: Biopsy Sequencing Results and Analysis Form  ................................ ......................  133 
APPENDIX G: Molecular Tumor Board Members ................................ ................................ .......  136 
APPENDIX H: Example Tumor Variant Patient Report ................................ ................................  137 
APPENDIX I: Veliparib  plus Temozolomide (Proprietary I nformation) ................................ ...........  138 
APPENDIX J: AZD1775 (Proprietary Information)  ................................ ................................ ..... 141 
APPENDIX K: Trametinib DMSO (Proprietary Information)  ................................ ........................  145 
APPENDIX L: NCI Correlative Imaging Studies  ................................ ................................ .........  150 
CTEP #9149 (01 -07-2020 ) 
 
7 
 1. OBJECTIVES  
1.1 Primary  
Evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in 
patients with advanced refractory cancers.  
 
2. BACKGROUND  
The initial design of this targeted pi[INVESTIGATOR_735810] s of interest (DNA repair, PI3K, or RAS /RAF /MEK ) are 
more likely to derive clinical benefit (defined as objective response or progression -free survival) 
if treated with agents targeting tha t specific pathway th an with agents that do not .  The study 
design was developed in conjunction with experts in clinical trial design, genetic sequencing, 
molecular oncology, cell biology, and statistics, who developed an algorithm that d efines  clinical 
action based on genetic variants  reported in the genes of inte rest ( Table 1  and Section 2.2 ).  
Aberrations in the  PI3K -Akt, KRAS  and RAF/MEK/ERK pathways and defects in the DNA 
repair pathways are common in several cancers .  Each of these pathways and the selected 
targeted agents are discussed below.  The genes of interest and mutations to be analyzed have 
been prospectively defined based on the recommendations of the multidisciplinary Molecular 
Tumor Board convened for this s tudy (membership list included in Appendix G ). 
 
This study was placed on hold in January 2018 for interim futility analysis of the AZD1775 plus 
carboplatin and Trametinib DMSO arms (see Section 13 ), at w hich time a total of 193 patients 
had biopsies collected for screening and 99 (51%) had an actionable mutation of interest for 
randomizing to study drug.  The major conclusions from this analysis are summarized below; a 
manuscript describing study results is in progress:  
 
1. No confirmed objective responses were measured among the initial 18 patients of the 
AZD1775 plus carboplatin cohort ; this cohort was terminated in March 2018.   
2. One confirmed response was measured among 20 patients starting treatment on th e 
Trametinib DMSO experimental cohort (accrual beyond 12 patients was due to delayed 
outcome reporting from participating sites) ; this cohort was terminated in March 2018.  
3. There were insufficient numbers of patients treated on the e verolimus experimental c ohort to 
assess response rate , but no responses were measured;  this cohort was terminated in March 
2018.   
4. There were insufficient numbers of patients treated on the veliparib plus temozolomide arm 
to assess response rate, but no responses were measured;  however, the study team have 
revised the eligibility criteria to include BRCA mutations, which is projected to increase the 
hit rate.   
5. Using the percentage of patients who started their assigned treatment as a measure of 
compliance, the overall percentage of patients assigned to experimental arm B who elected 
not to receive treatment was 47%, unexpectedly higher than the rate for patients assigned to 
experimental arm A (23%) (p=.02, [ADDRESS_1005308]).  Interim analysis therefore 
suggests that patients at participating sites were choosing not to participate on the assigned 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005309] (e.g., from 
Foundatio nOne reports) led to expectation of treatme nt assignment.  Our hypothesis, that 
conducting genetic analysis and choosin g targeted therapy based on genomic analysis will 
result in improved response rate and PFS, cannot be evaluated in light of this —indeed,  the 
utility of the randomized phase 2 desig n to determine whether targeted therapy based on 
presence of drug -susceptible tumor mutations will result in improved response rate is clearly 
in doubt [1].  Based on these data it was determined that the study will reopen without 
randomization; patients with actionable mutations of interest will be assigned to targeted 
treatment ar m(s) to assess the proportion of patients with objective response.  T he 
performance of each individual mutational status cohort will be compared to that of historical 
controls . 
 
With the current non -randomized  study design  and statistical analysis plan , there is  less of a  
rationale for blinding  randomized  patient s, treating physician s, and the study team  to the actual 
sequencing data until disease progression .  As of Amendment Y ( January 7, 2020 ) one patient 
who was randomized  to the Trametinib DMSO cohort under the original study  design remain s on 
treatment  with prolonged stable disease  (22+ cycles) , blinded to sequencing results and arm 
assignment.  Amendment Y allow s this patient to consent to  having her mutational status and 
arm ass ignment (i.e., experimental or control) disclosed to herself and/or her treating physician 
now, rather than waiting until disease progression .  The study team would also be informed.  The 
patient , in discussion with the  treating physician , will continue to  have the option to receive the 
other study treatment prospectively identified to work on th e identified  mutation/pathway  per the 
original study design  if she is currently on the control arm.   As noted above, the responses in the 
experimental cohorts were insufficient to indicate that a patient is more likely to derive clinical 
benefit if treated with agents targeting that pathway than if treated with agents that do not . 
 
The agents and respective pathways being evaluated  in this study are:  
1. Veliparib  (PARP inhibitor) with t emozolomide for defects in DNA repair pathways  
2. AZD1775 (Wee1 inhibitor) plus carboplatin for defects in DNA repair pathways (closed 
March 2018)  
3. Everolimus  (mTOR inhibitor) for mutations in the PI3K pathway  (closed March 2018)  
4. Trametinib DMSO  (MEK i nhibitor) for mutations in the RAS/RAF/MEK pathway  
(closed March 2018)  
 
Genetic sequencing will be performed in the CLIA -certified Molecular Characterization 
Labo ratory at the Frederick National Laboratory for Cancer Research (FNLCR) .  In view of the 
complexity  of information collected , each patient’s data will be reviewed by [CONTACT_735864] a n F on the cover page  or (in their absence) , their designees for internal 
consistency.   The genetic variants to be assessed and treatment algorithms have been 
prospectively defined to proceed with assigning specific treatments to the patients on study .  The 
potential risks associated with obtaining genetic information are discussed in Section 2.5 .  
 
Patients with CLIA tumor reports from Foundation Medicine (FoundationOne) , CARIS 
(Molecular Intelligence ), or other  EAY131 MATCH -Designated Laboratories (https://ecog -
acrin.org/nci -match -eay131 -designated -labs)  may be eligible if they have a study actionable 
mutation.  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005310] -of-care images (CT or MRI) that 
qualified the patient for inclusion in this  trial, along with the images taken during image -guided 
biopsy , and any follow up imaging studies during restaging (optional) , will be collected to allow 
research into correlation of the image phenotypic features with the genomic analyses, an area of 
activ e research in radiology [2] [3].  All images w ill be de -identified of personal health 
information at the CCR Molecular Imaging Program before leaving the NIH Clinical Center site 
and will be stored in The Cancer Imaging Archive (http://www.cancerimagingarchive.net/), an 
NIH policy -compliant internet -accessible collection, with controlled access.  The process is 
defined in Appendix L.  
 
2.1 Targeted Mutations and Pathways  
2.1.1 Mutations in DNA Repair P athways  and PARP Inhibitor s 
DNA damage by [CONTACT_735865].  Recent research has suggested that directly 
targeting DNA repair pathways may result in effective killing of tumor cells, particularly 
in patients with pre -existing defects in DNA repair pathways.   There are 6 major DNA 
repair pathways : direct repair (DR) , base excision repair (BER) , nucleotide excision 
repair (NER), mismatch repair (MMR), ho mologous recombination (HR), and non -
homologous end -joining (NHEJ) [4].  Each pathway consists of a complex interaction of 
different molecu lar characteristics (Figure 1) .   
 
 
CTEP #9149 (01 -07-2020 ) 
 
10 
  
Figure 1 . DNA repair pathways and potential analytes  for assessment of DNA repai r [4]. 
 
The BER pathway exerts its biological role by [CONTACT_735866] a vital role in repairing DNA single -strand breaks (SSBs) caused by [CONTACT_100660] -
damaging factors such as anticancer agents [5].  This pathway includes the poly(ADP -
ribose) polymerase (PARP) family of enzymes.  PARP -[ADDRESS_1005311] abundant of 
the PARPs and are essential nuclear enzymes that play a role in recog nition of DNA 
damage and facilitation of DNA repair  [6, 7].  PARP -1 and -2 bind rapi[INVESTIGATOR_735811], which leads to the separation of PARP from DNA.  This leads to modulation 
of DNA damage response proteins (XRCC1/ligase III complex, Polβ) that bind to sites of 
DNA damage.  Double -strand breaks (DSBs) are also strong activators of PARP -1, 
resulting in PARP -1–mediated activation of DNA -PK and Ku80, important components 
of NHEJ repair pathway [8, 9].  Inhibition of PARP sensitizes tumor cells to cytotoxic 
agents (e.g., temozolomide) which induce DNA damage that would normally be repaired 
through the BER system.  PARP inhibitors do not potentiate agents that do not cause 
DNA damage.  
 
Expression of PARP is higher in tumor cells than normal cells.  This overexpression has 
been linked to drug resistance and the ability of tumor cells to withstand genotoxic stress.  
In knockout mouse models, deletion of PARP -1 is sufficient to impair DNA repair [10-
12].  Hence, it is anticipated that PARP inhibitors will function as sensitizing agents for 

CTEP #9149 (01 -07-2020 ) 
 
11 
 chemotherapy and radiation therapy administered to induce  DNA damage.   Recent data 
preclinical data that i socitrate dehydrogenase 1 (IDH1) and IDH2 mutat ions induce a 
homologous recombination defect and a sensitivity to PARP inhibition  suggest  that these 
targets may have may have therapeutic relevance  [13].  
 
Wee1 is a tyrosine kinase implicated in the inhibitory phosphorylation of CDK1/CDC2 -
bound cyclin B complex responsible for G2 arrest  [14].  Originally identified in fission 
yeast  [15], wee [ADDRESS_1005312].  Wee1 belongs to a family of protein kinases involved in the terminal 
phosphorylation and inactivation of (CDK1/CDC2) -bound cyclin B via p hosphorylation 
of its Tyr15 residue near the ATP -binding pocket, resulting in G2 cell cycle arrest in 
response to DNA damage.  Wee1 overexpression has been demonstrated in hepatocellular 
carcinoma  [16], luminal and HER -[ADDRESS_1005313] cancers  [17], colon, lung carcinoma, 
and seminoma tumor samples  [18]. 
2.1.[ADDRESS_1005314]: KRAS, NRAS, BRAF  
MEK is a critical kinase in the mitogen -activated protein (MAP) kinase signal 
transduction pathway for many growth factor receptors that provide growth signals to 
cancer cells, including epi[INVESTIGATOR_294781] (EGF R), insulin -like growth 
factor -1 receptor  (IGFR1) , and platelet -derived growth factor  receptor.  Cell signaling 
through growth factor receptors and protein kinases plays an essential role in cell 
survival, proliferation,  and differe ntiation.  The RAS/RAF kinase pathway is o ne of the 
most important and best understood MAP kinase pathways involved in normal and 
uncontrolled cell growth.  In proliferative diseases, genetic mutations and/or over 
expression of growth factor receptors, dow nstream signaling proteins, or protein kinases 
involved in the RAS/RAF MAP kinase pathway lead to uncontrolled cell proliferation 
and, eventually, tumor formation.    
 
RAS:RAF  association promotes translocation  of the normally cytoplasmic RAF  protein 
to the  plasma membrane, resulting in activation of its kinase function.  Constitutive 
activation of the RAS pathways occurs through mutation  activation of the RAS oncogene 
or of downstream effectors of RAS [19].  Mutated, oncogenic forms of RAS  are found in 
50% of colon and >90% of pancreatic cancers [20], as well as many others types of 
cancers [21], including 15 to 30% of non -small cell lung cancer (NSCLC) [22].   
 
CTEP #9149 (01 -07-2020 ) 
 
12 
  
 
Figure 2:  RAS Pathway (Figure from SABiosciences.com)  
 
KRAS mutations, specifically in codon 12, have been shown to be important for cancer 
progression and may predispose to more aggressive biological behavior in patients with 
advanced colorectal cancer  [23].  Recently, BRAF  (a member of the RAF kinase family)  
gene mutations, which result in a constitutively active MAP kinase cascade, have been 
identified in more than 60% of malignant melanomas [24].  Studies of primary tumor 
samples and cell lines  have also sho wn constitutive activation or overactivation of the 
MAP kinase pathway in  cancers of the pancreas, colon, lung, ovary, and kidney [25].  
Thus, there is a  strong correlation between cancers and an overactive MAP kinase 
pathway resulting from  genetic mutations.  
 
Because  activation of the RAS/R AF MAP kinase cascade plays a pi[INVESTIGATOR_735812], inhibition of this pathway is believed to be beneficial in hyperproliferative  
diseases.  It is anticipated that inhibition of MEK activity should inhibit transduction of 
the mitogenic signal s from multiple pathways, resulting in an effect on tumor 
proliferation,  differentiation,  and survival.   Inhibition of MEK has been shown to have 
potential therapeutic benefit in several studies  [26, 27].   

CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005315]   
The phos phatidylinositol 3 -kinase  (PI3K ) family of lipid kinases converts  
phosphatidylinositol -4,5-bisphosphate to phosphatidylinositol -3,4,5 -trisphosphate, which 
initiates a signaling cascade that promotes cell growth , proliferation, motility,  and 
survival  [28].  PI3 kinases activate A KT.  The PI3K -AKT pathway is downstream of the 
common growth factor  receptor tyrosine kinases (RTKs) , including EGFR, HER2, and 
IGFR, and is a likely driver of tumor progression in most carcinomas [29-31].  AKT 
promotes cell survival, growth, proliferation, migration; as well as angiogenesis and 
invasion by [CONTACT_735867].   
 
AKT protein kinase is activated in a su bstantial pr oportion of human solid tumors, 
including breast, endometrial, ovarian, prostate, pancreatic, colon, gastric , and NSCLC .  
Upregulation of A KT can be caused by [CONTACT_735868]/mutation of A KT, or by 
[CONTACT_735869], PI3K , and RAS, an d/or by [CONTACT_735870]  [32, 33].  AKT  activates and/or inhibits other proteins including BAD, FOXO, and 
mTOR  [34].   
 
Activation of AKT is an important mechanism of chemotherapy/radiotherapy resistance, 
and is therefore of great interest as a potential pathway to overcome resistance.  
Numerous references provide support for AKT  inhibitor s in the treatment of various 
malig nancies [29-31, 35-65].  AKT phosphorylatio n as a pharmacodynamic (PD) marker 
has also been explored in early phase clinical trials [34].   
 
Inactivation or  hypoactivation of PTEN causes overactivation of the PI3K -AKT pathway 
[34].  PTEN inactivation is caused by a variety of m echanisms including somatic 
mutations, deletions, promoter methylation, and/or loss of heterozygosity.  These changes 
are commonly found in many cancers including prostate cancer, endometrial cancer, and 
glioblastoma and are often associated with advanced disease stage.  mTOR is a 
serine/threonine kinase that is structurally related to PI3K.  When mTOR binds to other 
intracellular proteins; there are two distinct complexes formed known as mTORC1 and 
mTORC2 [34].  The currently approved mTOR inhibitors: rapamycin (sirolimus), 
everolimus, and temsirolimus only block mTORC1.  mTORC1 is made up of mTOR, 
regulatory -associated protein of mTOR (raptor), and mLST8/GβL.  Results from a recent 
Phase I study of dox orubicin, bevacizumab, and temsirolimus in patients with advanced 
gynecologic and breast malignancies indicated that a high percentage of responders had 
PI3K aberrations [66]. 
 
CTEP #9149 (01 -07-2020 ) 
 
14 
  
Figure 3: AKT/ PI3K signaling  cascade  (SABiosciences.com) . 
 
2.2 Targeted Genes /Locus Selection  
Patients  enrolled on study will have a tumor biopsy  sequenced for one or more of the specific 
mutations  of interest  listed in Table 1.  This sequencing may be performed prior to enrollment, to 
determine eligibility, or once the patient has started treatment, to confirm the results from 
previous CLIA sequencing.  
 
A minimum of two  biopsy specimens will be shipped directly to the L aboratory of Molecular 
Characterization (MoCha) , located at FNLCR.  Biopsy samples (FFPE blocks) collected as part 
of another study or from a procedure performed due to me dical necessity may be acceptable if 
the samples were collected within [ADDRESS_1005316] and the patient has 
not received any investigational or targeted treatment since that time.   Upon receipt of 
specimens, a visual examination will  be performed for acceptance.  If all acceptance criteria are 
met, the specimen will be logged into the laboratory database for processing.  Biopsy cores will 

CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005317] 50% (with minimal necrosis and stromal tissue) will be subjected to nucleic acid 
extraction using Qiagen’s AllPrep FFPET nucleic acid extraction methodo logy.  Samples with 
tumor content less than 50% will undergo tumor enrichment  (described below) .  Resultant DNA 
and RNA will be quantified by , but not limited to , NanoDrop spectroscopy.  If su fficient DNA is 
obtained, 20 ng  will be used for library preparation using a c ustom AmpliSeq kit, “MATCHv3 ” 
(until Amendment P, the assay used MPACTv2.0).   This custom panel was designed and 
developed by [CONTACT_735871].  The panel employs AmpliSeq multiplex 
PCR te chnology to amplify and prepare clinical specimens for sequencing of genetic loci 
(targets) used for therapy selection in this trial.  The panel currently includes 13 DNA damage 
repair  actionable genes (Table 1 ).  The genes were s elected using se veral criteria :  
• Genes within the  DNA damage repair  pathway were selected based on demonstrating a 
minimum frequency (5%) of somatic variants as listed in the COSMIC [ catalogue of 
somatic mutation in cancer] database1 version # 86. 
• Addition al genes were added, including the target s of the study drugs.   
• The Molecular Tumor B oard further assessed the genes selected and agreed upon a final 
reportable variant protocol based on reported frequency  as well as preclinical and clinical 
literature asso ciated with a given gene and it s variant.  
All sequencing will be performed in a Clinical Laboratory Improvement Amendments (CLIA) -
certified laboratory .  All of the DNA damage repair genes covered by [CONTACT_735872] (Table 1).  These  loss of 
function mutations  have been previously reported in the COSMIC database (version 86) or 
ClinVar .  In addition to the hotspot aMOIs, the panel will also report on novel loss of functi on 
mutations that create a frameshift of premature stop codon in the predicted protein.  
 
The sequencing data for these genes will be shared with the patient ( Appendix H ) once the 
results are available .  Targeted analysis will not include analyzing for known mutations in 
receptor tyrosine kinases  or TP53 .   
  
The clinical specimen will be sequenced using the Ion Torrent Personal Genome Machine.  A 
variety of specimen and assay quality checks are built into the assay process and deta iled in the 
SOPs.  MoCha has prepared an analytical validation plan with assay performance testing, 
validation, and quality control metrics.  These metrics include DNA yield and quality, minimum 
percentage tumor nuclei per specimen, read depth , and positiv e and negative controls (see 
summary below) to ensure valid assay performance and result reporting.   
 
  
 
1 http://www.sanger.ac.uk/genetics/CGP/cosmic/  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005318]  (DNA rep air genes only after Amendment U ) 
 
Gene Name  [CONTACT_735934]/Function  Gain or Loss of Function?   
ATM  DNA repair pathway  Loss  
NBN  DNA repair pathway  Loss  
RAD51  DNA repair pathway  Loss  
RAD51B  DNA repair pathway  Loss  
RAD51C  DNA repair pathway  Loss  
RAD51D  DNA repair pathway  Loss  
PALB2  DNA repair pathway  Loss  
BRCA1  DNA repair pathway  Loss  
BRCA2  DNA repair pathway  Loss  
CHEK1 DNA repair pathway  Loss  
CHEK2 DNA repair pathway  Loss  
FANCA  DNA repair pathway  Loss  
MRE11A  DNA repair pathway  Loss  
IDH1  DNA repair pathway  Loss  
IDH2  DNA repair pathway  Loss  
 
 
Quality Metrics  Threshold  
Tissue Specimen Review  >50% non-necrotic  tumor nuclei present in section  
DNA Recovery  > 20 ng  
Library Yield  > 10 pM 
Testing Fragments  TF-A/D > 80% AQ17, Read Length Histogram >90 bp  
Reads per Sample  >350,000  
Amplicon Coverage  > 80% of amplicons coverage >450x  
Positiv e (CPSC) C ontrol  Detect and call all plasmid variants  
Negative Control CEPH  Detect no false -positive aMOIs  
LibNTC Sequence Data  Total reads < 2% read libraries  OR <120 bp mean read length  
 
After a clinical specimen has completed sequencing and passed all quality checks and filters, the 
data will be analyzed.  The report will be reviewed (by [CONTACT_735873] a n F on the 
cover page) and treatment assignments made based on the locked down  algorithm defined in the 
protocol.    All delinked RNA and  DNA will be stored under appropriate conditions until further 
sample s tudies are indicated .  Delinking of patient identifiers will be performed in a secure 
manner prior to use performing , but not limited to,  whole exome sequencing and circulating 
tumor DNA (ctDNA) for research purposes.  
 
Mutations will be reported based on their presence in tumor cells and the percent  of cells 
demonstrating the pre defined mutation.   
 
An adequate tumor biopsy sample will contain at least 50% tumor  with minimal necrosis and 
stromal tissue ; samples with less than 50% tumor will be reflexed for tumor enrichment using a 
standardized  macrodissection protocol.  In case of samples with insufficient  tumor content or 
DNA  yield , the patient will be given the option to undergo a repeat tumor biopsy to obtain more 
CTEP #9149 (01 -07-2020 ) 
 
17 
 tissue.  Patients from whom sufficient tumor DNA material cannot be obtained for targeted 
analysis will be taken off -study.  
2.3 Study  Agent s 
Proprietary  information  about each of the  study agents is included in this protocol document as 
an appendix.  Veliparib  will be administered with temozolomide.  
2.3.1 Veliparib  
Veliparib  is an orally available, small molecule inhibitor of PARP.  Preclinical and clinical 
data show that inhibition of PARP potentiates the effects of DNA -damaging 
chemotherapeutic drugs such as the alkylating agent temozolomide  [67].  In this study, 
Veliparib  and temozolomide will be administered to patients with defects in DNA repair 
pathways.  Please refer to Appendix I  for more information.     
2.3.2 Temozolomide  
Temozolomide is an oral alkylating agent  approved by [CONTACT_735874].  Temozolomide is spontaneously 
hydrolyzed at  physiologic pH to the active species, 3 -methyl -(triazen -1-yl)imidazole -4-
carboxamide (MTIC).  MTIC is further hydrolyzed  to 5-amino -imidazole -4-carboxamide 
(AIC) which is kno wn to be an intermediate in  purine and nucleic acid biosynthesis and 
to methylhydrazine, which is believed to be  the active alkylating species.  
2.3.3 Trametinib dimethyl sulfoxide ([COMPANY_004] 1120212 ) (This arm was closed to new 
accrual with Amendment U) 
Trametinib DMSO  is a reversible, highly selective allosteric inhibitor of MEK1/MEK2  
activation and kinase activity.  The safety, pharmacokinetic ( PK), and  pharmacodynamic 
(PD) profiles, and activity of trametinib DMSO  are currently being evaluated in 13 
ongoing monotherapy and combination therapy clinical trials involving subjects with a 
variety of cancers.   Trametinib DMSO was recently approved for the treatment of patients 
with unresectable or metastatic melanoma with BRAFV600E or BRAFV600K  mutations  based 
on a statistically significant prolongation of progression free survival over chemotherapy 
(4.8 months vs. 1.5 months) in 322 patients on a randomized active -control trial.  
2.3.4 AZD1775 (This arm was closed to new accrual with Amendment U) 
AZD1775 is a select ive, adenosine -triphosphate (ATP) competitive, small molecule 
inhibitor of Wee1 kinase that  directly inhibits phosphorylation of CDC2.  In vitro  
experiments have demonstrated that AZD1775 has synergistic antitumor effects when 
administered in combination with various DNA damaging agents that have d ivergent 
mechanisms of action.  In this study, AZD1775 will be administered with carboplatin .  
Results from preclinical and clinical studies suggest that the combination of AZD1775 
with carboplatin ha s antitumor efficacy and is well tolerated ; refer to Appendix J  for more 
information.    
2.3.5 Carboplatin  (This arm was closed to new accrual with Amendment U) 
The alkylating agent carboplatin acts by [CONTACT_735875] -
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005319] cancer.  Carboplatin is eliminated by [CONTACT_735876]; c learance is 
related to the glomerular filtration rate  (GFR), t herefore the drug is dosed based on the 
GFR and the target area under  the concentration versus time curve (AUC).  The main side 
effects of carboplatin are  myelosuppression , nausea, vomiting, renal  toxicity,  and 
neurotoxicity.   
2.3.6 Everolimus  (This arm was closed to new accrual with Amendment U) 
The mTOR inhibitor e verolimus was approved by [CONTACT_735877] (RCC)  based on results from a multicenter, randomized, double -
blind Phase III trial comparing everol imus (10 mg daily) and placebo in 416 patients with 
metastatic RCC  whose disease had progressed despi[INVESTIGATOR_735813] -targeted therapy (sunitinib, sorafenib, or both sequentially)  [68, 
69].  Median progression -free survival was 4.9 months in the everolimus arm and 1.9 
months in the placebo arm; objective response rates were 2% and 0%, respectively.   As 
described in Section 2.1.3 , the serine -threonine kinase mTOR is an essential component 
of the multiprotein mTOR complex 1 (mTOR C1), along with regulatory -associated 
protein of mTOR (raptor).  Once activated through PI3K activation of AKT, mTORC1  
functi ons as a key regulator of cell grow th by [CONTACT_735878] 4E-binding protein 1 (4E -
BP1) and p70S6K (S6K), translation initiation factors required for protein synthesis  [70, 
71].  Everolimus binds to the intracellular protein, FKBP -12, which  in turn binds mTOR , 
impairing its activity and inhibiting translation of proteins essential for cell cycle 
progression and survival.  The main side effects of everolimus reported in patients with 
RCC are stomatitis, infections, asthenia, fatigue, cough, a nd diarrhea.  The recommended 
dose of everolimus for the treatment of patients with advanced RCC is 10  mg, to be taken 
once daily; this dose will be administered o n this trial.   
2.[ADDRESS_1005320] therapy and/or there are no standard therapi[INVESTIGATOR_735814].  This tumor 
biopsy will be sequenced for presence of specific mutations of interest in a CLIA -certified 
laboratory .  The following specific mutations  in pathways will be assessed:  
1. Mutations in DNA repair pathways  
2. Mutations in the PI3K pathway  (Not currently accruing)  
3. Mutations in the RAS /RAF/MEK  pathway  (Not currently accruing)  
2.[ADDRESS_1005321] a mutation (s) in one or more  of the pathway of interest.  We will screen for 
pre-defined variations in genes in a CLIA -certified laboratory for assignment of patient treatment 
on study .  As treatment options and data analyses will be based on this information, de -
identifying the samples is not feasible.  Designing the study therefore poses challenging 
CTEP #9149 (01 -07-2020 ) 
 
19 
 questions about informed consent, the privacy of the patient and the patient’s family, the 
researchers’ obligation to disclose genetic information to the patient, and the use and storage of 
research data, as well as of the selection and interpretation of gene variants  [72-74].  In the vast 
majority of cases we do not know the medical significance of genetic var iants  [75, 76].  These 
challenges will continue to be evaluated to maintain the  rigor and integrity of the study  and the 
wellbeing of our patients .  A Certifi cate of Confidentiality has been obtained  from the NIH to 
help protect the privacy of all study participants.    
 
The protocol includes separate informed consent forms for the screening biopsy and treatment  
parts of the study ; each patient will know whether or not their tumor has a variation in a gene of 
interest .  Patients with actionable mutations that may establish eligibility for other clinical  trials 
or targeted agents, including MATCH ( Targeted Therapy Directed by [CONTACT_735879], Lymphomas, or Multiple Myeloma , 
[STUDY_ID_REMOVED]), which uses the same custom AmpliSeq screening panel as MPACT , will be 
informed that they may have other treatment options.   Information on tumor gene variants that 
form the basis of treatment assignment will be stored in  the patient’s medical records.  
 
Whole exome sequencing (performed for research purposes) of  tumor and blood can detect 
nonambiguous ge rmline variants , which may raise  healt h and privacy implications for the  patient 
and his or her family .  Whole exome sequencing will not be validated for clinical use and no 
clinical decisions can be m ade based on its results.  In addition, given the uncertain clinical 
significance of some of these variants  and the ethical implications, we will perform such research 
analysis on de-identified samples only.  Once each patient has completed treatment on st udy and 
is taken off study, patient identifiers will be de -linked and we will perform whole exome 
sequencing on the de-identified samples.  No genetic data will be shared with the patient other 
than the data from the targeted sequencing panel .  All other a nalysis will be performed on de-
identified  samples.  The process for de-identifying  the samples is described in Section 9.4.[ADDRESS_1005322] information about the prevalence of mutations 
in genes associated with cancer, as well as how patients’ tumors respond to targeted therapy in 
the refractory tumor setting; DNA variants and changes in RNA e xpression from tumors 
collected when patients progress on study drugs is anticipated to illuminate resistance 
mechanisms that will inform subsequent studies and improve patient outcomes.   
2.5.1 NIH Genomic Data Sharing Policy  
The NIH Genomic Data Sharing (GDS) Policy ensures broad and responsible sharing of 
genomic research data from all NIH -funded research2.  Providing that patient consent has 
been obtained, whole-exome sequencing data generated for research purposes  from 
samples unlinked from patient identifi ers will be submitted to the Database of Genotypes 
and Phenotypes (dbGaP)  for controlled -access use within a time frame consistent with 
study CRADAs and data publication.  T he identities of research participants will not be 
disclosed to dbG aP or to  seconda ry users of the data.  Genomic data generated from 
 
2 https://gds.nih.gov/index.html  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005323] than if treated with agents tha t do not , as well as to 
address  this question , in a non -randomized f ashion, for each separate cohort  defined by [CONTACT_735880].  Randomization was taken out of the study design with Amendment U.  
 
Patients will receive one of the agent s/regimens defined t o work on on e of their identified 
mutations.  In the absence of a randomized control arm, the performance of each individual 
mutational status cohort will be compared to that of historical controls.  If no objective responses 
are observed among the initial  12 patients of a 30 -patient Arm A agent cohort, the cohort will be 
terminated early.   An optional tumor biopsy will be performed at the time of disease progression 
to assess for new acquired mutations ; this biopsy may, if feasible, be collected on day 1 ( ± 2 
days) of the cycle following any restaging at which a 10 -19% increa se in tumor volume is 
observed (per RECIST criteria) if the patient has been on study for at least 4 cycles .   
 
The treatment regimens and number of treatment regimens may change over time as long as the 
same set of regimens is offered to a given set of patients .  The doses t hat will be administered are 
Phase II -recommended doses.    
2.6.1 Veliparib plus T emozolomide  arm 
As of Amendment U , this is the only arm open to accrual.   Seven patients had been 
assigned to this arm prior to the study being placed on hold for futility analysis (targeted 
plus control arms).   
 
The combination of veliparib with temozolomide in patients with DNA damage 
mutations is supported by [CONTACT_735881] -derived xenograft (PDX)  mouse  
models.  Overall, [ADDRESS_1005324] been treated with this combination; [ADDRESS_1005325] 
demonstrated  delayed tumor growth (unpublished data).  C omplete or partial r esponse, as 
well as  an increase in  relative median event -free survival , has been observed with 
veliparib plus temozolomide  in tumors  with a range of DNA damage mutations.  Based 
on these data, we have r evised the list of actionable mutations of interest  for the veliparib 
plus temozolomide  arm.  We expect that the new eligibility criteria, including variants in 
DNA repair genes BRCA1, BRCA2, CHK2, and ATM , will allow more patients with 
potential to benefit from this combination to enroll on this treatment ar m. 
 
3. PATIENT SELECTION  (TUMOR SEQUENCING /DRUG TREATMENT ) 
Patients meeting the criteria defined below will be enrolled on study, then undergo a tumor 
biopsy.  The t umor will be sequenced for specific mutations  of interest  defined in  Section 
2.2; only if such mutations are detected  will the patient continue on study  to the  
randomization/ treatment part of this protocol .  The eligibility criteria for both the tumor 
CTEP #9149 (01 -07-2020 ) 
 
21 
 sequencing and treatment parts of this protocol are similar, such that in general, a patient 
eligible for tumor sequencing will be eligible for the subsequent treatmen t part of the 
protocol  if his/her tumor contains a mutation of interest.  Additional agent -specific 
treatment exclusions are listed in Section 3.4 ; agent-specific exclusions are to ensure 
patient safety.    
3.1 Eligibility Criteria : Tumor Biopsy Sequencing  
3.1.[ADDRESS_1005326] therapy  and/or no standard of 
treatment  exists that has been shown to prolong survival . 
3.1.[ADDRESS_1005327] tumor amenable to percutaneous or excisional  skin biopsy  and 
be willing to undergo a tumor biopsy , or  
Biopsy samples (FFPE blocks) collected on another study or from a procedure 
performed due to medical necessity may be acceptable if collected within [ADDRESS_1005328] and providing that the patient has not 
received any investigational or targeted treatment since that time , or 
A report from a n MATCH  study designated CLIA laboratory  (see https://ecog -
acrin.org/nci -match -eay131 -designated -labs) that a patient has a variant in the 
genes of interest .   
3.1.[ADDRESS_1005329] one dimension (longest diameter to be recorded) as 
≥ 20 mm with conventional techniques or as ≥  [ADDRESS_1005330] scan.  
3.1.4 Patients with bone metastases or hypercalcemia  on intravenous bisphosphonate 
treatment, denosumab , or similar agents  are eligible to participate  and may 
continue this treatment.  Patients with prostate cancer may continue LHRH 
agonists or antagonists .  
3.1.5 Age ≥  18 years.   Children  are excluded from this study, but may b e eligi ble for 
future pediatric trials.  
3.1.6 Karnofsky performance status ≥  70%, see Appendix A . 
3.1.7 Life expectancy > [ADDRESS_1005331] adequate  organ and marrow function as defined below:  
− absolute neutrophil count   ≥1,000/L (mcL)  
− platelets        ≥100,000 L (mcL)  
− total bilirubin      < 1.5 X institutional upper limit of normal  
− AST(SGOT)/ALT(SGPT)   ≤ 3 X institutional upper limit of normal  
− creatinine       < 1.5 X institutional upper limit of normal  
OR 
CTEP #9149 (01 -07-2020 ) 
 
22 
 − creatinine clearance     ≥ 60 mL/min for patients with creatinine 
levels ≥1.[ADDRESS_1005332] been on stable doses of anti -seizure medicine 
and had no seizures for  4 weeks will be eligible.  Enzyme -inducing 
anticonvulsants are contraindicated.  
3.1.11  Ability to understand  and the willingness to sign a written informed consent 
document  (subjects with impaired decision -making capacity are not eligible).  
3.2 Exclusion Criteria : Tumor Biopsy Sequencing  
3.2.1 Women who are p regnant or breastfeeding . 
3.2.2 Patients who are receiving any other investigational agents.   Patients on other 
trials will be eligible as long as they are no longer receiving study treatment.  
3.2.3 Patients with uncontrolled intercurrent illnes s including, but not limited to 
psychiatric  illness/social situations that would  limit compliance with study 
requirements, s ymptomatic congestive heart failure, unstable angina pectoris, 
cardiac arrhythmia, myocardial infarction in the past 6 months , invasive fungal 
infections, or active (acute or chronic) or uncontrolled severe infec tion, liver 
disease such as cirrhosis, decompensated liver disease, and active and chronic 
hepatitis (i.e., q uantifiable HBV -DNA and/or positive HbsAg, quantifiable HCV -
RNA)  are not eligible to participate.   Testing for hepatitis B or other infections for 
eligibility will be performed only if clinically indicated.   
3.2.4 Patients with gastrointestinal conditions that might predispose for drug 
intolerability or poor drug absorption (e.g., inability to take oral medication or a 
requirement for IV alimentation, prior surgical procedures affecting absorption, 
malabsorption syn drome, and active  peptic ulcer disease) are excluded.  Subjects 
with Crohn’s disease  or a partial or complete small bowel obstruction are also 
excluded , as are any patients who cannot swallow  tablets or capsules whole .  
Tablets or c apsules  must not be crus hed or chewed; nasogastric or G -tube 
administration is not allowed.    
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005333]  (defined in Section 2. 2) will be eligible  to participate 
in the t reatment part of this protocol.  If the patient does not meet the criteria in Section 
3.3 or the patient has any of the conditions listed in Section 3.4 , the patient is not 
eligible for this trial.   
3.3 Eligibility Criteria: Targeted Treatment  
3.3.[ADDRESS_1005334] one dimension (longest diameter to be recorded) as 
≥ 20 mm with conve ntional techniques or as ≥ [ADDRESS_1005335] been completed 
≥ 3 weeks (> 6 weeks for nitrosoureas or mitomycin C) or 5 half -lives of the agent 
(whichever is shorter)  prior to enrollment o n protocol, and the participant must 
have recovered to eligibility levels from prior toxicity .  RFA of localized lesions 
should have been performed ≥ 2 weeks prior to starting treatment .  
3.3.5 Patients with bone metastases or hypercalcemia on intravenous bisphosphonate  
treatment , denosumab, or similar agents  are eligible to participate  and may 
continue this treatment.  Patients with prostate cancer may continue LHRH 
agonists or antagonists . 
3.3.6 Age ≥ 18 years.   Because no dosing or adverse event da ta are currently available 
on the use of study investigational agents in patients < 18 years of age, children 
are excluded from this study, but may be eligible for future pediatric trials.  
3.3.7 Karnofsky performance status ≥ 70 %, see Appendix A . 
3.3.8 Adequate organ and marrow function as defined in Section 3.1.8  
CTEP #9149 (01 -07-2020 ) 
 
24 
 3.3.9 Life expectancy > [ADDRESS_1005336] agree to use highly 
effective contraception (see list below ) prior to study entry, for the duration of 
study participation, and for 3 months  after completion of study.  
Total abstinence: When this is in line with the preferred and usual lifestyle of 
the subject.   (Periodic abstinence (e.g., calendar, ovulation, sym ptothermal, 
post-ovulation methods) and withdrawal are not acce ptable methods of 
contraception).  
Sterilization: have had surgical bilateral oophorectomy (with or without 
hysterectomy) or tubal ligation at least six weeks before taking study treatment.  
In case of oophorectomy alone, only when the reproductive status of the 
woman has been confirmed by [CONTACT_735882] (with the appropriate post -vasectomy documentation 
of the absence of sperm in the ejaculate).   (For female subjects on the study, 
the vasectomised male partner should be th e sole partner for that subject) . 
Use of a combination of any two of the following (a+b or a+c or b+c):  
a. Use of oral, injected, implanted or other hormonal methods of 
contraception  
b. Placement of an intrauterine device (IUD) or intrauterine system (IUS)  
c.  Barrier methods of contraception: Condom or Occlusive cap (diaphragm 
or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal 
suppository  
In case of use of or al contraception, women should have been stable on the oral 
agent before taking study treatment.  
 
Sexually active males must use a condom during intercourse  
3.3.[ADDRESS_1005337] received approved  PARP  inhibitor therapy ; these patients are eligible 
for the Veliparib plus temozolomide arm unless the PARP inhibitor was 
administered with temozolomide .   
3.3.[ADDRESS_1005338] received prior temozolomide or PARP inhibitor with or 
without other chemotherapy/targeted agent should not be excluded.   
3.3.[ADDRESS_1005339]  ≥10.0 g/dL Hb and no blood transfusion in the past 28 da ys to 
CTEP #9149 (01 -07-2020 ) 
 
25 
 receive Veliparib.  
3.4 Exclusion Criteria : Targeted Treatment  
3.4.[ADDRESS_1005340] a histor y of seizures are not eligible to 
receive Veliparib  
3.4.4 Patients with uncontrolled intercurrent illness including, but not limited to  
psychiatric illness/social situations th at would limit compliance with study 
requirements, symptomatic congestive heart failu re, unstable angina pectoris, 
cardiac arrhythmia, myocardial infarction in the past 6 months , invasive fungal 
infections, or active (acute or chronic) or uncontrolled severe infection, liver 
disease such as cirrhosis, decompensated liver disease, and activ e and chronic 
hepatitis (i.e., quantifiable HBV -DNA and/or positive HbsAg, quantifiable HCV -
RNA) are not eligible to participate.  Testing for hepatitis B or other infections for 
eligibility will be performed only if clinically indicated.  
3.4.5 Patients with gastrointestinal conditions that might predispose for drug 
intolerability or poor drug absorption (e.g., inability to tak e oral medication or a 
requirement for IV alimentation, prior surgical procedures affecting absorption, 
malabsorption syndrome, and act ive peptic ulcer disease) are excluded.  Subjects 
with Crohn’s disease  or a partial  or complete small bowel obstruction are also 
excluded, as are any patients who cannot swallow tablets or capsules whole.  
Tablets or capsules must not be crushed or chewed;  nasogastric or G -tube 
administration is not allowed.    
3.4.[ADDRESS_1005341] the activity or pharmacokinetics (i.e., CYP450 , PgP ) of 
any of the study drugs will be determined following review of their cases by [CONTACT_1600].  Patients on strong and moderate  cytochrome P450 system inducers or 
inhibitors ( Appendix B ) are ineligible .  Every effort would be made to switch 
patients off medications that are known substrates of CYP 450; if it is medically 
important for the patient to remain on such medications, these patients c an still be 
eligible to participate based on PI [INVESTIGATOR_9106].   Refer to Section 8  for more detailed 
information.    
3.4.8 Patients who require use of coumarin -derivative anticoagulants such as warfarin 
are excluded.  Low molecula r weight heparin is permitted  for prophylactic or 
therapeutic use.   
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005342] a history of another primary malignancy, with the exceptions 
of: non -melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast 
from which the patient has been disease free for > 3 years.  
3.4.10  Patients with treatment -related AML (t -AML)/MDS, or with features suggestive 
of AML/MDS, or who have had prior allogeneic bone marrow transplant or 
double umbilical cord blood transplantation, should not receive  Veliparib due to 
reports of MDS and leukemia secondary to oncology therapy on CTEP -sponsored 
studies utilizing Veliparib.  
3.5 Evaluation for Enrollment for Tumor Biopsy Screening  
3.5.1 Histologic confirmation  of solid malignancy .   
3.5.2 History and physical examinatio n: Complete history and physical examination 
(including height, weight, vital signs, performance score, EKG) will be conducted 
within 8 days  prior to enrollment.   
3.5.3 Imaging Studies (Baseline): Imaging studies to determine biopsiable disease.  
3.5.4 Laboratory Eva luation: Baseline laboratory data are to be obtained within  8 days 
prior to enrollment  (fasting blood  preferred ): 
• Hematologica l Profile: CBC with differential   
• Biochemical Profile: albumin, alkaline phosphatase, total bilirubin, BUN, 
calcium, creatinine, glucose, phosphorus, total protein, SGOT[AST], 
SGPT[ALT],  magnesium, potassium, and  sodium  
• Serum or urine pregnancy test for female partici pants of childbearing potential  
3.6 Evaluation for Treatment on Study  
3.6.1 History and physical examination: complete history and physical examination 
(including weight, vital signs, performance score, EKG) will be conducted within 
8 days  prior to enrollment.  If the patient’s condition deteriorates prior to initiation 
of treatme nt, evaluations should be repeated within 48 hours prior to initiating 
treatment.   
3.6.2 Imaging Studies (Baseline): Every participant should have an evaluation of 
known sites of disease as part of the baseline evaluation.  All patients will be 
required to under go a CT scan of the chest/abdomen/pelvis to evaluate sites of 
disease within [ADDRESS_1005343] of the brain, MRI liver , MRI for other disease sites,  ECHO/MUGA  or 
bone scan may be done as clinically indicated  before starting study drugs  (ECHO/ 
MUGA required for patients receiving trametinib or everolimus).  
3.6.3 Laboratory Evaluation: Baseline laboratory data are to be obtained within  8 days 
prior to enrollment  and within 3 days prior to starting  study drugs .  If the patient’s 
condition deteriorates prior to initiation of treatment, laboratory evaluations 
should be repeated within 48 hours prior to initiating  treatment : 
CTEP #9149 (01 -07-2020 ) 
 
27 
 a. Hematological Profile: CBC with differential.  
b. Biochemical Profile: albumin, a lkaline phosphatase, total bilirubin, BUN, 
calcium, creatinine, glucose, phosphorus, total protein, SGOT[AST], 
SGPT[ALT],  magnesium, potassium, and sodium.  
c. Serum or urine pregnancy test for female participants of childbearing potential.  
 
4. REGISTRATION PROCE DURES  
4.1 Investigator and Research Associate Registration with CTEP  
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy require 
all individuals contributing to NCI -sponsored trials to register and to renew their registration 
annually.  To register, all individuals must obtain a Cancer Therapy Evaluation Program (CTEP) 
Identity and Access Management (IAM) account ( https://ctepcore.nci.nih.gov/iam ).   
In addition, per sons with a registration type of Investigator (IVR), Non -Physician Investigator 
(NPI[INVESTIGATOR_6731]), or Associate Plus (AP) (i.e., clinical site staff requiring write access to OPEN or RAVE 
or acting as a primary site contact) must complete their annual registration u sing CTEP’s web -
based Registration and Credential Repository (RCR) ( https://ctepcore.nci.nih.gov/rcr ).  
Documentation requirements per registration type are outlined in the table below.  
Documentation Require d IVR NPI[INVESTIGATOR_6732] A 
FDA Form 1572  ✔ ✔   
Financial Disclosure Form  ✔ ✔ ✔  
NCI Biosketch (education, training, 
employment, license, and certification)  ✔ ✔ ✔  
HSP/GCP training  ✔ ✔ ✔  
Agent Shipment Form (if applicable)  ✔    
CV (optional)  ✔ ✔ ✔  
An active CTEP -IAM user account and appropriate RCR registration is required to access all 
CTEP and CTSU (Cancer Trials Support Unit) websites and applications.  In addition, IVRs and 
NPI[INVESTIGATOR_735815] 1572 in RCR to allow the following:  
• Added to a site roster  
• Assigned the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN  
• Act as the site -protocol PI [INVESTIGATOR_735816]://ctep.cancer.gov/investigatorResources/default.htm.  For questions, please contact [CONTACT_25514] [EMAIL_088] . 
4.2 Site Registration  
This study is supported by [CONTACT_6818] (CTSU).  
 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005344] obtain IRB approval for this 
protocol and submit IRB approval and supporting documentation to the CTSU Regulatory Office 
before they can be approved to enroll patients.  Assignment of site registration status in the 
CTSU Regulatory Support System (RSS) uses extensive data to make a determination of whether 
a site has fulfilled all regulatory criteria including but not limited to  the following :  
• An active Federal Wide Assurance (FWA) number  
• An active roster affiliation with the Lead Network or a participating organization  
• A valid IRB approval  
• Compliance with all protocol specific requirements.  
In addition, the site -protocol PI [INVESTIGATOR_735817]:  
• Active registration status  
• The IRB number of the site IRB of record listed on their Form FDA 1572  
• An active status on a participating roster at the registering site  
Sites participating on the NCI CIRB initiative that are approved by [CONTACT_735883].  For sites 
using the CIRB, IRB approval information is received from the CIRB and applied to the RSS in 
an automated process.  Signatory Institutions must submit a Study Specific Worksheet for Local 
Context (SSW) to the CIRB via IRBManager to indicate their intent to open the study locally.  
The CIRB’s approval of the SSW is then communicated to the CTSU Regulatory Office.  For the 
SSW approval to be pr ocessed, the Signatory Institution must inform the CTSU which CIRB -
approved institutions aligned with the Signatory Institution are participating in the study.  
 
Downloading Regulatory Documents  
 
Site registration forms may be downloaded from the [ADDRESS_1005345] be 
associated with the Corresponding or Participating protocol organization in the RSS.  
 
• Go to https://www.ctsu.org and log in using your CTEP IAM username [CONTACT_25558].  
• Click on the Protocols tab in the upper left of your screen.  
• Either enter the protocol # in the search field at the top o f the protocol tree, or  
• Click on the  By [CONTACT_25515], and then  select LAO-NCI, 
and protocol #9149 . 
• Click on LPO Documents, select the Site Registration documents link, and 
download and complete the forms provided.  (Note: For sites under the CIRB 
initiative, IRB data will load to RSS as described above.)  
 
Requirements for 9149 Site Registration:  
▪ IRB approval (For sites not participating via the NCI CIRB; local IRB 
documentation, an IRB -signed CTSU IRB Certification Form, Protocol of Human 
Subjects Assurance Identification/IRB Certification/Declaration of Exemption 
Form, or combinatio n is accepted)  
▪ Local informed consent document  
CTEP #9149 (01 -07-2020 ) 
 
29 
 ▪ Study chair approval  
 
Submitting Regulatory Documents  
 
Submit required forms and documents  to the CTSU Regulatory Office, where they will be 
entered and tracked in the CTSU RSS.   
Regulatory Submission Portal:  www.ctsu.org (members’ area) → Regulatory Tab → 
Regulatory Submission  
When applicable, original documents should be mailed to:  
CTSU Regulatory Office  
[ADDRESS_1005346] , Philadelphia, PA [ZIP_CODE]  
 
Institutions with patients waiting that are u nable to use the Portal should alert the CTSU 
Regulatory Office immediately at 1 -[PHONE_102] to receive further instruction and support.  
 
Checking Site Registration Status  
 
You can verify your site registration status on the members’ section of the CTSU website.  
• Go to https://www.ctsu.org and log in to the members’ area using your CTEP -
IAM username [CONTACT_2383]  
• Click on the Regulatory tab at the top of your screen  
• Click on  the Site Registration tab  
• Enter your 5 -character CTEP Institution Code and click on Go  
 
Note: The status given only reflects compliance with IRB documentation and institutional 
compliance with protocol -specific requirements as outlined by [CONTACT_735884].  It does not 
reflect compliance with protocol requirements for individuals participating on the protocol or the 
enrolling investigator’s status with the NCI or their affiliated networks.  
4.2.1 OPEN / IWRS  
Patient enrollment will be facilitated using the Onc ology Patient Enrollment Network 
(OPEN).  OPEN is a web -based registration system available to users on a 24/7 basis.  It  
is integrated with the CTSU Enterprise System for regulatory and roster data interchange 
and with the Theradex Interactive Web Response System (IWRS) for retrieval of patient 
registration/randomization assignment.  Patient enrollment data entered by [CONTACT_33979] / IWRS will automatically transfer to the NCI’s clinical data management system, 
Medidata Rave.  
 
As this trial has a  slot reservation requirement, OPEN will connect to IWRS at 
enrollment initiation to check slot availability.  Registration staff should ensure that a slot 
is available and secured for the patient before completing an enrollment.   Slots c an be 
reserved for a maximum of 14 calendar days.  
 
The OPEN  system will provide the site with a printable confirmation of registration and 
treatment information.   Please print this confirmation for your records.   
CTEP #9149 (01 -07-2020 ) 
 
30 
  
 OPEN/IWRS User Requirements  
OPEN/IWRS users must meet the following requirements:  
• Have a valid CTEP -IAM account (i.e., CTEP username [CONTACT_2383]).  
• To enroll patients or request slot reservations:  Be on an ETCTN Corresponding 
or Participating Organization roster with the role of Reg istrar.   Registrars must 
hold a minim um of an AP registration type.   
• To approve slot reservations or access cohort management:  Be identified to 
Theradex as the “Client Admin” for the study.  
• Have regulatory approval for the conduct of the study at their s ite. 
 
Prior to accessing OPEN/IWRS, site staff should verify the following:  
• All eligibility criteria have been met within the protocol stated timeframes.    
• If applicable, all patients have signed an appropriate consent form and HIPAA 
authorization form.  
 
OPEN/IWRS Questions?  
Further instructional information on OPEN is provided on the OPEN tab of the CTSU 
website at https://www.ctsu.org or at https://open.ctsu.org.   For any additional questions 
contact [CONTACT_25518] 1 -[PHONE_103] or ctsucontact@wes tat.com.  
 
Theradex has developed a Slot Reservations and Cohort Management User Guide, which 
is available on the Theradex website: website 
http://www.theradex.com/clinicalTechnologies/?National -Cancer -Institute -NCI-[ADDRESS_1005347] th e Theradex Helpdesk: 609 -619-7862 or 
Theradex main number 609 -799-7580; [EMAIL_411].  
4.3 General Guidelines  
Following registration, patients should be  assigned to p rotocol treatment as specified in  Section 
5.1.  Issues that would cause treatment delays should be discussed with the Principal Investigator.  
If a patient does not receive protocol therapy following registration, the patient’s registration on 
the study may be canceled.  The Study Coordinator should be notified of cancellations as soon as 
possible.   Please make every effort not to schedule biopsy collections on a Friday as FN LCR 
cannot accept courier deliveries at weekends.  
4.4 Randomization Procedures  (N/A)  
 
5. TREATMENT PLAN  
5.1 Study Design  
After signing the consent form and enrolling on the study, patients will undergo mandatory 
tumor biopsy as described in Section 9  unless a CLIA -certified tumor mutation report from an 
CTEP #9149 (01 -07-2020 ) 
 
31 
 MATCH study designated lab (see https://ecog -acrin.org/nci -match -eay131 -designated -labs) 
indicating a study aMOI is provided .  Reports from other academic, clinical, or commercial 
testing organizations will not be accepted due to the level of evidence needed for this research 
protocol.   Genetic sequencing at the NCI will be performed in the CLIA -certified laboratory of 
[CONTACT_90342],  Director, Molecular Characterization and Clinical Assay Development 
Laboratory (MoCha) , to assess for the presence of specific, pre -defined mutations of interest.      
 
The laboratory will return notification of whether a mutation of in terest has been detected in 
approximately 2 weeks , including details about the specific mutation /pathway  for assignment to 
the treatment arm based on predefined criteria.  Patients in whom mutations of interest are not 
detected will be taken off study .  Patients considered eligible for the study due to results from  a 
MATCH -designated lab  will have a biopsy collected during cycle [ADDRESS_1005348] Oncominev3 assay ; patients who do not have their actionable mutation confirmed 
can cho ose to continue treatment but will not count towards evaluable patients and will be 
replaced for futility analysis.    
 
All treatment will be open -label in this trial.  Drugs will be administered at the recommended 
Phase II doses  and schedules .  A new cycl e may begin [ADDRESS_1005349] scans will be performed at baseline, and repeat imaging scans will be performed 
every 2  cycles (8  weeks  for 28 -day schedules, 6  weeks for 21 -day schedules ).  Once a patient has 
been on a treatment for more than [ADDRESS_1005350] scans will be performed every 3 cycles for 28 -
day cycles  or every 4 cycles for 21 -day cycles.  
 
History and physical exa m, labs (CBC with differential; serum chemistries, including fasting 
glucose) will be performed at the start of each cycle (within 3 days prior to start of new cycles).  
Additional evaluations will be conducted as clinically indicated at the investigator’s  discretion , 
or more frequently for patients on certain treatment arms as specified in Section 10 .   
 
Lipid monitoring (triglycerides and cholesterol) will be performed at restaging (every 2  cycles  or 
as defined above)  and urinary protein the start of each cycle for patients on everolimus only.  
 
Patients will be asked to maintain a Study Medication Diary  (Appendix D) and record each dose 
of medication.  Patients will be given instructions for completing the medication diary and will 
be asked to return it to the clinic staff at the end of each cycle.  All patients will be carefully 
monitored for side effects while on study.  Appropriate dose modifications are described in 
Section 6 . 
5.2 Targeted Therapy  Arms  
Treatment assignment is made by [CONTACT_735885], an informatics system that performs treatment 
assignments based on the locked down algorithm defined in the protocol.  The assignment will 
be sent to the treating physician once it is verified within 24 -48 hours.   The treating physician 
and the patient  will not be blinded to the sequencing data .   
 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005351] will receive an agent prospectively identified to work 
on that mutation/pathwa y (see below).   As long as the same set of protocols are offered to a 
given set of patients, the number and actual treatments regimens can vary over time.  
 
At the time of Amendment Y,  the last patient  randomized to the Trametinib DMSO cohort under 
the original study design remain s on treatment with the option that she and/or her physician may 
now be  informed  prior to, rather than at, disease progression  about her mutational status and arm 
assignment .  The study team would also be informed.  The patient, in discussion with the treating 
physician, may still crossover to a study treatment prospectively identified to work on the 
identified mutation/pathway per the original study design  (see list below) .  The patient may not 
switch to another treatment and then back to Trametinib DMSO.  
 
The treatment regimens are as follows:  
• Veliparib  plus temozolomide for defects in DNA repair pathways  
• AZD1775 (Wee1 inhibitor) plus carboplatin for defects in DNA repair pathways  (no 
longer an active study drug as of March 2018)  
• Everolimus (mTOR  inhibitor ) for mutations in the PI3K pathwa y (no longer an active 
study drug as of March 2018)  
• Trametinib DMSO  (MEK i nhibitor) for mutations in the RAS /RAF/MEK  pathway  (no 
longer an active study drug as of March 2018)  
 
Treatment ex ceptions are also listed in Section 3.3 .  The following patients will not receive 
certain treatments on this protoc ol: 
1) Patients with ovarian cancer and B RCA mutations must have received specific PARP 
inhibitor therapy.   
 
2) Patients with treatment -related AML (t -AML)/MDS , or with features suggestive of 
AML/MDS, or who have had prior allogeneic bone marrow transplant or d ouble umbilical cord 
blood transplantation , should not receive Veliparib due to reports of MDS and leukemia 
secondary to oncology therapy on CTEP -sponsored studies utilizing Veliparib.  
 
Information on whether a mutation(s)  of interest was detected for a given  patient  as well as what 
drugs are allowed for assignment of a treatment regimen will be provided to the study team; t he 
Biopsy Sequencing Results and Analysis  Form ( Appendix F ) will be provided to  the clinician .  
 
Arm  A:  Targeted treatment based on the detected genetic mutation  will be assigned.  
Mutations will be reported based on their presence in tumor cells and the percent of cells 
demonstrating the pre -defined mutation (as allele frequency ).   
 
At the time of disease progression  for all targeted  therapy  patients , an optional tumor biopsy may 
be collected to asses s for new acquired mutations ; this biopsy may instead be collected on day 1 
(± 2 days) of the cycle following any restaging at which a 10 -19% increase in tumor volume is 
observed (per RECIST  criteria) if the patient has been on study for at least 4 cycles.  
 
No more than 3 tumor  biops y procedures will be performed : one mandatory at baseline, one 
CTEP #9149 (01 -07-2020 ) 
 
33 
 optional repeat biopsy if sufficient tumor DNA cannot be isolated at baseline, and one optional 
biopsy at or near  time of disease progression  to assess for new acquired mutations .  
5.3 Agent Administration  
5.3.1 Veliparib  plus Temozolomide  
The Veliparib  dose of 40 m g BID on days 1-7 with temozolomide administered 
150 mg/m2 po QD days 1 -5 in 28 -day cycles was selected based on clinical results 
presented at ASCO  [77] [78].  The dose of temozolomide is based on BSA  then rounded 
off to the nearest [ADDRESS_1005352] elapsed, they should be 
instructed to skip the dose for that day.  The next day, they should take everolimus at the 
usual time ; patients should not take [ADDRESS_1005353] received live, attenuated 
vaccines (e.g.,  intranasal influenza).   
5.3.[ADDRESS_1005354] 
be taken  while fasting (water is permitted) [ADDRESS_1005355] two hours before or two hours after a meal.  
Carboplatin (AUC 5)  will be administered IV on day 1 of every cycle  over 30 -60 minutes 
concomitantly  with AZD 1775 ; the cycle length is [ADDRESS_1005356], ondansetron (Zofran) 8 mg PO BID or granisetron (Kytril) [ADDRESS_1005357] may be 
given by [CONTACT_735886].  Promethazine (Phenergan), prochlorperazine (Compazine), and 
benzodiazepi[INVESTIGATOR_735818]1775 
therapy.   Please note: aprepi[INVESTIGATOR_053] (Emend) and fosaprepi[INVESTIGATOR_252366] t are not permitted due to 
known DDIs.  
CTEP #9149 (01 -07-2020 ) 
 
34 
 5.4 General Concomitant Medication and Supportive Care Guidelines :  
All patients will be provided with the best available supportive care.  All concurrent medications 
should be documented prior to initiation of treatment and be periodically reviewed with the 
patient.  Particular attention must be paid to medications which may prolong the QTc interval 
(Appendix C ) and agents that interact with CYP450 isoenzymes or are PgP inhibitors  (Appendix 
B).  
 
Nausea/Vomiting : Nausea and vomiting will be considered refractory if they do not resolve to ≤ 
Grade [ADDRESS_1005358] 2 antiemetics.   Concomitant treatment with 
aprepi[INVESTIGATOR_735819]1775 because of potential drug-drug 
interaction.  
 
Diarrhea : If diarrhea develops and does  not have an identifiable cause other than  study drug 
administration , loperamide [ADDRESS_1005359] unformed stool with 2 mg po  
every 2 hours as long as unformed stools continue (4 mg every 4 hours while asleep).   This 
regimen can be rep eated for each diarrheal epi[INVESTIGATOR_1865] .  Diarrhea will be considered refractory if it 
does not resolve within 24 hours to ≤ Grade  1 with the above regimen (total of 16 mg of 
loperamide a day) .  If the patient develops blood or mucus in the stool, dehydration, or  
hemodynamic instability, or fever along with the diarrhea, loperamide will be discontinued and 
the patient will be treated with IV fluids and antibiotics as medically indicated.   
 
Seizures : Seizures  were seen in some animal toxicology studies  with Velipa rib, although at 
doses much higher than those anticipated for this study.  Seizures in animals were successfully 
treated with lorazepam .  Therefore, lorazepam should be considered as a possible first choice for 
controlling seizures, should they occur on this study .  All patients experiencing a seizure on 
study need to be evaluated (e.g., imaging of the brain) to determine the cause.  
 
Anemia : Symptomatic anemia should be treated with red blood cell transfusion and is 
recommended if the hemoglobin falls below 8 mg/dL.  Use of erythropoietin is allowed per 
accepted guidelines.  
 
Thrombocytopenia : Thrombocytopenia will be treated conservatively.  In the absence of 
bleeding, fever, or a necessary invasive procedure, platelet transfusions should be give n for a 
platelet count below 10,000/µL (mcL).  If the patient is febrile, platelet transfusions should be 
given for a platelet count below 20,000/µL (mcL).  If an invasive procedure is planned or the 
patient develops bleeding, platelet transfusions should be administered in accordance with 
standard of practice, usually maintaining a platelet count above 50,000/µL (mcL).  
 
Neutropenia : Febrile neutropenia is a life -threatening complication requiring hospi[INVESTIGATOR_623207] -spectrum antibiotics, as we ll as an aggressive search for the source and microbial 
cause of the epi[INVESTIGATOR_1865] .  If clinically indicated , filgastrim may be initiated for Grade 4 neutropenia 
at the study investigator’s discretion .  Study medications will not be reinitiated until at least 
24 hours after filgastrim administration.  
 
CTEP #9149 (01 -07-2020 ) 
 
35 
 Reflux/Gastritis : Antacids and other anti -ulcer medications such as histamine H2 -receptor 
antagonists may be used if clinically indicated.  To avoid significantly altering  gastric pH, when 
needed, these medications should be used 4 hours after study drug administration.   
 
Skin Rash : Appropriate clinical management of skin rash may be utilized as clinically indicated.  
Patients will be allowed to use to pi[INVESTIGATOR_39669], topi[INVESTIGATOR_8826], antihistamine agents, and 
topi[INVESTIGATOR_282915].  A suggested step -wise approach follows:  
• Grade 1 rash: Start  with topi[INVESTIGATOR_8826] (e.g.,  hydrocortisone, triamcinolone acetonide) , 
topi[INVESTIGATOR_735820], or no treatment if the patient is asymptomatic.  
Use of topi[INVESTIGATOR_735821].  
• Grade 2 rash: Topi[INVESTIGATOR_6702] , consider addition of an oral antibiotic (e.g. , 
minocycline 100 mg PO BID ) or a similar agent.  
• Grade 3 rash that does not respond to our measures: Dose interruption and/or dose 
reduction, in  addition to supportive care as above.   
• Pruritus of any grade may be treated with an antihistamine, such as diphenhydramine or 
hydroxyzine hydroc hloride.  
• Xerosis can be treated with classical emollients.  
 
Hyperglycemia : Blood glucose home monitoring will be initiated in patients with persistently 
elevated fasting glucose (> 160 mg/dL, CTCAE Grade ≥ 2).   Appropriate clinical management 
including ora l anti -hyperglycemic medication or insulin, and supportive care (e.g., electrolyte 
management and hydration) will be provided as clinically indicated.  
5.5 Definition of Off -Study Parameters  
In the absence of treatment delays due to adverse events, treatment m ay continue per protocol  
until one of the following criteria applies:  
• Disease progression   
• Intercurrent illness that prevents further administration of treatment,  
• Patient requires more than 2 dose reductions  (see Section 6.0 )  
At which point, the patient is taken off that particular treatment.   
 
Duration of T herapy on MPACT  Study:  
• Pre-defined mutation is not identified   
• Disease progression   
• All treatment regimens on study specifi c for the patient’s mutation(s)  of interest have 
been exhausted   
• Intercurrent illness that prevents further administration of treatment,  
• Patient receives any other investigational agent or anticancer therapy  
• Patient decides to withdraw from the study . 
At which point, the patient is taken off the MPACT study.   
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005360] dose is administered or until one of the following occurs: patient enrolls on 
another  protocol, patient  receives standard of care, or death, whichever comes first.  The follow -
up will consist of a phone call between Days [ADDRESS_1005361] dose to evaluate adverse events 
that were ongoing and any new events that might be deemed related to the therapy.  
Unacceptable toxicities (i.e., AEs related to the intervention) that have not resolved by [CONTACT_2006] [ADDRESS_1005362] study for one of the following reasons:  
• mutation  of interest not detected on pre -treatment biopsy   
• inability to obtain pre -treatment biopsy on study  
• completion of 3 0-day follow -up period  
• toxicities are unresolved but stabilized  
• patient enrolls on another  protocol  
• patient receives standard of care    
• pregnancy  
• death  
 
The reason for study removal and the date the patient was removed must be documented in the 
medical record.  
 
6. DOSING DELAYS/DOSE MODIFICATIONS  
6.[ADDRESS_1005363] resolved to ≤ Grade 1 (except electrolyte abnormalities, 
which should resolve to ≤ Grade 2) and hematologic toxicities to ≤ Grade 2 (except 
lymphopenia) prior to starting the next cycle .  Doses of study drugs will not  be held or reduced 
for a ny grade of lymphopenia.  The treatment day count will continue through days when doses 
are held.  A new cycle will not start until the patient starts dosing on the next cycle.   Treatment 
may be delayed for toxicity a maximum of 2  weeks beyond the actual cycle length; in case 
toxicities do not resolve as defined above, the patient will not receive further treatment with that 
regimen and will receive no further therapy on this protocol and will be followed for resoluti on 
of toxicities.   Patients will be allowed up to 2 dose reductions  before being taken off a treatment 
regimen .   
 
For the purp oses of dose reduction , the follow ing dose levels will be used :  
 
Drug  Dose and Schedule  Dose Level -1 Dose Level -2 
Veliparib :  
Temozolomide : 40 mg po BID d1-7 
150 mg/m2 po qd d1-5  20 mg po BID d1-7 
150 mg/m2 po qd d1 -5 20 mg po BID d1-7 
100 mg/m2 po qd d1 -5 
 
CTEP #9149 (01 -07-2020 ) 
 
37 
 Drug  Dose and Schedule  Dose Level -1 Dose Level -2 
AZD1775 : 
Carboplatin : 225 mg po BID x5 doses  
AUC5 IV d1 175 mg po BID  x5 doses  
AUC 5 IV d1  175 mg po BID x5 doses  
AUC 4 IV d1  
 
Everolimus : 10 mg po qd 5 mg po qd  2.5 mg po qd 
 
Trametinib DMSO : [ADDRESS_1005364] resolved to Grade ≤ 1 (except electrolyte abnormalities, 
which should resolve to Grade ≤ 2) and hematologic toxicitie s should have resolved to grade 2 or 
less prior to starting the next cycle.  Doses will not be held or changed for alopecia, any grade 
lymphopenia, leucopenia in the absence of neutropenia, nausea/vomiting/diarrhea (unless it is 
refractory to palliative tr eatment), or electrolyte abnormalities .  Patients receiving Veliparib who 
have persistent myelosuppression should be evaluated for the possible development of 
AML/MDS using a bone marrow aspi[INVESTIGATOR_54877]  (Section 6.4).   
6.1.1 Grade 2 Drug -Related Toxicity:  No changes will be made to the study treatment  
for Grade 2 toxicities.  
6.1.2 Grade 3 -4 Drug -Related Non -Hematologic Toxicities:  Doses will be held until 
toxicities recover to Grade ≤ 1 (with the exception of electrolyte abnormalities  
which should resolve to grade 2 or less ; no dose adjustments will be made for 
electrolyte abnormalities ) prior to re -initiating therapy at the next l ower dose 
level .   
6.1.3 Grade 3 Drug -Related Hematologic Toxicities: Doses will be held until 
hematolo gic toxicities (except lymphopenia, leucopenia in the absence of 
neutropenia) have resolved to Grade  ≤ 2 or baseline  prior to re -starting study 
treatment.  The rapy will be re -initiated at the same dose level.  
6.1.4 Grade 4 Drug -Related Hematologic Toxicities:  Doses will b e held until 
hematologic toxicities (except lymphopenia, leucopenia in the absence of 
neutropenia) have resolved to ≤  Grade  2 or baseline  prior to r e-starting study 
treatment.  Therapy will be re -initiated at the next lower dose level .  
 
6.2 Agent -specific Dose Modifications: Trametinib DMSO  
6.2.[ADDRESS_1005365] been observed in patients receiving tra metinib, and can be caused by 
[CONTACT_735887][INVESTIGATOR_70341] (RPED) or Retinal Vein Occlusion (RVO).   
Patients are required to have a standard ophthalmic exam performed by [CONTACT_735888] , at the start of cycle 2,  and any time patien ts report visual 
disturbance.  The exam will include best corrected visual acuity, visual field examination, 
tonometry, slit lamp biomicroscopic examination, and indirect fundoscopy .  Optical 
coherence tomography may be performed at scheduled visits and if  retinal abnormalities 
CTEP #9149 (01 -07-2020 ) 
 
38 
 are suspected.  Other types of ancillary testing including visual field examination, fundus 
photography, and fluorescein angiography may also be indicated as determined by 
[CONTACT_461].  Special attention should be given to retinal (e.g., RPED) or retinal vein 
abnormalities (e.g., RVO).   
 
Guidelines regarding event management and dose reduction for visual changes 
considered to be related to study treatment are provided in the table below.  
  
CTEP #9149 (01 -07-2020 ) 
 
39 
 Management and Trametinib Dose Modification for Visual Changes  
and/or Ophthalmic Examination Findings  
Event  
CTCAE Grade  Management Guideline  Dose Modification  
Grade 1*  
 
 • Consult ophthalmologist 
within 7 days of onset.  
 • If dilated fundus examination cannot be performed within [ADDRESS_1005366]/ophthalmologist.  
• If RPED and RVO excluded, continue/or restart trametinib at 
same dose level.  
• If RPED suspected/diagnosed:  See RPED dose modification 
table below (follo wing this table); report as SAE . 
• If RVO diagnosed:  Permanently discontinue trametinib 
and report as SAE . 
Grade 2 and 
Grade 3  
 • Consult ophthalmologist 
immediately.  
 • Hold trametinib  
• If RPED or RVO excluded, restart trametinib at same dose 
level after visual AE is < grade 1.  If no recovery within 3 
weeks, discontinue trametinib  
• If RPED diagnosed:  See RPED dose modification table 
below; report as SAE . 
• If RVO:  Permanently discontinue trametinib and report 
as SAE . 
Grade 4  
 • Consult ophthalmologist 
immediately.  
• Report as SAE.  • Hold Trametinib  
• If RPED/RVO excluded, may restart trametinib at same or 
reduced dose after discussion with the CTEP Medical 
Monitor.  
• If RVO or RPED, permanently discontinue trametinib . 
Abbreviations: RPED = retinal pi[INVESTIGATOR_70341] ; RVO = retinal vein occlusion; SAE = serious 
adverse event  
*If visual changes are clearly unrelated to study treatment (e.g., allergic conjunctivitis), monitor closely but 
ophthalmic examination is not required.  
 
 
Trametinib Dose Modification for RPED  
Event  
CTCAE Grade  Action and Dose Modification  
Grade 1 RPED  (Asymptomatic; 
clinical or diagnostic observations 
only)  • Continue treatment with retinal evaluation monthly until resolution.  If 
RPED worsens, follow instructions below.  
Grade 2 -3 RPED  (Symptomatic 
with mild to moderate decrease in 
visual acuity; limiting instrumental 
ADL)  • Interrupt trametinib.  
• Retinal evaluation monthly.  
• If improved to ≤ Grade 1, restart trametinib with one dose level reduction 
(reduced by 0.5 mg) or discontinue in patients taking trametinib 1 mg 
daily.  
• If no recovery within 4 weeks permanently discontinue trametinib  
 
6.2.2 Rash  
Rash is a frequent AE observed in patients receiving trametinib DMSO (Investigator’s 
Brochure, 2012).  Recommendations for supportive care and guidelines for dose 
modifications for rash are based on experience with other MEK inhibitors and EGFR 
inhibitors [79, 80].  
  
CTEP #9149 (01 -07-2020 ) 
 
40 
 Guidelines for Supportive Care of Rash  
Type of Care  Action  
Prevention/Prophylaxisa 
 • Avoid unnecessary exposure to sunlight.  
• Apply broad -spectrum sunscreen (containing titanium dioxide or zinc oxide) 
with a skin protection factor (SPF) ≥[ADDRESS_1005367] twice daily.  
• Use thick, alcohol -free emollient cream (e.g., glycerine and cetomacrogol 
cream) on dry areas of the body at least twice daily.  
• Topi[INVESTIGATOR_190722], start ing 
on Day [ADDRESS_1005368], and upper back.   
• Use mild -strength topi[INVESTIGATOR_27560] (hydrocortisone 1% cream) or topi[INVESTIGATOR_15877] (e.g., clindamycin) or oral antibiotics (e.g., doxycycline 100 mg 
BID, minocycline 100 m g BID).  
Symptomatic Careb 
 • Pruritic  lesions:  Cool compresses and oral antihistamine therapi[INVESTIGATOR_014].  
• Fissuring lesions:  Monsel’s solution, silver nitrate, or zinc oxide cream.  
• Desquamation:  Thick emollients and mild soap.  
• Paronychia:  Antiseptic bath, local potent corticosteroids in addition to 
antibiotics; if no improvement, consult dermatologist or surgeon.  
• Infected lesions:  Appropriate bacterial/fungal culture -driven systemic or 
topi[INVESTIGATOR_8163].  
a Rash prophylaxis is recommended for the first 6 weeks of study treatment.  
b Patients who develop rash/skin toxicities should be seen by a qualified physician and should receive evaluation 
for symptomatic/supportive care management.  
 
 
Trametinib DMSO Dose Modification Guidelines and Management for Rash  
Rash Severity  Management Guideline  Dose Modification  
Grade 1  
 • Initiate prophylactic and 
symptomatic treatment measures.1 
• Use moderate strength topi[INVESTIGATOR_159811].2 
• Reassess after 2 weeks.  • Continue trametinib.  
• If rash does not recover to baseline within [ADDRESS_1005369] supportive care, reduce trametinib 
DMSO by [CONTACT_30560] .3 
Grade 2  
 • Initiate prophylactic and 
symptomatic treatment measures.1 
• Use moderate strength topi[INVESTIGATOR_159811].2 
• Reassess after 2 weeks.  
 • Reduce trametinib by [CONTACT_30560].  
• If rash recovers to ≤ grade 1 within 2 weeks, 
increase dose to previous dose level.  
• If no recovery to ≤ grade 1 within 2 weeks, 
interrupt trametinib until recovery to ≤ grade 1.  
• Restart trametinib at reduced dose level.3 
Grade ≥3  
 • Use moderate strength topi[INVESTIGATOR_190723] -
prednisolone dose pack.2 
• Consult dermatologist.  • Interrupt trametinib until rash recovers to ≤ grade 1.  
• Restart with trametinib reduced by [CONTACT_37387].3,4 
• If no recovery to ≤ grade [ADDRESS_1005370] 6 weeks of study treatment.  
2.  Moderate -strength topi[INVESTIGATOR_8826]:  Hydrocortisone 2.5% cream or fluticasone priop ionate 0.5% cream.  
3.  Approval of CTEP Medical Monitor is required to restart study treatment after >4 weeks of interruption.  
4.  Trametinib may be escalated to previous dose level if no rash is evident 4 weeks after restarting study treatment.  
 
 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005371] occurred in patients receiving trametinib DMSO 
(Investigator’s Brochure, 2012).  Other frequent causes may include concomitant 
medications (e.g., stool softeners, laxatives, antacids, etc.), infections by C. difficile  or 
other pathogens, or partial bowel obstruction.  Those conditions should be excluded.  
Guidelines regarding management and dose modification for diarrhea considered related 
to trametinib are provided in the table below.  
Management and Trametinib DMSO Dose M odification Guidelines for Diarrhea  
CTCAE Grade  Adverse Event Management  Action and Dose Modification  
Uncomplicated 
Diarrhea,1 
Grade 1 or 2  • Diet:   Stop all lactose containing products; eat 
small meals, BRAT -diet (banana, rice, apples, 
toast) recommended.  
• Hydration:  8-10 large glasses of clear liquids 
per day (e.g., Gatorade or broth).  
• Loperamide3:  Initially 4 mg, followed by 2 mg 
every 4 hours or  after every unformed stool; 
maximum 16 mg/day.  Continue until  diarrhea -
free for 12 hours.  
• Diarrhea  >24 hours :  Loperamide  2 mg every 2 
hours; maximum 16 mg/day.  Consider adding 
oral antibiotics.  
• Diarrhea  >48 hours :  Loperamide  2 mg every 2 
hours; maximu m 16 mg/day.  Add  budesonide  
or other second -line therapi[INVESTIGATOR_014] (otreotide , or 
tincture of opi[INVESTIGATOR_1890]) and oral antibiotics.  • Continue trametinib DMSO.  
• If diarrhea  is grade 2 for > 48 h,  
interrupt trametinib until  diarrhea  
resolves to grade ≤1.  
• Restart trametinib at the same dose 
level  
• If treatment delay is > 1 4 days, 
discontinue trametinib.  
Uncomplicated 
Diarrhea,1 
Grade 3 or 4  
 
Any Complicated 
Diarrhea2 
 • Clinical evaluation mandatory.  
• Loperamide3:  Initially 4 mg, followed by 2  mg 
every 4 hours or after every unformed stool; 
maximum 16 mg/day.  Continue until diarrhea -
free for 12 hours.  
• Oral antibiotics and second -line therapi[INVESTIGATOR_681783]  
• Hydration:  Intravenous fluids if clinically 
indicated.  
• Antibiotics  (oral or intravenous) if clinically 
indicated.  
• Intervention should be continued until the 
subject is diarrhea -free for ≥24 hours.  
• Intervention may require hospi[INVESTIGATOR_681784] -threatening 
complications.  • Interrupt trametinib until diarrhea 
resolves to ≤ grade 1.  
• Restart with trametinib reduced by [CONTACT_23615].4 
• If 3 dose reductions of study treatment 
are clinically indicated, permanently 
discontinue trametinib DMSO . 
• If treatment delay is >21 days, 
discontinue trametinib.  
1.  Uncomplicated diarrhea  defined by [CONTACT_190771][INVESTIGATOR_007], nausea/vomiting, ≥ grade 2, 
decreased performance status, pyrexia, sepsis, neutropenia ≥ grade 3, frank bleeding, and/or dehydration requiring 
intravenous fluid substitution.  
2.  Complicated diarrhea  defined by [CONTACT_190772][INVESTIGATOR_007], nausea/vomiting, ≥ grade 2, 
decreased performance status, pyrexia, sepsis, neutropenia ≥ grade 3, frank bleeding, and/or dehydration requiring 
intravenous fluid substitution.  
3.  Loperamide should be made  available prior to start of study treatment so loperamide administration can begin at 
the first signs of diarrhea.  
4.  Escalation of trametinib to previous dose level is allowed after consultation with the medical monitor and in the 
absence of another epi [INVESTIGATOR_190721] 4 weeks subsequent to dose reduction.  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005372] Abnormalities  
Event  Treatment modifications and assessment/monitoring  
ALT ≥3x ULN but <5x ULN 
and TB <2x ULN, without 
symptoms considered related 
to liver injury or 
hypersensitivity and who can 
be monitored weekly for 4 
weeks  
 May continue study drug.  
Report as SAE if CTEP -AERS reporting criteria are met. 
If liver chemistry stoppi[INVESTIGATOR_485166], proceed as 
described below.  
 
MONITORING:  
Repeat LFT (ALT, AST, ALK, bilirubin) until they return to 
normal/baseline or stabilise (LFT may be every 2 weeks after 4 weeks 
if ALT <3x ULN and TB <[ADDRESS_1005373]).  
Criteria for discontinuing study  
drug:  When any of the liver 
stoppi[INVESTIGATOR_735822], 
discontinue trametinib   
 
ALT ≥3xULN and bilirubin 
≥2x ULN or >35% direct 
bilirubin 1, 2 
ALT  3xULN and INR >1.5, 
if INR measured2 (INR 
threshold does not apply if 
subject is on anticoagulant)  
ALT ≥5x ULN  
ALT ≥3x ULN persists for 4 
weeks  
ALT ≥3x ULN and cannot be 
monitored weekly for 4 weeks  
ALT ≥3x ULN associated with 
symptoms3 (new or worsening) 
believed to be related to liver 
injury or hypersensitivity  
 
 Immediately discontinue study treatment.  
Do not restart/rechallenge unless approved by [CONTACT_485191].   
Report as SAE if:  1) CTEP -AERS reporting criteria ar e met, or 2) 
patients meet criteria 1 -2. 
Perform liver event ASSESSMENT AND WORKUP (see below).  
Monitor the subject until liver chemistries resolve, stabilize, or return to 
baseline (see MONITORING below).  
If applicable, provide details on required follow up assessments (e.g., 
follow up for overall survival or disease recurrence or progression).   
 
MONITORING:  
In patients stoppi[INVESTIGATOR_485168] 1 -2 (with abnormal TB and INR, 
indicating potentially more signif icant liver toxicities):  
Repeat liver chemistries (ALT, AST, ALK, bilirubin) and perform liver 
event follow -up assessments within 24 hours.  
Monitor subjects twice weekly until LFT return to normal/baseline or 
stabilize.  
A specialist or hepatology consultat ion is recommended.  
In patients stoppi[INVESTIGATOR_485168] 2 -6: 
Repeat LFT and perform liver event follow up assessments within   
24-72 hrs  
Monitor subjects weekly until LFTs return to normal/baseline or 
stabilize.  
 
ASSESSMENT and WORKUP:  
Viral hepatitis serology.4 
If possible, obtain blood sample for PK analysis.5 
Serum CPK and LDH.  
Fractionate bilirubin, if total bilirubin ≥2x ULN.  
CBC with differential to assess eosinophilia.  
Record clinical symptoms of liver injury, or hypersensitivity on AE 
CRF.  
Record concomitant medications (including acetaminophen, herbal 
remedies, other over the counter medications) . 
Record alcohol use.  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005374] Abnormalities  
Event  Treatment modifications and assessment/monitoring  
Additional work up for patient stoppi[INVESTIGATOR_485168] 1 -2 (with abnormal 
TB and INR, indicating potentially more signific ant liver toxicities) : 
Anti-nuclear antibody, anti -smooth muscle antibody, Type 1 anti -liver 
kidney microsomal antibodies, and quantitative total immunoglobulin G 
(IgG or gamma globulins).  
Serum acetaminophen adduct HPLC assay (in subjects with likely 
acetaminophen use in the preceding).  
If there is underlying chronic hepatitis B (e.g. positive hepatitis B 
surface antigen):  quantitative hepatitis B DNA and hepatitis delta 
antibody.6 
Liver imaging (ultrasound, MRI, CT) and /or liver biopsy.  
Footnotes:  
1.  Serum bilirubin fractionation should be performed if testing is available.   If serum bilirubin 
fractionation testing is unavailable, record presence of detectable urinary bilirubin on dipstick, which 
indicates direct bilirubin elevations and suggesting liver injury.  
2.  All events of ALT ≥3xULN and bilirubin ≥2xULN (>35% direct b ilirubin) or ALT 3x ULN and 
INR >1.5 (if INR measured) may indicate severe liver injury (possible “Hy’s Law”).  INR measurement 
is not required, and the threshold value stated will not apply to subjects receiving anticoagulants.  
3.  New or worsening sympt oms believed to be related to liver injury (such as fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such 
as fever, rash , or eosinophilia)  
4.  Includes: Hepatitis A IgM antibody ; Hepatitis B surface antigen and Hepatitis B Core Antibody 
(IgM); Hepatitis C RNA ; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM 
antibody (or if unavailable, obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody  
5.  PK sample is desired if feasible.  Record the date/time of the PK blood sample draw and the 
date/time of the last dose of study treatment prior to blood sample draw on the CRF.  If the date or time 
of the last dose is unclear, provide the subject’s be st approximation.  If the date/time of the last dose 
cannot be approximated OR a PK sample cannot be collected in the time period indicated above, do not 
obtain a PK sample.   
6.  If hepatitis delta antibody assay cannot be performed, it can be replaced wi th a PCR of hepatitis D 
RNA virus (where needed) (Le Gal et al. , 2005).  
 
6.2.5 Pneumonitis  
Pneumonitis has been observed in patients receiving trametinib DMSO.  To reduce the 
risk of pneumonitis, patients will be monitored closely for symptoms and evaluated with 
imaging and functional tests.  Dose modification and supportive care guidelines for 
pneumonitis are described in the tables below.  
 
 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005375] scan (high -resolution with lung windows) 
recommended.  
Work -up for infection.  
Monitoring of oxygenation via pulse -
oximetry  recommended.  
 Consultation with pulmonologist 
recommended.  Continue trametinib at current dose.  
Grade [ADDRESS_1005376] scan (high -resolution with lung 
windows).  
Work -up for infection.  
Consult pulmonologist.  
Pulmonary function tests:  If < normal, repeat 
every 8 weeks until ≥ normal.  
Bronchoscopy  with biopsy and/or BAL 
recommended.  
Symptomatic therapy including 
corticostero ids if clinically indicated.  Interrupt trametinib until recovery to 
grade ≤1.  
Restart treatment with trametinib 
reduced by [CONTACT_735889] 4 weeks may be considered 
after consultation with medical 
monitor  
If no recovery to grade ≤1 within 4 
weeks, permanently discontinue 
trametinib  
Grade 3  Same as grade 2  Interrupt trametinib until recovery to 
grade ≤1.  
After consultation with medical 
monitor, trametinib may be restarted 
reduced by [CONTACT_735890] ≤1 within 4 
weeks, permanently discontinue 
trametinib  
Grade 4  Same as grade 2 Permanently discontinue trametinib.  
Abbreviations:  BAL = bronchoalveolar lavage; CT = computed tomography.  
 
6.2.6 Reduced Left Ventricular Ejection Fraction (LVEF)  
Decreases of LVEF have been observed in patients receiving trametinib DMSO.  
Therefore, ECHOs must be performed in regular intervals outlined in the Study Calendar.   
The same procedure (either ECHO or MUGA, although ECHO  is prefer red) should be 
performed at baseline , every three cycles, and as clinically indicated .   
  
CTEP #9149 (01 -07-2020 ) 
 
45 
 Trametinib Dose Modification Guidelines and Stoppi[INVESTIGATOR_190726] -drop (%) or  
CTCAE grade  Action and Dose  
Modification  
Asymptomatic  
 Absolute decrease of >10% in 
LVEF compared to baseline 
and ejection fraction below the 
institution’s LLN.  • Interrupt trametinib and repeat ECHO /MUGA  within 2 
weeks.a 
• If the LVEF recovers  within 4 weeks (defined as LVEF 
≥LLN and absolute decrea se ≤10% compared to baseline):  
− Consult with the CTEP trametinib medical monitor and 
request approval for restart.  
− Restart treatment with trametinib at reduced dose by [CONTACT_23615].  
− Repeat ECHO /MUGA  2, 4, and 12 weeks after re -start; 
continue in intervals  of 12 weeks thereafter.  
• If LVEF does not  recover within 4 weeks:  
− Consult with cardiologist.  
− Permanently discontinue trametinib.  
− Repeat ECHO /MUGA  after 2, 4, 8, 12, and 16 weeks or 
until resolution.  
− Consult with the CTEP trametinib medical monitor.c 
Symptomaticb 
 • Grade 3:  resting LVEF 39 -
20% or >20% absolute 
reduction from baseline  
• Grade 4:  Resting LVEF 
≤20%.  • Permanently discontinue trametinib.  
• Report as SAE.  
• Consult with cardiologist.  
• Repeat ECHO after 2, 4, 8, 12, and 16 weeks or until 
resolution.  
a If ECHO /MUGA  does not show LVEF recovery after 2 weeks, repeat ECHO /MUGA  2 weeks later.  
b Escalation of trametinib to previous dose level can be considered if LVEF remains stable for 4 weeks after 
restarting of trametinib.  Approval from the CTEP trametinib medical monitor is required.  
c Symptoms may include:  dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema  
 
6.2.7 QTc Prolongation  
 
Trametinib Withholding and Stoppi[INVESTIGATOR_485169]  
• QTcB ≥501 msec, or  
• Uncorrected QT >600 msec, or  
• QTcB >530 msec for subjects with 
bundle branch block  
 • Interrupt study treatment until QTcB prolongation resolves to grade 1 or 
baseline.  
• Test serum potassium, calcium, phosphorus, and magnesium.  If 
abnormal, correct p er routine clinical practice to within normal limits.  
• Review concomitant medication usage for a prolonged QTc.  
• Restart at current dose level.b 
• If the event does not resolve or recurs after restarting, permanently 
discontinue study treatment.  
Abbreviations:  msec = milliseconds; QTcB = QT interval on electrocardiogram corrected using Bazett’s formula  
a Based on average QTc value of triplicate ECGs.  For example, if an ECG demonstrates a prolonged QT interval, 
obtain two or more ECGs over a brie f period, and then use the averaged QTc values of the three ECGs to 
determine if study treatments should be interrupted or discontinued.  
b if the QTc prolongation resolves to grade [ADDRESS_1005377] will benefit from further treatment.  
 
CTEP #9149 (01 -07-2020 ) 
 
46 
 6.2.8 Hypertension  
Increases in blood pressure (BP) have been observed in patients receiving trametinib 
DMSO.  Recommendations for BP monitoring and management are provided below.  
 
Monitoring:   All BP assessments should be performed under the following optimal 
conditions:  
• The subject has been seated with back support, ensuring that legs are uncrossed and 
flat on the floor.  
• The subject is relaxed comfor tably for at least 5 minutes.  
• Restrictive clothing has been removed from the cuff area, and the right cuff has been 
selected.  
• The subject’s arm is supported so that the middle of the cuff is at heart level.  
• The subject remains quiet during the measurement.  
• In subjects with an initial BP reading within the hypertensive range, a second 
reading should be taken at least 1 minute later, with the two readings averaged to 
obtain a final BP measurement.  The averaged value should be recorded in the eCRF.  
• Persistent hypertension is defined as an increase of systolic blood pressure (SBP) 
>140 mmHg and/or diastolic blood pressure (DBP) >90 mmHg in three consecutive 
visits with blood pressure assessments from two readings as described above.   Visits 
to monitor  increased blood pressure can be scheduled independ ently  from the per -
protocol visits outlined in the study calendar.  Ideally, subsequent blood pressure 
assessments should be performed within 1 week.  
  
CTEP #9149 (01 -07-2020 ) 
 
47 
  
Management and Trametinib Dose Modification for Hype rtension  
Event  Management Guideline  Dose Modification  
Definitions used in the table:  
− Persistent hypertension:  Hypertension detected in two separate readings during up to three subsequent visits.  
− Well-controlled hypertension:  Blood pressure of SBP ≤140 mmHg and DBP ≤90 mmHg in two separate 
readings during up to three subsequent visits.  
− Symptomatic hypertension:  Hypertension associated with symptoms ( e.g., headache, light -headedness, 
vertigo, tinnitus, epi[INVESTIGATOR_735823]) that resolve after the blood 
pressure is controlled within the normal range.  
− Asymptomatic hypertension: SBP >140 mmHg and/or DBP >90 mmHg in the absence of the above symptoms.  
(Scenario A)  
• Asymptomatic and persistent SBP 
of ≥140 and <160  mmHg, or DBP 
≥90 and <100 mmHg,  
or 
Clinically significant increase in 
DBP of 20 mmHg (but still below 
100 mmHg).  • Adjust current or initiate new 
antihypertensive medication(s).  
• Titrate antihypertensive 
medic ation(s) during the next [ADDRESS_1005378] and go to scenario (B).  Continue trametinib at the current 
dose.  
(Scenario B)  
• Asymptomatic SBP ≥160 mmHg, 
or DBP ≥100  mmHg,  
or 
Failure to achieve well -controlled BP 
within 2 weeks in Scenario A.  • Adjust current or initiate new 
antihypertensive medication(s).  
• Titrate antihypertensive 
medication(s) during the next 2 
weeks to achieve well -controlled 
BP. • Interrupt trametinib if clinically 
indicated.  
• Once BP is well -controlled, restart 
trametinib reduced by [CONTACT_37387] .a 
(Scenario C)  
• Symptomatic hypertension  
or 
Persistent SBP ≥160 mmHg, or DBP 
≥100 mmHg, despi[INVESTIGATOR_485171]  • Adjust current or initiate new 
antihypertensive medication(s).  
• Titrate antihypertensive 
medication(s) during the next 2 
weeks to achieve well -controlled 
BP. 
• Referral to a specialist for further 
evaluation and follow -up is 
recommended.  • Interrupt trametinib.  
• Once BP is well -controlled, restart 
trametinib reduced by [CONTACT_37387] .a 
(Scenario D)  
Refractory hypertension 
unresponsive to above interventions 
or hypertensive crisis.  Continue follow -up per protocol.  Permanently discontinue 
trametinib . 
a. Escalation of trametinib to previous dose level can be considered if BPs remain well controlled for 4 weeks 
after restarting of trametinib.  Approval from Medical Monitor is required.  
 
6.3 Agent -specific Dose Modifications: Everolimus  
6.3.1 Hyperglycemia : Grade  2 or higher elevations in blood glucose with the patient 
non-fasting should be confirmed by [CONTACT_735891].  Grade 3 will result in temporary dose reduction, 
management with appropriate therapy, and re -initiation at a lower dose.   
CTEP #9149 (01 -07-2020 ) 
 
48 
 6.3.2 Hyperlipi[INVESTIGATOR_735824] : Grade 3  (measured by [CONTACT_735892])  will result in holding study drug until resolution of toxicity to 
Grade [ADDRESS_1005379] dose level.  Grade 4 elevation in either serum cholesterol or 
triglyceride levels will result in study drug discontinuation.  
6.3.3 Skin Toxicity:   For patients with grade [ADDRESS_1005380] be reported as an AE.  Patients with grade 
2 or higher toxicity may be treated with the following suggested supportive 
measures at the discretion of the investigator: oral minocycline, topi[INVESTIGATOR_735825], topi[INVESTIGATOR_47288], topi[INVESTIGATOR_2855] s ilver sulfadiazine, diphenhydramine, 
oral prednisolone (short course), topi[INVESTIGATOR_11930], or pi[INVESTIGATOR_031].  
6.3.4 Angioedema with concomitant use of angiotensin -converting enzyme (ACE) 
inhibitors: Patients taking concomitant ACE inhibitor therapy may be at 
increased risk for angioedema (e.g., swelling of the airways or tongue, with or 
without respi[INVESTIGATOR_88739]).  
Dosing Guidelines for > Grade [ADDRESS_1005381] everolimus treatment 
discontinued and will be taken off study.   
 
Co-administration with moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole) or 
PgP inhibitors should be used with caution.   If a patient requires co -administration of 
moderate CYP3A4 inhibitors or PgP inhibitors, reduce the dose of everolimus as 
specified in Section 6.0 .  If the inhibitor is discontinued, the Everolimus dose should be 
returned to the dose used prior to initiation of the moderate CYP3A4/PgP inhibitor after a 
washout period of [ADDRESS_1005382] or ALT elevation Grade 3  Interrupt Everolimus administration until resolution to ≤ grade 1 
(or ≤ grade 2 if baseline values were within the range of grade 
2).  If resolution o ccurs ≤ 7 days , Everolimus  should be re -
started at the dose level prior to interruption.  
If resolution takes > 7 days, or if event recurs within 28 days, 
hold Everolimus until recovery to ≤ grade 1 or baseline grade / 
value and reintroduce Everolimus at on e dose level lower, if 
available.  
CTEP #9149 (01 -07-2020 ) 
 
49 
 Intolerable grade 2 mucositis, or 
grade 3 AE  Interrupt Everolimus administration until resolution to ≤ grade 1 
or baseline grade / value.  
If resolution occurs within ≤ 7 days, Everolimus should be re -
started at the dose level prior to interruption.  
If resolution takes > 7 days, or if event recurs within 28 days, 
hold Everolimus until recovery to ≤ grade 1 or baseline grade / 
value and reintroduce Everolimus at one dose level lower, if 
available.  
Drug will be discontinued if patients fail to recover to  grade 1 
or baseline grade / value within 28 days.  
Recurrence of intolerable grade 2 
mucositis or grade 3 event after 
dose reduction  Reduce dose to the next lower dose level, if available.  If toxicity 
recurs at Grade 3, consider discontinuation  
Grade 3 clinical liver failure 
(asterixis or encephalopathy/coma)  Discontinue Everolimus  
Any non -hematologic toxicity 
requiring Everolimus in terruption 
for > 28 days  Discontinue Everolimus  
Dosing guidelines for Grade 3 Everolimus -related hematologic toxicities  
Grade 3 thrombocytopenia  Interrupt Everolimus until resolution to grade 1  
If resolution occurs ≤ 7 days, reintroduce Everolimus at the 
dose level prior to interruption.   If resolution occurs > 7 days, 
or event occurs within 28 days, reintroduce Everolimus at one 
dose level lower, if available.  
Grade 3 neutropenia or anemia  Interrupt Everolimus until resolution to grade ≤1 or baseline 
value .  If AE resolution occurs ≤ 7 days, reintroduce 
Everolimus at the same dose level.   If AE resolution occurs > 
7 days, or event occurs within 28 days, reintroduce 
Everolimus at one dose level lower, if available.  
Grade 4 neutropenia or anemia  Interrupt Everolimus until recovery to grade  1 or baseline 
value.  Reintroduce Everolimus at one  dose level lower, if 
available * 
Febrile neutropenia  Interrupt Everolimus  until resolution to grade  1 (or baseline 
value) and no fever.  Reintroduce Everolimus at one dose 
level lower, if available*  
Recurrence of grade 3 toxicity after 
dose reduction  Reduce dose to the next lower dose level, if available.    
Any hematologic toxicity requiring 
Everolimus interruption for > 28 days  Discontinue Everolimus  
 
Patients with a clinical history of stomatitis/mucositis/mouth ulcers and those with 
gastrointestinal morbidity associated with mouth/dental infections, irrit ation of esophageal 
mucosa such as gastroesophageal reflux disease (GERD) and pre -existing stomatitis/mucositis 
must be monitored even more closely.   Patients should be instructed to report the first onset of 
buccal mucosa irritation/reddening to their stu dy physician immediately.  
CTEP #9149 (01 -07-2020 ) 
 
50 
  
Management of stomatitis/oral mucositis/mouth  ulcers  
Grade 1 (Minimal 
symptoms, normal diet)  Manage with non -alcoholic or salt water (0.9%) mouth wash several times a 
day. 
Grade 2 (Symptomatic 
but can eat and swallow 
modified diet)  Temporary dose interruption until recovery to grade ≤1.  Manage with topi[INVESTIGATOR_735826] (e.g., benzocaine,  butyl aminobenzoate, tetracaine 
hydrochloride, menthol or phenol)  with or without topi[INVESTIGATOR_11930] (i.e. , 
triam cinolone oral paste  0.1% )*.  Re-initiate everolimus at the same dose .  If 
stomatitis recurs at grade 2, interrupt dose until recovery to grade ≤1.  Re -
initiate everolimus at a lower dose.  
Grade 3 (Symptomatic 
and unable to adequately 
eat or hydrate orally ) Temporary dose interruption until recovery to grade ≤1.  Manage with 
topi[INVESTIGATOR_032] (i.e., benzocaine,  butyl aminobenzoate, 
tetracaine hydrochloride, menthol or phenol) with or without topi[INVESTIGATOR_030] (i.e., triamcinolone oral paste  0.1% )* Re-initiate everolimus 
at lower dose.  
*Do not use agents containing alcohol, hydrogen peroxide, iodine, or thyme derivatives in management of 
stomatitis as they may worsen mouth ulcers . 
 
Non-infectious pneumonitis is a class effect of rapamycin derivatives.   Cases of non -infectious 
pneumonitis (including interstitial lung disease) have also been described in patients taking Everolimus.  
 
Management of non -infectious pneumonitis  
Worst grade  Suggested investigations  Management of pneumonitis  
Grade [ADDRESS_1005383] scans with lung windows.  No specific therapy is required ; initiate 
appropriate monitoring  
Grade [ADDRESS_1005384] scan with lung windows.   Consider 
pulmonary function testing includes: 
spi[INVESTIGATOR_038], DLCO, and room air O [ADDRESS_1005385].  Consider a bronchoscopy with biopsy 
and/or BAL. Monitoring at each visit until 
return to ≤ grade 1 .  Return to initial monitoring 
frequency if no recurren ce. Symptomatic only.   Consider corticosteroids 
and/or other supportive therapy if symptoms 
are troublesome.   Rule out infection and 
consider interruption of Everolimus until 
symptoms improve to Grade ≤ 1.   Re-initiate 
Everolimus  at one dose level lower.  
Discontinue Everolimus if failure to recover 
within ≤ [ADDRESS_1005386] scan with lung windows and pulmonary 
function testing includes: spi[INVESTIGATOR_038], DLCO, 
and room air O [ADDRESS_1005387].  Monitoring 
at each visit until return to ≤  grade 1.   Return to 
initial monitoring frequency if no recurrence.  
Bronchoscopy with biopsy and/or BAL is 
recommended.  Consider corticosteroids if infective origin is 
ruled out.  Taper as medically indicated.   
Interrupt Everolimus until symptoms improve 
to Grade ≤ 1.  Consider re -initiating 
Everolimus at one dose level lower.  
Discontinue Everolimus if failure to recover 
within ≤ [ADDRESS_1005388] scan with lung windows and r equired 
pulmonary function testing, if possible, 
includes: spi[INVESTIGATOR_038], DLCO, and room air O [ADDRESS_1005389].  Monitoring at each visit until 
return to ≤ grade 1.   Return to initial monitoring 
frequency if no recurrence.  Bronchoscopy with 
biopsy and/or  BAL is recommended if possible.  Consider corticosteroids if infective origin is 
ruled out.  Taper as medically indicated.   
Discontinue everolimus.   
CTEP #9149 (01 -07-2020 ) 
 
51 
 Note: Patients taking concomitant ACE inhibitor therapy may be at increased risk for 
angioedema (e.g., swelling of the airways or tongue, with or without respi[INVESTIGATOR_88739]).  
6.4 Agent -specific Dose Modifications: Veliparib  
If a patient taking Veliparib in combi nation with temozolomide develops bone marrow findings 
consistent with AML/MDS or severe persistent anemia, he or she may be allowed  to continue the 
other therapy  if they are experiencing clinical benefit and the toxicity is no t related to the other 
therapy , based on the opi[INVESTIGATOR_1237].   
 
Hematologic toxicities should have resolved to ≤ Grade 2 (except lymphopenia) prior to starting 
the next cycle.  Doses of study drugs will not be held or reduced for any grade of lymphopenia.  
Treatment may be delayed for toxicity a maximum of [ADDRESS_1005390] of care National Comprehensive Cancer 
Network (NCCN) and/or institutional guidelines, iron supplements, and/or transfusions as 
clinically  indicated for management of  anemi a.   Prescribing information for the er ythropoiesis 
stimulating  agents (including Aranesp, Epogen and Procrit) highlight that there is a potential risk 
of shortening the time to  tumor  progression or dis ease-free survival.   Primary  proph ylaxis with 
granuloc yte colon y-stimulating factor ( G-CSF) is not recommended .  Aranesp, Epogen and 
Procrit may not alleviate fatigue or increase energ y and should not be used in patients with 
uncontrolled h ypertension.  The package inserts for these agents should be consulted.  
 
If a patient develops febrile neutropenia,  Veliparib  should be stopped and appropriate 
management including G-CSF should be given according to local hospi[INVESTIGATOR_48799].    Please 
note that G -CSF should not be used within at least [ADDRESS_1005391] week ly until recover y; these data should be recorded in eCRF as 
extra laboratory  examinations.   If counts do not improve to CTCAE Grade  [ADDRESS_1005392] for fur ther 
assessment.    A bone marrow ana lysis should be considered.  
 
Management of anemia   
Anemia is a common adverse drug reaction related to Veliparib; m anagement of anemia is in 
accordance with the table below:  
 
CTCAE 
Grade  Definition  Dose  
3 Hb <8 g/dL Give appropriate supportive treatment and investigate causality.  
Interrupt veliparib  until improved to ≥  Grade 2 or baseline .  Upon 
recovery, therapy will be re -initiated at the same dose level.  
CTEP #9149 (01 -07-2020 ) 
 
52 
 CTCAE 
Grade  Definition  Dose  
4 
 Hb <8 g/dL  Give appropriate supportive treatment and investigate causality.  
Interrupt veliparib until improved to ≥ Grade 2 or baseline.  Upon 
recovery, dose reduce veliparib to 20 mg BID.  
BID = twice daily; Hb = hemoglobin  
 
Common treatable causes of anemia (e.g., iron, vitamin B12 or folat e deficiencies and 
hypothyroidism) should be investigated and appropriately  managed.   In some cases , management 
of anemia may  require blood transfusions.  Any  subsequently  required dose interruptions related to 
developme nt of anemia, or coexistent with new ly developed neutropenia, and/or 
thromboc ytopenia, will require veliparib dose reductions to 20 m g twice daily (BID) . 
 
If Hb drops to <8 g/ dL despi[INVESTIGATOR_735827], veliparib should be 
permanently  discontinued.  
 
Management of prolonged hematological toxicities while on study tr eatment   
If a patient develops prolonged hematological toxicit y such as:  
 
• ≥2-week  interruption/delay  in veliparib  due to CT CAE Grade ≥3 anemia (Hb <8 g/dL) and/or 
development of blood transfusion dependence  
 
• ≥2-week  interruption/delay  in veliparib due to CTCAE  Grade ≥3 neutropenia (ANC <1 x 109/L) 
 
• ≥2-week  interruption/delay  in veliparib  due to CTCAE Grade ≥3 thromboc ytopenia and/or 
development of platelet transfusion dependence (Platelets <50 x 109/L) 
 
Check  week ly differential blood counts including reticuloc ytes and peripheral blood smear.    If 
any blood parameters remain clini cally abnormal after [ADDRESS_1005393] 
hematological oncology pra ctice.    
 
Patients who d evelop MDS/AML  on treatment should discontinue veliparib treatment and be 
managed appropriate ly. 
 
7. ADVE RSE EVENTS: LIST AND REPORTING REQUIREMENTS  
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of AEs ( Section 7.1 ) and the characteristics of an observed AE ( Section 7.2 ) will 
CTEP #9149 (01 -07-2020 ) 
 
53 
 determine whether the event requires expedited  (via CTEP -AERS ) in addition  to routine  
reporting.   
7.1 Comprehensive Adverse Events and Potential Risks Lists (CAEPRs)  
7.1.[ADDRESS_1005394](s) for Commercial Agents  
Please refer to Section s 8.1 and 8.2 for adverse events related to carboplatin  and 
temozolomide.   
7.1.2 CAEPR for Veliparib  (NSC 737664)   
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform 
presentation of events by [CONTACT_6764].  In addition to the comprehensive list , a subset, the 
Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column and 
is identified with bold and italicized text.  This subset of AEs (SPEER) is a list of events that are 
protocol specific exceptions to expedited re porting to NCI (except as noted below).  Refer to the 
'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf  for 
further clarification.  Frequency is provided ba sed on 2310 patients.  Below is the CAEPR for 
ABT -888 (Veliparib).  
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses next to 
the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple 
investigational  agents and has an AE listed on different SPEERs, use the lower of the grades to 
determine if expedited reporting is required.  
 
Version 2.4, May 13, 2018  
 Adverse Events with Possible  
 Relationship to ABT -888 (Veliparib)  
 (CTCAE 5.0 Term)  
[n= 2310]    
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
 Anemia    Anemia (Gr 3)  
 Febrile neutropenia    Febrile neutropenia (Gr 3)  
GASTROINTESTINAL DISORDERS    
 Abdominal pain     
 Constipation    Constipation (Gr 2)  
 Diarrhea    Diarrhea (Gr 3)  
Nausea     Nausea (Gr 3)  
 Vomiting    Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
Fatigue     Fatigue (Gr 3)  
INVESTIGATIONS    
 Lymphocyte count decreased    Lymphocyte count decreased  
(Gr 4)  
 Neutrophil count decreased    Neutrophil count decreased (Gr 4)  
Platelet count decreased     Platelet count decreased (Gr 4)  
 Weight loss    Weight loss (Gr 2)  
 White blood cell decreased    White blood cell decreased (Gr 4)  
CTEP #9149 (01 -07-2020 ) 
 
54 
  Adverse Events with Possible  
 Relationship to ABT -888 (Veliparib)  
 (CTCAE 5.0 Term)  
[n= 2310]    
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
METABOLISM AND NUTRITION DISORDERS    
 Anorexia    Anorexia (Gr 2)  
 Dehydration    Dehydration (Gr 3)  
 Hypophosphatemia    Hypophosphatemia (Gr 3)  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND 
POLYPS)    
  Leukemia secondary to 
oncology chemotherapy    
  Myelodysplastic syndrome    
  Treatment related secondary 
malignancy    
NERVOUS SYSTEM DISORDERS    
 Dizziness     
 Dysgeusia    Dysgeusia (Gr 2)  
 Headache    Headache (Gr 3)  
  Seizure    
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
 Rash maculo -papular     
VASCULAR DISORDERS    
  Thromboembolic event2   
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412].   Your name, the name [CONTACT_6823], the protocol and the agent should 
be included in the e -mail.  
 
2Thromboembolic events, including deep vein thrombosis and pulmonary embolism, have been observed 
at a higher frequency compared to control arm when admini stered in combination with temozolomide.  
 
Adverse events reported on ABT -888 (Veliparib) trials, but for which there is insufficient evidence 
to suggest that there was a reasonable possibility that ABT -888 (Veliparib) caused the adverse 
event : 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Bone marrow hypocellular; Blood and 
lymphatic system disorders - Other (pancytopenia)  
CARDIAC DISORDERS  - Cardiac disorders - Other (Takotsubo cardiomyopathy); Heart failure; Left 
ventricular systolic dysfunction; Pal pi[INVESTIGATOR_814]; Sinus bradycardia; Sinus tachycardia  
EAR AND LABY[CONTACT_33993]  - Vertigo  
EYE DISORDERS  - Blurred vision  
GASTROINTESTINAL DISORDERS  - Abdominal distension; Ascites; Colitis; Colonic obstruction; 
Dental caries; Dry mouth; Duodenal ulcer; Dyspeps ia; Dysphagia; Enterocolitis; Esophagitis; Flatulence; 
Gastritis; Gastroesophageal reflux disease; Lower gastrointestinal hemorrhage; Mucositis oral; 
Obstruction gastric; Rectal hemorrhage; Rectal pain; Small intestinal obstruction  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Chills; Edema limbs; 
Fever; Flu like symptoms; Malaise; Non -cardiac chest pain; Pain  
HEPATOBILIARY DISORDERS  - Hepatic failure; Hepatobiliary disorders - Other (cirrhosis)  
CTEP #9149 (01 -07-2020 ) 
 
55 
 INFECTIONS AND INFESTATIONS  - Appendi citis; Catheter related infection; Infections and 
infestations - Other (peritonsillar abscess); Lung infection; Lymph gland infection; Mucosal infection; 
Sepsis; Shingles; Skin infection; Upper respi[INVESTIGATOR_4416]; Urinary tract infection  
INJURY, POISONI NG AND PROCEDURAL COMPLICATIONS  - Bruising; Dermatitis radiation; 
Radiation recall reaction (dermatologic)  
INVESTIGATIONS  - Alanine aminotransferase increased; Alkaline phosphatase increased; Aspartate 
aminotransferase increased; Blood bilirubin increased;  Cardiac troponin I increased; Creatinine increased; 
Electrocardiogram QT corrected interval prolonged; Lipase increased  
METABOLISM AND NUTRITION DISORDERS  - Hyperglycemia; Hypernatremia; 
Hypoalbuminemia; Hypocalcemia; Hypokalemia; Hypomagnesemia; Hyponatr emia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  - Arthralgia; Arthritis; Back 
pain; Bone pain; Generalized muscle weakness; Muscle cramp; Myalgia; Neck pain; Pain in extremity  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  -
Tumor pain 
NERVOUS SYSTEM DISORDERS  - Ataxia; Cognitive disturbance; Depressed level of consciousness; 
Dysarthria; Extrapyramidal disorder; Intracranial hemorrhage; Lethargy; Memory impairment; 
Movements involuntary; Paresthesia; Peripheral motor neuropathy; Per ipheral sensory neuropathy; 
Presyncope; Reversible posterior leukoencephalopathy syndrome; Stroke; Syncope; Tremor  
PSYCHIATRIC DISORDERS  - Agitation; Anxiety; Confusion; Depression; Insomnia; Psychiatric 
disorders - Other (emotional instability); Psychosis ; Restlessness  
RENAL AND URINARY DISORDERS  - Dysuria; Hematuria; Proteinuria  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  - Cough; Dyspnea; Epi[INVESTIGATOR_3940]; 
Hypoxia; Nasal congestion; Pharyngolaryngeal pain; Pleural effusion; Pneumonitis; Respi[INVESTIGATOR_138712]  - Alopecia; Dry skin; Hyperhidrosis; Nail 
changes; Palmar -plantar erythrodysesthesia syndrome; Pruritus; Purpura; Rash acneiform  
VASCULAR DISORDERS  - Flushing; Hot flashes; Hypertension; Hypotension; Vascular disorde rs - 
Other (brainstem infarction)  
 
Note : Veliparib  (ABT -888) in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by [CONTACT_6767], or the combination may result in 
events never previously associ ated with either agent.  
7.1.3 CAEPR for AZD1775 (NSC 751084)  
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform presentation 
of events by [CONTACT_6764]. In addition to the comprehensive list,  a subset, the Specific Protocol 
Exceptions to Expedited Reporting (SPEER), appears in a separate column and is identified with bold 
and italicized text.  This subset of AEs (SPEER) is a list of events that are protocol specific 
exceptions to expedited rep orting to NCI (except as noted below).  Refer to the 'CTEP, NCI 
Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf  for further 
clarification.   Frequency is provided bas ed on 299 patients.  Below is the CAEPR for AZD1775 
(MK -1775, NSC 751084).  
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses next to the 
AE in the SPEER.   If this CAEPR is part of a combination protocol using multiple invest igational 
agents and has an AE listed on different SPEERs, use the lower of the grades to determine if 
expedited reporting is required.  
NOTE: Many  adverse events on this CAEPR are treatment -emergent events that have been observed 
in trials of AZD1775 in co mbination with chemotherapy including carboplatin, cisplatin, 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005395] 3, 2016 
 Adverse Events with Possible  
 Relationship to AZD1775  
 (CTCAE 4.0 Term)  
[n= 299]    Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER)  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
Anemia     Anemia (Gr 3)  
 Febrile neutropenia     
CARDIAC DISORDERS    
  Atrial fibrillation    
  Supraventricular tachycardia    
EAR AND LABY[CONTACT_452256] (Gr 2)  
Constipation     Constipation (Gr 2)  
Diarrhea     Diarrhea (Gr 2)  
 Dyspepsia     
 Flatulence     
 Mucositis oral    Mucositis oral (Gr 2)  
Nausea     Nausea (Gr 2)  
 Oral pain     
Vomiting     Vomiting (Gr 2)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
 Chills     
 Edema limbs    Edema limbs (Gr 2)  
Fatigue     Fatigue (Gr 3)  
Fever     Fever (Gr 2)  
 Flu like symptoms     
 Malaise     
 Non-cardiac chest pain     
 Pain    
HEPATOBILIARY DISORDERS    
  Hepatobiliary disorders - 
Other (hepatitis)    
IMMUNE SYSTEM DISORDERS    
 Allergic reaction     
INFECTIONS AND INFESTATIONS    
Infection  (2)    Infection [81] (Gr 3)  
INVESTIGATIONS    
 Alanine aminotransferase 
increased    Alanine aminotransferase 
increased (Gr 2)  
 Alkaline phosphatase 
increased     
 Aspartate aminotransferase 
increased     
CTEP #9149 (01 -07-2020 ) 
 
57 
  Adverse Events with Possible  
 Relationship to AZD1775  
 (CTCAE 4.0 Term)  
[n= 299]    Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER)  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
 Blood bilirubin increased     
 Creatinine increased     
 Lymphocyte count decreased     
Neutrophil count decreased     Neutrophil count decreased (Gr 
4) 
Platelet count decreased     Platelet count decreased (Gr 4)  
 Weight loss     
 White blood cell decreased    White blood cell decreased (Gr 
4) 
METABOLISM AND NUTRITION DISORDERS    
 Anorexia    Anorexia (Gr 2)  
 Dehydration     
 Hyperglycemia     
 Hypoalbuminemia     
 Hypocalcemia     
 Hypokalemia    Hypokalemia (Gr 2)  
 Hypomagnesemia    Hypomagnesemia (Gr 2)  
 Hyponatremia     
 Hypophosphatemia     
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Arthralgia     
 Back pain    Back pain (Gr 2)  
 Musculoskeletal and 
connective tissue disorder - 
Other (muscle spasms)     
 Myalgia    Myalgia (Gr 2)  
 Pain in extremity     
NERVOUS SYSTEM DISORDERS    
 Dizziness    Dizziness (Gr 2)  
 Dysgeusia     
 Headache    Headache (Gr 2)  
  Intracranial hemorrhage    
 Paresthesia     
PSYCHIATRIC DISORDERS    
 Insomnia     
RENAL AND URINARY DISORDERS    
 Acute kidney injury  (3)     
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS    
 Cough    Cough (Gr 2)  
 Dyspnea    Dyspnea (Gr 2)  
 Epi[INVESTIGATOR_735828] #9149 (01 -07-2020 ) 
 
58 
  Adverse Events with Possible  
 Relationship to AZD1775  
 (CTCAE 4.0 Term)  
[n= 299]    Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER)  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
 Hyperhidrosis     
 Pruritus     
 Rash (4)    Rash [82] (Gr 2)  
VASCULAR DISORDERS    
  Phlebitis    
 Thromboembolic event     
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412].   Your name, the name [CONTACT_6823], the protocol and the agent should 
be included in the e -mail.  
2Infection includes all [ADDRESS_1005396] 
that there was a reasonable possibility that AZD1775 caused the adverse event : 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Blood and lymphatic system disorders - Other 
(pancytopenia) ; Blood and lymphatic system disorders - Other (thrombocytosis); Leukocytosis  
CARDIAC DISORDERS  - Acute coronary syndrome; Cardiac disorders - Other (cardiomegaly); Chest 
pain - cardiac; Myocardial infarction; Palpi[INVESTIGATOR_814]; Sinus bradycardia; Sinus tachyca rdia 
EAR AND LABY[CONTACT_33993]  - Ear pain  
EYE DISORDERS  - Blurred vision; Cataract; Conjunctivitis; Eye disorders - Other (eye swelling); Eye 
disorders - Other (visual impairment); Eye pain; Keratitis; Photophobia; Scleral disorder; Watering eyes  
GASTROINTESTINAL DISORDERS  - Anal pain; Ascites; Bloating; Cheilitis; Colitis; Dry mouth; 
Duodenal ulcer; Dysphagia; Gastric ulcer; Gastritis; Gastrointestinal disorders - Other (duodenitis); 
Gastrointestinal disorders - Other (eructation); Hemorrhoids; Lo wer gastrointestinal hemorrhage; Rectal 
pain; Small intestinal obstruction  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Edema trunk; Gait 
disturbance; General disorders and administration site conditions - Other (catheter site pain); Infusion sit e 
extravasation  
INJURY, POISONING AND PROCEDURAL COMPLICATIONS  - Fall; Injury, poisoning and 
procedural complications - Other (excoriation); Injury, poisoning and procedural complications - Other 
(ligament sprain)  
INVESTIGATIONS  - Electrocardiogram QT corr ected interval prolonged; GGT increased; 
Investigations - Other (blood urea increased); Lymphocyte count increased  
METABOLISM AND NUTRITION DISORDERS  - Hypercalcemia; Hyperkalemia; Hyperuricemia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  - Arthritis; Bone pain; Flank 
pain; Generalized muscle weakness; Muscle weakness lower limb; Musculoskeletal and connective tissue 
disorder - Other (groin pain); Neck pain  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  - 
Neoplasms benign, malignant  and unspecified (incl cysts and polyps) - Other (carcinoid tumor); Tumor 
pain 
CTEP #9149 (01 -07-2020 ) 
 
59 
 NERVOUS SYSTEM DISORDERS  - Cognitive disturbance; Dysesthesia; Encephalopathy; Lethargy; 
Nervous system disorders - Other (hemiparesis); Peripheral neuropathy [83]; Presyncope; Somnolence; 
Syncope  
PSYCHIATRIC DISORDERS  - Agitation; Anxiety; Confusion; Depression  
RENAL AND URINARY DISORDERS  - Hematuria; Urinary frequency; Urinary incontinence; 
Urinary retention; Urinary tract pain  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Female genital tract fistula; Genital 
edema  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  - Allergic rhinitis; 
Bronchopulmonary hemorrhage; Nasal congestion; Pleural effusion; Pneumonitis; Pulmonary 
hypertension; Respi[INVESTIGATOR_696], thoracic and mediastinal disorders - Other (diaphragmalgia); Wheezing  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Bullous dermatitis; Dry skin; Pain of skin; 
Palmar -plantar erythrodysesthesia syndrome; Purpura ; Rash acneiform; Skin ulceration; Urticaria  
VASCULAR DISORDERS  - Flushing; Hematoma; Hot flashes; Hypertension; Hypotension  
 
Note : AZD1775 in combination with other agents could cause an exacerbation of any adverse event 
currently known to be caused by [CONTACT_3433] e other agent, or the combination may result in events never previously 
associated with either agent.  
7.1.4 CAEPR for Trametinib DMSO (NSC 763093)  
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of reported 
and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by 
[CONTACT_6764]. In addition to the comprehensive list,  a subset, the Specific Protocol Exceptions to Expedited 
Reporting (SPEER), appears in a separate column and is identified with bold and italicized text. This subset 
of AEs (SPEER) is a list of events that are protocol specific exceptions to expedited repo rting to NCI 
(except as noted below). Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopm ent/electronic_applications/docs/aeguidelines.pdf  for further 
clarification. Frequency is provided based on 1111 patients. Below is the CAEPR for Trametinib 
([COMPANY_004]1120212B).  
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses nex t to the 
AE in the SPEER. If this CAEPR is part of a combination protocol using multiple investigational 
agents and has an AE listed on different SPEERs, use the lower of the grades to determine if 
expedited reporting is required.  
 
   Version 2.6, October 10, [ZIP_CODE] 
 
 Adverse Events with Possible  
 Relationship to Trametinib ([COMPANY_004]1120212B)  
 (CTCAE 5.0 Term)  
[n= 1111]   
 Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)   
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
 Anemia    Anemia (Gr 3)  
CARDIAC DISORDERS    
  Heart failure    
  Left ventricular systolic 
dysfunction    
 Sinus bradycardia     
EYE DISORDERS    
 Blurred vision     
 Dry eye     
CTEP #9149 (01 -07-2020 ) 
 
60 
  
 Adverse Events with Possible  
 Relationship to Trametinib ([COMPANY_004]1120212B)  
 (CTCAE 5.0 Term)  
[n= 1111]   
 Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)   
  Eye disorders - Other 
(chorioretinopathy also known as 
retinal pi[INVESTIGATOR_23553])    
  Eye disorders - Other (retinal vein 
occlusion)    
 Eye disorders - Other (visual 
disorders)2    
  Papi[INVESTIGATOR_735829] (Gr 2)  
  Colitis    
  Colonic perforation    
 Constipation    Constipation (Gr 2)  
Diarrhea     Diarrhea (Gr 3)  
 Dry mouth    Dry mouth (Gr 2)  
 Dyspepsia    Dyspepsia (Gr 2)  
 Mucositis oral    Mucositis oral (Gr 3)  
Nausea     Nausea (Gr 3)  
 Vomiting    Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
 Chills    Chills (Gr 2)  
 Edema face     
Fatigue     Fatigue (Gr 3)  
 Fever    Fever (Gr 2)  
Generalized edema3    Generalized edema3 (Gr 2)  
IMMUNE SYSTEM DISORDERS    
 Allergic reaction4    
INFECTIONS AND INFESTATIONS    
 Folliculitis    Folliculitis (Gr 2)  
 Lung infection     
 Paronychia    Paronychia (Gr 2)  
 Skin infection    Skin infection (Gr 2)  
INVESTIGATIONS    
 Alanine aminotransferase increased    Alanine aminotransferase 
increased (Gr 3)  
 Alkaline phosphatase increased    Alkaline phosphatase increased 
(Gr 2)  
 Aspartate aminotransferase 
increased    Aspartate aminotransferase 
increased (Gr 3)  
 CPK increased     
 Ejection fraction decreased     
METABOLISM AND NUTRITION DISORDERS    
 Anorexia    Anorexia (Gr 3)  
 Dehydration    Dehydration (Gr 3)  
CTEP #9149 (01 -07-2020 ) 
 
61 
  
 Adverse Events with Possible  
 Relationship to Trametinib ([COMPANY_004]1120212B)  
 (CTCAE 5.0 Term)  
[n= 1111]   
 Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)   
 Hypoalbuminemia     
 Hypomagnesemia    Hypomagnesemia (Gr 2)  
 Hyponatremia    Hyponatremia (Gr 3)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Arthralgia     
 Back pain    Back pain (Gr 2)  
 Pain in extremity    Pain in extremity (Gr 2)  
  Rhabdomyolysis    
NERVOUS SYSTEM DISORDERS    
 Dizziness    Dizziness (Gr 2)  
 Headache    Headache (Gr 2)  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS    
 Cough    Cough (Gr 2)  
 Dyspnea    Dyspnea (Gr 3)  
  Pneumonitis    
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
 Alopecia    Alopecia (Gr 2)  
 Dry skin    Dry skin (Gr 2)  
 Nail changes     
  Palmar -plantar erythrodysesthesia 
syndrome    
 Pruritus    Pruritus (Gr 2)  
  Skin and subcutaneous tissue 
disorders - Other (drug reaction 
with eosinophilia and systemic 
symptoms [DRESS])   
Skin and subcutaneous tissue 
disorders - Other (rash)5     Skin and subcutaneous tissue 
disorders - Other (rash)5 (Gr 3)  
  Stevens -Johnson syndrome6   
VASCULAR DISORDERS    
 Hypertension    Hypertension (Gr 3)  
  Thromboembolic event (venous)    
 Vascular disorders - Other 
(hemorrhage)7    
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412].   Your name, the name [CONTACT_6823], the protocol and the agent should be 
included in the e -mail.  
 
2Visual disorders include visual disturbance that can be associated with conjunctival hemorrhage, corneal 
graft rejection, cyclitis, eye nevus, halo vision, iritis, macular edema, retinal hemorrhage, visual acuity 
reduced, visual impairment, and vitreous detachment.  
 
3Generalized edema includes edema, lymphedema, and edema limbs.  
 
CTEP #9149 (01 -07-2020 ) 
 
62 
 4Hypersensitivity (allergic react ions) may present with symptoms such as fever, rash, increased liver function 
tests, and visual disturbances.  
 
5Skin and subcutaneous tissue disorders - Other (rash) may include rash, rosacea, rash acneiform, 
erythematous rash, genital rash, rash macular, exfoliative rash, rash generalized, erythema, rash papular, 
seborrhoeic dermatitis, dermatitis psoriasiform, rash follicular, skin fissures, and skin chapped.  
 
6Stevens -Johnson syndrome has been observed in patients treated with trametinib and dabrafenib 
combination.  
 
7The majority of hemorrhage events were mild.  Major events, defined as symptomatic bleeding in a critical 
area or organ (e.g., eye, GI hemorrhage, GU hemorrhage, respi[INVESTIGATOR_36393]), and fatal intracranial 
hemorrhages have been reported.  
 
 
Adverse events reported on trametinib dimethyl sulfoxide ([COMPANY_004]1120212B) trials, but for which there is 
insufficient evidence to suggest that there was a reasonable possibility that trametinib dimethyl 
sulfoxide ([COMPANY_004]1120212B) caused the advers e event : 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Disseminated intravascular coagulation; Febrile 
neutropenia; Leukocytosis  
CARDIAC DISORDERS  - Atrial fibrillation; Cardiac arrest; Myocardial infarction; Restrictive 
cardiomyopathy; Sinus tachycardia  
EYE DIS ORDERS  - Corneal ulcer; Eyelid function disorder; Flashing lights; Floaters; Glaucoma; 
Photophobia  
GASTROINTESTINAL DISORDERS  - Ascites; Duodenal ulcer; Esophageal necrosis; Esophageal ulcer; 
Esophagitis; Gastric hemorrhage7; Gastric ulcer; Gastritis; Gast rointestinal disorders - Other (intestinal 
obstruction); Gastrointestinal disorders - Other (pneumatosis intestinalis); Gastrointestinal fistula; Gingival 
pain; Hemorrhoidal hemorrhage7; Ileus; Obstruction gastric; Pancreatitis; Small intestinal obstructio n 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Flu like symptoms; General 
disorders and administration site conditions - Other (axillary pain); Localized edema; Malaise; Non -cardiac 
chest pain; Pain  
HEPATOBILIARY DISORDERS  - Cholecystitis; Hepatic failure; Hepatic pain; Hepatobiliary disorders - 
Other (hepatic encephalopathy)  
INFECTIONS AND INFESTATIONS  - Biliary tract infection; Catheter related infection; Device related 
infection; Endocarditis infective; Enterocolitis inf ectious; Hepatitis viral; Infections and infestations - Other 
(abscess limb); Infections and infestations - Other (necrotizing fasciitis); Infections and infestations - Other 
(oral infection); Pharyngitis; Sepsis; Upper respi[INVESTIGATOR_4416]; Urinary tract  infection  
INJURY, POISONING AND PROCEDURAL COMPLICATIONS  - Bruising  
INVESTIGATIONS  - Blood bilirubin increased; Blood lactate dehydrogenase increased; Creatinine 
increased; Electrocardiogram QT corrected interval prolonged; GGT increased; Lipase increased ; 
Lymphocyte count decreased; Platelet count decreased; Serum amylase increased; White blood cell decreased  
METABOLISM AND NUTRITION DISORDERS  - Hyperglycemia; Hyperkalemia; Hyperphosphatemia; 
Hyperuricemia; Hypocalcemia; Hypoglycemia; Hypokalemia  
MUSCULOS KELETAL AND CONNECTIVE TISSUE DISORDERS  - Generalized muscle weakness; 
Muscle cramp; Musculoskeletal and connective tissue disorder - Other (compression fracture); Myalgia; Neck 
pain 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  - Tum or 
hemorrhage7; Tumor pain  
NERVOUS SYSTEM DISORDERS  - Dysgeusia; Encephalopathy; Intracranial hemorrhage7; Lethargy; 
Nervous system disorders - Other (diplopia); Seizure; Somnolence; Stroke; Syncope; Transient ischemic 
attacks  
PSYCHIATRIC DISORDERS  - Anxie ty; Confusion; Delirium; Depression; Hallucinations; Insomnia; 
Personality change  
RENAL AND URINARY DISORDERS  - Acute kidney injury; Cystitis noninfective; Dysuria; Hematuria; 
Proteinuria; Urinary incontinence  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Vaginal fistula; Vaginal hemorrhage7 
CTEP #9149 (01 -07-2020 ) 
 
63 
 RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  - Bronchopulmonary hemorrhage7; 
Hypoxia; Laryngeal edema; Oropharyngeal pain; Pleural effusion; Pneumothorax; Productive cough; 
Pulmonary hypertension; Respi[INVESTIGATOR_1399]; S inus disorder  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Bullous dermatitis; Photosensitivity; Purpura; 
Skin and subcutaneous tissue disorders - Other (erythema nodosum); Skin ulceration; Urticaria  
VASCULAR DISORDERS  - Hematoma; Hot flashes; Hypotension  
 
 
Note : Trametinib ([COMPANY_004]1120212B) in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by [CONTACT_6767], or the combination may result in events never 
previously associated with either agent.  
 
7.1.5 CAEPR for Everolimus (RAD -001, NSC 733504)  
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of reported 
and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by 
[CONTACT_6764].  In addition to the comprehensive list, a subset, the Specific Protocol Exceptions to 
Expedited Reporting (SPEER), appears in a separate column and is identified with bold and italicized 
text.  This subset of AEs (SPEER) is a list of events that are protoco l specific exceptions to expedited 
reporting to NCI (except as noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting 
Requirements' http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf  
for further cla rification. Frequency is provided based on 3033 patients.   Below is the CAEPR for 
Everolimus (RAD -001).  
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses next to the AE 
in the SPEER.  If this CAEPR is part of a combination protocol using multiple investigational agents and 
has an AE listed on different SPEERs, use the lower of the grades to determine if expedited reporting is 
required.  
Version 2.5, July 3, 2018 
 Adverse Events with Possible  
 Relationship to Everolimus (RAD -001)  
 (CTCAE 5.0 Term)  
[n= 3033]    
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
Anemia     Anemia (Gr 3)  
GASTROINTESTINAL DISORDERS    
 Abdominal pain     
 Constipation     
Diarrhea2    Diarrhea2 (Gr 3)  
Mucositis oral3    Mucositis oral3 (Gr 3)  
 Nausea    Nausea (Gr 3)  
 Vomiting    Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
 Edema limbs    Edema limbs (Gr 2)  
Fatigue     Fatigue (Gr 3)  
 Fever    Fever (Gr 2)  
IMMUNE SYSTEM DISORDERS    
  Allergic reaction    
  Anaphylaxis    
INFECTIONS AND INFESTATIONS    
 Infection4   Infection4 (Gr 3)  
CTEP #9149 (01 -07-2020 ) 
 
64 
  Adverse Events with Possible  
 Relationship to Everolimus (RAD -001)  
 (CTCAE 5.0 Term)  
[n= 3033]    
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
INJURY, POISONING AND PROCEDURAL COMPLICATIONS    
  Wound complication5   
INVESTIGATIONS    
 Alanine aminotransferase 
increased    Alanine aminotransferase increased 
(Gr 2)  
 Alkaline phosphatase 
increased    Alkaline phosphatase increased (Gr 2)  
 Aspartate aminotransferase 
increased    Aspartate aminotransferase increased 
(Gr 2)  
 Cholesterol high    Cholesterol high (Gr 2)  
 Creatinine increased    Creatinine increased (Gr 2)  
 Lymphocyte count decreased    Lymphocyte count decreased (Gr 2)  
 Neutrophil count decreased    Neutrophil count decreased (Gr 4)  
 Platelet count decreased    Platelet count decreased (Gr 4)  
 Weight loss     
 White blood cell decreased    White blood cell decreased (Gr 4)  
METABOLISM AND NUTRITION DISORDERS    
 Anorexia    Anorexia (Gr 2)  
 Hyperglycemia6   Hyperglycemia6 (Gr 3)  
 Hypertriglyceridemia    Hypertriglyceridemia (Gr 4)  
 Hypophosphatemia    Hypophosphatemia (Gr 2)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Arthralgia     
 Back pain     
 Pain in extremity     
NERVOUS SYSTEM DISORDERS    
 Dysgeusia     
 Headache    Headache (Gr 2)  
RENAL AND URINARY DISORDERS    
  Acute kidney injury    
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS    
 Cough    Cough (Gr 2)  
 Dyspnea    Dyspnea (Gr 3)  
 Epi[INVESTIGATOR_33948] (Gr 2)  
 Pneumonitis7    
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
 Dry skin     
 Pruritus     
Rash maculo -papular     Rash maculo -papular (Gr 2)  
  Skin and subcutaneous tissue 
disorders - Other 
(angioedema)8    
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412]. Your name, the name [CONTACT_6823], the protocol and the agent should 
be included in the e -mail.  
2Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steator rhea.  
CTEP #9149 (01 -07-2020 ) 
 
65 
 3Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip 
ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.  
4Infection includes all 75 infection sites under the INFECTIONS AND I NFESTATIONS SOC.  
5Everolimus delays wound healing and increases the occurrence of wound -related complications like 
wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.  
6Hyperglycemia may result in either exacerbation of or developm ent of new onset diabetes mellitus.  
7Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, 
pulmonary toxicity, alveolitis, pulmonary fibrosis, and restrictive pulmonary disease.  
8Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema.  
9Includes agitation, anxiety, panic attack, aggression, abnormal behavior, and obsessive compulsive 
disorder.  
 
Adverse events reported on everolimus (RAD -001) trials, but for whi ch there is insufficient 
evidence to suggest that there was a reasonable possibility that everolimus (RAD -001) caused the 
adverse event : 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Thrombotic thrombocytopenic purpura  
CARDIAC DISORDERS  - Atrial fibrillation; Cardiac disorders - Other (myocardial abnormality); Chest 
pain - cardiac; Heart failure; Left ventricular systolic dysfunction; Myocardial infarction; Sinus 
bradycardia; Sinus tachycardia; Supraventricular tachycardia  
ENDOCRINE DIS ORDERS  - Endocrine disorders - Other (increased blood follicle stimulating 
hormone [FSH] levels); Endocrine disorders - Other (increased blood luteinizing hormone [LH] levels); 
Hypothyroidism; Testosterone deficiency  
EYE DISORDERS  - Blurred vision; Keratit is 
GASTROINTESTINAL DISORDERS  - Ascites; Colitis; Dry mouth; Dyspepsia; Dysphagia; 
Flatulence; Gastroesophageal reflux disease; Gastrointestinal disorders - Other (Dieulafoy's lesion); 
Hemorrhoids; Intra -abdominal hemorrhage; Oral pain; Pancreatitis; Perio dontal disease; Toothache  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Chills; Edema face; 
Edema trunk; Flu like symptoms; Non -cardiac chest pain; Pain  
HEPATOBILIARY DISORDERS  - Hepatic failure; Hepatobiliary disorders - Other (hepatomegaly)  
INVE STIGATIONS  - Activated partial thromboplastin time prolonged; Blood bicarbonate decreased; 
Blood bilirubin increased; Blood lactate dehydrogenase increased; CPK increased; GGT increased; INR 
increased; Investigations - Other (low density lipoprotein raised ); Investigations - Other 
(thrombocythemia).  
METABOLISM AND NUTRITION DISORDERS  - Dehydration; Glucose intolerance; 
Hypercalcemia; Hyperkalemia; Hyperlipi[INVESTIGATOR_035]; Hypoalbuminemia; Hypocalcemia; Hypokalemia; 
Hypomagnesemia; Hyponatremia; Metabolism and nutrit ion disorders - Other (high ammonia)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  - Bone pain; Chest wall pain; 
Generalized muscle weakness; Muscle cramp; Muscle weakness lower limb; Myalgia  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND PO LYPS)  - 
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other (ovarian cysts)  
NERVOUS SYSTEM DISORDERS  - Dizziness; Encephalopathy; Hydrocephalus; Lethargy; 
Paresthesia  
PSYCHIATRIC DISORDERS  - Agitation; Anxiety [76]; Delirium; Depression; Insomnia; Irritability; 
Mania  
RENAL AND URINARY DISORDERS  - Hematuria; Proteinuria; Urinary frequency  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Dysmenorrhea; Genital edema; Irregular 
menstruation; Menorrhagia; Vaginal hemorrhage  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  - Bronchopulmonary 
hemorrhage; Phar yngolaryngeal pain; Pleural effusion; Respi[INVESTIGATOR_1399]; Respi[INVESTIGATOR_696], thoracic and 
mediastinal disorders - Other (rales); Rhinorrhea; Sore throat; Voice alteration  
CTEP #9149 (01 -07-2020 ) 
 
66 
 SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Nail loss; Palmar -plantar erythrodysesthesia 
syndrome; Rash acneiform; Skin and subcutaneous tissue disorders - Other (nail disorder); Skin and 
subcutaneous tissue disorders - Other (skin lesion); Skin ulceration  
VASCULAR DISORDERS  - Flushing; Hypertension; Lymphedema; Phlebitis; Thromboembolic event; 
Vascular disorders - Other (acute bowel ischemia); Vascular disorders - Other (hemorrhage)  
 
Note : Everolimus (RAD -001) in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by [CONTACT_6767], or the c ombination may result in events 
never previously associated with either agent.  
 
7.2 Adverse Event Characteristics  
• CTCAE term (AE description) and grade:  The descriptions and grading scales found 
in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 
4.[ADDRESS_1005397] access to a copy of the CTCAE version 5.0.  A copy of the CTCAE version 5.0 can 
be downloaded from the CTEP Web site (http://ctep.cancer.gov) . 
 
• ‘Expectedness’ : AEs can be ‘Unexpected’ or ‘Expected’ (see Section 7.1  above) for 
expedited reporting purposes only.  Specific Protocol Exceptions to Expedited Reporting 
(SPEER) appears as bold and italicized  text in the CAEPR ( Section 7.1 ). 
 
• Attribution  of the AE:  Definite – The AE is clearly related  to the study treatment ; 
Probable – The AE is likely related to the study treatment; Possible – The AE may be 
related  to the study treatment; Unlikely – The AE is doubtfully related to the study 
treatment; Unrelated – The AE is clearly NOT related  to the study treatment.  
7.[ADDRESS_1005398] use CTEP -AERS  (CTEP Adverse 
Event Reporting System), accessed via the CTEP home page 
(http://ctep.cancer.gov ).  The reporting p rocedures to be followed are presented in 
the “CTEP, NCI Guidelines: Adverse Event Reporting Requirements” which can 
be downloaded from the CTEP home page ( http://ctep.cancer.gov ).  These 
requirements are briefly outlined in the table below ( Section 7.3.2 ). 
 
In the rare event when Internet connectivity is disrupted, a 24 -hour notification is 
to be made to NCI by [CONTACT_1381]: ([PHONE_034] .  An electronic report MUST 
be submitted immediately upon re -establishment of internet connection.  
 
CTEP -AERS  is programme d for automatic electronic distribution of reports to the 
following individuals: Study Coordinator of the Lead Organization, lead 
organization study research nurses, Principal Investigator, and the l ocal treating 
physician.  CTEP -AERS  provides a copy featu re for other e -mail recipi[INVESTIGATOR_840].  
7.3.2 Phase 1 and Early Phase 2 Studies: Expedite d Reporting Requirements for 
Adverse Events that Occur on Studies under an IND/IDE within [ADDRESS_1005399] Administration of the Investigational agent/Intervention 1,2 
CTEP #9149 (01 -07-2020 ) 
 
67 
 FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE:   Invest igators MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not 
they are considered related to the investigational agent(s)/intervention (21 CFR 312.64)  
An adverse event is considered serious if it results in ANY  of the foll owing outcomes:   
• Death  
• A life -threatening adverse event  
• An adverse event that results in inpatient hospi[INVESTIGATOR_1328] ≥ 24 hours  
• A persistent or significant incapacity or substantial disruption of the ability  to conduct normal life functions  
• A congenital anomaly/birth defect.  
• Important Medical Events (IME) that may not result in death, be life threatening, or require hospi[INVESTIGATOR_34502], based upon medical judgment, they may jeopar dize the patient or subject and may 
require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 
312.32; ICH E2A and ICH E6).  
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the NCI via electronic 
submission within the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_317] 1 and Grade 2 Timeframes  Grade 3 -5 
Timeframes  
Resulting in 
Hospi[INVESTIGATOR_059]  
≥ 24 hrs  10 Calendar Days  
24-Hour 5 Calendar Days  
Not resulting in 
Hospi[INVESTIGATOR_059]  
≥ 24 hrs  Not required  
NOTE:   Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific Protocol 
Exceptions to Expedited Reporting (SPEER) portion of the CAEPR.  
Expedited AE reporting timelines are defined as:  
1) “24-Hour; 5 Calendar Days” - The AE must initially be submitted electronically within 24 hours of learning of the 
AE, followed by a complete expedited report within 5 calendar days of the initial 24 -hour report.  
2) “10 Calendar Days” - A complete expedited report on the AE must be submi tted electronically within [ADDRESS_1005400] administration of investigational agent/intervention 
and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24 -hour notification followed by [CONTACT_432] 5 calendar days for:  
• All Grade 3, 4, and Grade 5 AEs  
Expedited 10 calendar day reports for:  
• Grade [ADDRESS_1005401] whole day, after the agent/intervention was last administered.  Footnote “1” above applies after this 
reporting period.  
Effective Date:  May 5, 2011  
 
7.3.3 Protocol -specific expedited AE reporting exclusions.  
Lymphopenia (any grade), alopecia (any grade), anemia (grade 2),  electrolytes (grade 2: 
sodium, potassium, phosphorous, and magnesium),  albumin (grade 2), hyperuricemia 
(grade 3), INR (grade 2), and PTT (grade 2)  will NOT be reported through CTEP -AERS  
but will be reported in the routine data submissions.  
 
CTEP #9149 (01 -07-2020 ) 
 
68 
 7.3.4 Pregnancy, Pregnancy Loss , and Death Neonatal  
NOTE : When submitting CTEP -AERS  reports for “Pregnancy”, “Pregnancy loss”, or  
“Neonatal loss”, the Pregnancy Information Form should be completed and faxed along  
with any additional medical information to [PHONE_100].  The potential risk of exposure 
of the fetus to the investigational agent(s) or chemotherapy agent(s) should be 
documented in the “Description of Event” section of the CTEP -AERS  report.  
 
[IP_ADDRESS] Pregnancy  
• Because p atients who become pregnant on study risk intrauterine exposure of the 
fetus to agents which may be teratogeni c, DCTD/DCP is requesting that  
pregnancy should be reported in  an expedited manner via CTEP -AERS  as Grade 
3 “Pregnancy, puerperium and perinatal conditions - Other (pregnancy )” under 
the Pregnancy, puerperium and perinatal conditions SOC.  
• The pregnancy out come for patients o n study should be reported via CTEP -AERS  
at the time the outcome becomes known, accompanied by [CONTACT_735893]  
 
[IP_ADDRESS] Pregnancy loss  
• Pregnancy loss is defined in CTCAE as “Death in utero.”  
• Any pregnancy loss should be reported expeditiously, as Grade 4 “Pregnancy  
loss” under the Pregnancy, puerperium and perinatal conditions SOC.  
• A pregnancy loss should NOT be reported as a Grade 5 event under the 
Pregnancy, puerperium and perinatal conditions SOC, as currently CTEP -AERS  
recognizes this event as a patient death.  
 
[IP_ADDRESS] Death Neonatal  
• Neonatal death, defined in CTCAE as “A disorder characterized by [CONTACT_735894] 28 days of life” that is felt by [CONTACT_735895]/intervention, should be reported 
expeditiously.  
• A neonatal death should be reported expeditiously as Grade 4 “ Death neonatal ” 
under the General disorders and administration SOC.  
• Neonatal death should NOT be reported as Grade 5 “Death neonatal” under the 
General disorders and administration SOC.  If reported as such, the CTEP -AERS  
interprets this as a death of the patient being treated.  
 
7.[ADDRESS_1005402] also be reported in routine study data 
submissions.  
 
Adverse event data collection and reporting, which are required as part of every clinical tri al, are 
done to ensure the safety of patients enrolled in the studies as well as those who will enroll in 
future studies using similar agents.   AEs are reported in a routine manner at scheduled times 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005403].  
7.5 Secondary Malignancy  
A secondary malignancy is a cancer caused by [CONTACT_437] a previous malignancy ( e.g., 
treatment with investigational agent/intervention, radiation,  or chemotherapy) .  A secondary 
malignancy is not considered a metastasis of the initial neoplasm.  
 
CTEP requires all secondary malignancies that occur following treatment with an agent under a n 
NCI IND/IDE be reported via CTEP -AERS .  Three options are available to describe the event:  
 
1. Leukemia secondary to oncology chemotherapy ( e.g., acute myelocytic leukemia [AML])  
2. Myelodysplastic syndrome (MDS)  
3. Treatment -related secondary malignancy  
 
Any malignancy possibly related to cancer treatment (including AML/MDS) should also be 
reported via the routine reporting mechanisms outlined in each protocol.  
7.6 Second Malignancy  
A second malignancy is one unrelated to the treatment of a prior malignancy (and  is NOT a 
metastasis from the initial malignancy).   Second malignancies require ONLY routine reporting 
via CDUS unless otherwise specified.  
 
8. PHARMACEUTICAL INFORMATION  
A list of the adverse events and potential risks associated with these agents can be found in 
Section 7.1 . 
8.1 Temozolomide (NSC 362856)  
Availability : Please refer to the FDA -approved package insert for complete product information.  
Commercial supplies of temozolomide will be purchased by [CONTACT_22688], NCI and distributed by 
[CONTACT_25523], CTEP.   
 
Toxicities:  The most common adverse events across the cumulative temozolomide  experience 
were alopecia, na usea, vomiting, anorexia, headache, and constipation.  Forty -nine percent 
(49%) of patients treated with temozolomide reported one or more severe or life -threatening 
events, most commonly fatigue (13%), convulsions (6%), headache (5%), and thrombocytopenia  
(5%).  Myelosuppression  (neutropenia and thrombocytopenia), which is a known DLT for most 
cytotoxic agents, was observed , as were Grade 3 or Grade 4 neutrophil abnormaliti es including 
neutropenic events, and Grade 3 or Grade 4 platelet abnormalities, incl uding thrombocytopenic 
events.  
 
Chemical Name: 3,4-dihydro -3-11 methyl -4-oxoimidazo( 5,1-d)-as-tetrazine -8-carboxamide.  
 
Other Names:  Temodar®, Temodal, Temcad  
CTEP #9149 (01 -07-2020 ) 
 
70 
  
CAS Registry Number : [ZIP_CODE] -93-1 
 
Molecular Formula:  C6H6N6O2   M.W.:  194.15  
 
Mode of Action :  Temozolomide is not directly active but undergoes rapid  nonenzymatic 
conversion at physiologic pH to the reactive compound MTIC.  The cytotoxicity of MTIC is 
thought to be primarily due to alkylation of DNA.   Alkylation  (methylation) occurs mainly at the 
O6 and N7 positions of guanine.  
 
How Supplied:   PMB, CTEP, DCTD distributes commercially labeled Temozolomide as [ADDRESS_1005404] 5 mg.  The manufacturer of the NCI -
purchased supplies may vary throughout the course of the trial.  Temozolomide capsules contain 
the following inactive ingredients: lactose anhydrous, colloidal silicon dioxide, sodium starch 
glycolate, tartaric acid, and stearic acid in varying quantities per capsule strength.  Refer to the 
approved package insert for complete product information and physical description of the 
supplied product.  
 
Storage:  Store at 25°C (77°F); excursions permit ted to 15° -30°C (59° -86°F).  
 
Stability:   Refer to the package label for shelf life.  
 
Route  of Administration:   Oral.   
 
Method of Administration:   Take each day ’s dose of capsules at one time, with a full glass of 
water.  They should be swallowed whole and never chewed .  If capsules are vomited do not take 
a second dose.  New capsules should not be taken until the next planned dose.   The incidence of 
nausea and vo miting is decreased when temozolomide is taken on an empty stomach.  
8.2 Carboplatin  (NSC 241240)  
Availability:  Please refer to the FDA -approved package insert for complete product information. 
Commercial supplies of Carboplatin will be purchased by [CONTACT_22688], N CI and distributed by [CONTACT_124438], CTEP.  
 
How supplied: PMB, CTEP, DCTD distributes commercially -labeled supplies of Carboplatin 
aqueous solution Injection as 450 mg/45 mL (10 mg/mL in Water for Injection) multi -dose vials.  
The manufacturer of the NCI -purchased supplies may vary throughout the course of the trial.  
Refer to the approved package insert for complete product information and description of the 
supplied product.  
 
Preparation: Carboplatin aqueous solution can be furthe r diluted to concentrations as low as 0.5 
mg/mL with 5% Dextrose in Water (D5W) or 0.9% Sodium Chloride Injection, USP.  
 
CTEP #9149 (01 -07-2020 ) 
 
71 
 Storage and Stability:  Unopened vials of Carboplatin aqueous solution are stable to the date 
indicated on  the package when stored at 25 °C (77° F); excursions pe rmitted from 15° -30°C (59° -
86°F) [see USP Controlled Room Temperature]. Protect from light.  
Carboplatin aqueous solution multi -dose vials maintain microbial, chemical, and physical 
stability for up to 14 days at 25° C following initi al vial entry. When prepared as directed, 
carboplatin solutions for infusion are stable for 8  hours at room temperature (25° C). Prepared 
solutions for infusion are to be discarded 8 hours after preparation.  
 
NOTE: Aluminum reacts with carboplatin, causing precipi[INVESTIGATOR_165987]. 
Therefore, needles or intravenous sets containing aluminum parts that may come in contact [CONTACT_735896].  
 
Dosing and Administration : Carboplat in will be administered concomitantly with AZD1775 as 
an i.v. infusion over 30 -70 minutes.  The dose will be calculated based on the patient’s actual 
body weight at each treatment visit and the AUC (area under curve) dosing according to the 
formula provided below.   
 
The calculated GFR for the carboplatin dose will be based on the calculated creatinine clearance 
using the Cockroff -Gault formula.   
Calvert Formula for carboplatin dose:  AUC Dose = 5.0 x (GFR + 25)  
Where GFR (Cockroff -Gault):  
GFR = (140 – pt. age in years) (weight in Kg) x  0.85 (females) or 1.0 (males)   
   serum creatinine x  72 
 
The GFR (calculated by [CONTACT_3158] -Gault or any other means using creatinine) used in the 
Calvert formula to calculate AUC -based dosing should not exceed 125  mL/min under any 
circumstance.   By [CONTACT_108], this results in the following upper limits on the dose to be 
administered, by [CONTACT_579823]:  
 
AUC target  
(mg•min/mL)  Maximum carboplatin dose  
(mg)  
4 600 
5 750 
 
 Questions about this calculation should be directed at the study  investigator.  
 
Toxicities : Some of the expected adverse events from carboplatin are listed below.  For further 
description of adverse events , see Package Insert.   
 
Hematologic : Myelosuppression  
Gastrointestinal:  Nausea, vomiting, diarrhea, weight loss, constipation, gastrointestinal pain  
Metabolic:  Electrolyte imbalances, hypomagnesemia, hypocalcemia, hyponatremia, 
hyperuremia , hypokalemia  
Hepatic: Elevated alkaline phosphatase, AST, and total bilirubin  
CTEP #9149 (01 -07-2020 ) 
 
72 
 CNS:  Peripheral neuropathies (mild paresthesias, clinical ototoxicity and other sensory 
abnormalities are rare)  
Genitourinary:  Renal tubular damage, renal insufficiency, impotence, sterility, amenorrhea, 
gynecomastia  
Allergy:  Anaphylactoid and urticarial reactions (acute), flushing, rash, pruritis , and rarely 
hypotension or bronchospasm  
Other : Alopecia, pain, asthenia , and mucosal side effects  
Patient Care Implications: Patients taking carboplatin should avoid the use of live vaccines and 
close contact [CONTACT_735897].  Examples of live vaccines include 
intranasal in fluenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and 
TY21a typhoid vaccines.  
8.3 Everolimus (NSC 733504)  
Chemical Name: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S, 35R) -1,18-
dihydroxy -12-{(1R) -2-((1S,3R,4R) -4-(2-hydroxyethoxy) -3-methoxycyclohexyl) -1-
methylethyl} -19,30 -dimethoxy -15,17,21,23,29,35 -hexam ethyl -11,36 -dioxa -4-
azatricyclo( [IP_ADDRESS],9 )hexatriaconta -16,24, 26,28 -tetraene -2,3,10,14,20 -pentaone  
 
Other Names:  RAD001, Afinitor  
 
Classification:  mTOR inhibitor  
 
CAS Registry Number:  159351 -69-6 
 
Molecular Formula:   C53H83NO 14  M.W.: 958.2  
 
Mode of Action:  Everolimus is an inhibitor of selective mammalian target of rapamycin 
(mTOR), the effects of which specifically t arget the mTOR -raptor signal transduction complex 1 
(mTORC1).   Inhibition of mTORC1, an essential regulator of global protein synthesis 
downstream on the PI3K/AKT/mTOR pathway, reduces tumor cell proliferation, glycolysis , and 
angiogenesis.  The PI3K/AKT/m TOR pathway is dysregulated in the majority of human cancers 
and is the object of many targeted agents.  
 
Description:  White to faintly yellow powder  
 
How Supplied: [COMPANY_001] supplies and PMB, CTEP, DCTD di stributes commercially labeled 
Everolimus as 2.5 mg, 5 mg , and 10 mg tablets for oral administration.  Each box of 28 tablets 
contains 4 blistercards of 7 tablets each.  The white to slightly yellow, elongated tablets are 
distinguished as follows:  
 
• 2.5 mg tablet is engraved with “LCL” on one site and “NVR” on the other  
• 5 mg tablet is engraved with “5” on one side and “NVR” on the other  
• 10 mg tablet is engraved with “UHE” on one side and “NVR” on the other  
 
CTEP #9149 (01 -07-2020 ) 
 
73 
 Tablet excipi[INVESTIGATOR_735830], 0.2% b utylated hydroxytoluene (BHT), magnesium 
stearate, lactose anhydrous/anhydrous lactose, lactose monohydrate, 
hypromellose/hydroxypropyl methylcellulose , and crospovidone.  
 
Storage: Store at 25°C (77°F) [excursions permitted between 15 to 30°C (59 to 85°F].   
 
Stability: Refer to the package label for shelf life.  Store tablets in the original container and 
protect from light and moisture.  
 
Route  and Method  of Administration:  Oral administration.  Tablets should be swallowed whole 
with a glass of water .  They  can be taken with or without food but should be taken consistently the 
same time every day.  If a dose is missed, it can still be taken up to 6 hours after the usual time of 
administration.   Missed doses more than 6 hours late should be skipped for that day.  
 
Potential Drug Interactions: Everolimus is a substrate of CYP3A4 and P -glycoprotein (PgP).   
Concomitant treatment with strong inhibitors or inducers of CYP3A4 or PgP should be avoided.  
Use caution when everolimus is given concomitantly with moderate inhibitors or inducers of 
CYP3A4 and PgP.  Consult the protocol document or study investigator prior to making any 
dose adjustments related to potential drug -drug interactions.  
 
In vitro , eve rolimus is a competitive inhibitor of CYP3A4, a mixed inhibitor of CYP2D6, an 
inhibitor of transport proteins, OATP1B1 and OATP1B3 and a moderate inhibitor of P -gp.  
Exercise caution when everolimus is taken in combination with orally administered substrat es of 
these enzymes and transporters, in particular, CYP3A4 substrates with a narrow therapeutic 
index.  
 
Co-administration with angiotensin -converting enzyme (ACE) inhibitors may increase the risk 
for angioedema based on results of a pooled analysis of ran domized, double blind studies.  
 
Patient Care Implications: Patients taking everolimus should avoid the use of live vaccines and 
close contact [CONTACT_735897].  Examples of live vaccines include 
intranasal influenza, measles, mump s, rubella, oral polio, BCG, yellow fever, varicella, and 
TY21a typhoid vaccines.  
8.4 Veliparib  (NSC 737664)  
Chemical Name: 1H-Benzimidazole -7-carboxamide, 2 -[(2R)-2-methyl -2-pyrrolidinyl] - 
Other Names :ABT -888, A-861695.0  
Classification : Poly (ADP -ribosome) polymerase (PARP) Inhibitor  
CAS Registry Number : 912444 -00-9 
Molecular Formula:  C13H16N4O  M.W.:  244.29  
Approximate Solubility : Freely soluble at pH < 6.9, soluble at pH 6.9 to 7.1, and slightly soluble 
at pH > 7.1.  
Mode of Action : Veliparib  inhibits the formation of poly (ADP -ribose) (PAR) polymers in vitro 
and in vivo.  It inhibits the repair of DNA when the DNA is damaged by [CONTACT_321875].  
CTEP #9149 (01 -07-2020 ) 
 
74 
 Veliparib  increases antitumor efficacy when added to DNA -damaging therapi[INVESTIGATOR_735831].  
Description:  White to light yellow solid.   
How Supplied: Veliparib  capsules are available in 10 mg, 20 mg, 40 mg,  and 50 mg immediate 
release capsules.  The inactive ingredients are microcrystalline  cellulose, colloidal silicon dioxide, 
magnesium stearate, gelatin, sodium lauryl sulfate, FD&C yellow #5 , and  titanium dioxide.  The 
capsules are packaged in HDPE bottles , and each HDPE bottle contains 16 capsules or 64 capsules.  
 
Veliparib  capsules may be repackaged from the supplied HDPE bottles into amber (or other low -
actinic) child resistant pharmacy dispensing bottles.  Expi[INVESTIGATOR_372286] 30 days from the 
repackaging  date (or the original retest date, whichever is earlier) when stored at 15°C to 25°C 
(59°F to 77°F).  
 
Storage:  Store the original bottle at 15 º to 25 º C (59 º to 77 º F).  
Stability:  Shelf -life stability stud ies for Veliparib  capsules are on going.   
Route (s) of Administration:   Oral 
Method of Administration:   Administer Veliparib  orally without regards to meals .  
Potential Drug Interactions:  Clinical studies evaluating the metabolism of Veliparib  have not been 
conducted.  However, results from the in vitro analysis reveal that this agent is metabolized by 
[CONTACT_321876] – CYP1A1, 2D6, 2C19 , and 3A4.  Veliparib  is neither a potent inhibitor nor a 
potent inducer of the CYP -[ADDRESS_1005405] parent drug along with metabolites suggesting that renal function 
plays an important role in the drug clearance and its metabolites.   
Patient Care Implications:  Patients may feel fatigue or tiredness.  Loss of appetite and losing 
weight are common.  Provide appropriate supportive care for diarrhea.  Avoid long -sun exposure as 
it might exacerbate skin rash.  
Availability:  Veliparib  is an investigational agent supplied to investigators by [CONTACT_735898] (DCTD), NCI.   Veliparib  is provided to the NCI under a 
Collaborative Agreement between the Pharmaceutical Collaborator  and the DCTD, NCI.  
8.5 AZD1775  (NSC 751084)  
Chem ical Name : 2-Allyl -1-[6-(1-hydroxy -1-methyl -ethyl) -2-pyridyl] -6-[4-(4-methylpi[INVESTIGATOR_9482] -
1-yl)anilino] pyrazolo[3,4 -d]pyrimidin -3-one hemihydrate  
 
Classification : Inhibitor of Wee1 -kinase  
 
CAS : 277170 -60-1 
 
Molecular Formula:   C27H32N8O2·0.5H2O  M.W.: 518.623  
 
Approximate Solubility : Aqueous solubility is 0.02 mg/mL .   
 
CTEP #9149 (01 -07-2020 ) 
 
75 
 Mode of Action : AZD1775  is an inhibitor of the Wee1 -kinase.   Wee1 is a tyrosine kinase 
upstream of  CDC2 thereby [CONTACT_735899], particularly the G2 
checkpoint.  As the majority of human cancers harbor abnormalities in the p53 pathway , they 
become more dependent on S - and G2 -phase checkpoints.  In preclinical models, AZD 1775  
selectively enhanced chemotherapy -induced death of cells deficient in p53 signaling.  
 
Description: AZD1775  is a crystalline, non -hygroscopic, monohydrate of the neutral drug.   It 
dehydrates upon heating leading to formation of a crystalline anhydrate . 
 
How Supplied: AZD1775  is supplied by [CONTACT_735900], CTEP/DCTD/NCI as capsules available in 25 mg (yellow color, size 2 gelatin 
capsule)  and 100 mg (orange col or, size 2 gelatin capsule) strengths.  Due to no further 
manufacturing, the 200 mg (light brown color, size 0 gelatin capsule) strength is available only as 
inventory allows until the shelf life is reached.  The capsules consist of a roller compacted gran ule 
of agent, lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.  Each 
high-density polyethylene (HDPE) bottle contains 20 capsules.  
 
Storage: Store bottles at controlled room temperature, not to exceed 30° C . 
 
Stability:   Shelf life studies of AZD1775  are on -going.  
 
Route  of Administration:  Oral administration.  Take AZD1775  at least  two hours before or two 
hours after a meal.  
 
Potential Drug Interactions : AZD1775  is primarily metabolized by [CONTACT_097]3A4 and is a weak, 
time-dependent inhibitor of CYP3A4.  Avoid concomitant CYP3A4 moderate or strong 
inhibitors/inducers, and sensitive substrates with a narrow therapeutic index.   AZD1775  is also a 
weak inhibitor of CYP2C19.   Caution should be exercised with concomitant administration of 
sensitive substrates or substrates with a narrow therapeutic index.  
 
In vitro transporter studies have shown that AZD1775  was an inhibitor of OATP1B1, OATP1B3, 
MATE1, MATE2K, P -glycoprotein ( P-gp) and breast cancer resistance protein (BCRP), and a 
substrate for P -gp and BCRP.   The PK parameters of AZD1775 could be altered if AZD1775  is 
co-administered with P -gp and BCRP inhibitors/inducers, and there is potential for drug -drug 
interactions whe n co-administered with OATP1B1, OATP1B3, MATE1, MATE2K, P -gp and 
BCRP substrates.  This finding is particularly relevant for drugs administered orally where 
exposure is normally limited by [CONTACT_69811] -mediated efflux, in particular some statins.  Modelling 
has pr edicted a substantial increase in the exposure of atorvastatin wh en co -administered with 
AZD1775  and the use of atorvastatin is therefore prohibited.  
 
Contraindications: Treatment with AZD1 [ADDRESS_1005406] feeding.  
 
CTEP #9149 (01 -07-2020 ) 
 
76 
 Availability  AZD1775  is an investigational agent supplied to investigators by [CONTACT_33997] (DCTD), NCI.   AZD1775  is provided to the NCI under a 
Collaborative Agreement between the Pharmaceutical Collaborator and DCTD, NCI.  
8.6 Trametinib dimethyl sulfoxide ([COMPANY_004]1120212B)  (NSC 763093)  
Chemical Name (IUPAC): equimolecular combination of acetamide, N -[3-[3-cyclopropyl -5-[(2-
fluoro -4-iodophenyl)amino] -3,4,6,7 -tetrahydro6,8 -dimethyl - 2,4,7 -trioxopyrido[4,3 -d]pyrimidin -
1(2H) -yl]phenyl ] with 1,1’ -sulfinylbis[methane]  
 
Other Names:  trametinib, [COMPANY_004]1120212, JTP -[ZIP_CODE], JTP -[ZIP_CODE], JTP -[ZIP_CODE], Mekinist  
 
CAS Registry Number: 1187431 -43-1 
 
Classification: MEK inhibitor  
 
Molecular Formula:   C26H23FIN 5O4 •  C2H6OS M.W.: 693.53  
  
Approximate Solubility: Trametinib dimethyl sulfoxide  is almost insoluble in water (<0.0001 
mg/mL at 25° C)  
 
Mode of Action:  Trametinib dimethyl sulfoxide  is a reversible, highly selective, allosteric 
inhibitor of mitogen -activated extracellular signal reg ulated kinase 1 (MEK1) and MEK2.  
Tumor cells commonly have hyperactivated extracellular signal -related kinase (ERK) pathways 
in which MEK is a critical component.  Trametinib  dimethyl sulfoxide inhibits activation of 
MEK by [CONTACT_190777].  
 
Description:  Trametinib dimethyl sulfoxide  is a white to almost white powder.  
 
How Supplied: [COMPANY_001] supplies and CTEP, NCI, DCTD distributes  0.5 mg and 2 mg (as free 
base) tablets.  Each commercially -labeled bottle contains 30 tablets with a desiccant.  
 
The tablet core contains mannitol, microcrystalline cellulose, hypromellose, croscarmellose 
sodium, magnesium stearate (non -animal), colloidal silicon dioxide , and sodium lauryl sulfate.  
 
• 0.5 mg tablets are yellow, modified oval, biconvex and film -coated with ‘GS’ debossed on one 
face and ‘TFC’ on the opposing face.  Aqueous film coating consists of hypromellose, titanium 
dioxide, polyethylene glycol, iron oxide yellow.  
• 2 mg tablets are pin k, round, biconvex and film -coated with ‘GS’ debossed on one face and 
‘HMJ’ on the opposing face.  Aqueous film coating consists of  hypromellose, titanium dioxide, 
polyethylene glycol, polysorbate 80, iron oxide red.  
 
Storage: Store tablets at 2°C -8°C in the original bottle.  Do not repackage tablets or remove 
desiccant.   Bottles should be protected from light and moisture.  
 
If a storage temperature excursion is identified, promptly return trametinib to 2°C -8°C and 
quarantine the supplies.  Provide a deta iled report of the excursion (including documentation of 
CTEP #9149 (01 -07-2020 ) 
 
77 
 temperature monitoring and duration of the excursion) to [EMAIL_087]  for 
determination of suitability.  
 
Stability: Refer to the package label for expi[INVESTIGATOR_1516].  
 
Route  of Administration:  Oral.  Take by [CONTACT_190802], either 1 hour before or 2 
hours after a meal.  If a dose of trametinib is missed, the dose can be taken if it is more than 12 
hours until the next scheduled dose.  
 
Potential Drug Interactions: In vitro studies suggest that trametinib dimethyl sulfoxide is not a 
substrate of CYP enzymes or of  human BCRP, MRP2, OATP1B1, OATP1B3, OATP2B1, OCT1 , 
or MATE1 transporters.  Trametinib elimination by [CONTACT_485192] M5 is dependent 
on carboxylester ases (CES1b, CES1c , and CES2).  M5 is eliminated by [CONTACT_097]3A4 and other 
pathways, presenting the clinically relevant, albeit low, potential for drug -drug interaction.  
Trametinib is a substrate for P -gp and BSEP, but this is not expected to be clinically rele vant due 
to trametinib’s high permeability.  
 
Trametinib dimethyl sulfoxide is an in vitro  inhibitor of CYP 2C8 and is anticipated to have 
overall low potential for drug interactions as a perpetrator.   It is also a weak CYP3A4 inducer 
and expected to have l ittle clinical effect on sensitive substrates.   Trametinib is not an inhibitor 
of CYP 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 , and 3A4 and not an inhibitor of P -gp, BCRP, 
OATP1B1, OATP1B3, OAT1, OAT3, OCT2 MRP2 and MATE1.  
 
Patient Care Implications: Advise women st udy participants of reproductive potential to use 
effective contraception while receiving study treatment and for [ADDRESS_1005407] to PMB.  
NCI-supplied agents may be requested by [CONTACT_6768] (or their authorized 
designee) at each participating institution.  The CTEP -assigned protocol number must be used 
for ordering all CTEP -supplied investigational agents.  The eligi ble participating investigators at 
each participating institution must be registered with CTEP, DCTD through an annual 
submission of FDA Form 1572 (Statement of Investigator), NCI Biosketch, Agent Shipment 
Form, and Financial Disclosure Form (FDF).  If the re are several participating investigators at 
one institution, CTEP -supplied investigational agents for the study should be ordered under the 
name [CONTACT_110726].  
Submit agent requests through the PMB Online Agen t Order Processing (OAOP) application.  
Access to OAOP requires the establishment of a CTEP Identity and Access Management (IAM) 
account and the maintenance of an “active” account status, a “current” password, and active 
person registration status.  For qu estions about drug orders, transfers, returns, or accountability, 
call or email PMB any time.  Refer to the PMB’s website for specific policies and guidelines 
related to agent management.   
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005408] of the receipt, dispensing and final disposition of all agents received from the PMB using 
the appropriate NCI Investigational Agent (Drug) Accountability Record (DARF) available on 
the CTEP for ms page.  Store and maintain separate NCI Investigational Agent Accountability 
Records for each agent, strength, formulation and ordering investigator on this protocol.  
Investigator Brochure Availability  
The current versions of the IBs for Everolimus, Veli parib, AZD1775,  and Trametinib dimethyl 
sulfoxide  will be accessible to site investigators and research staff through the PMB OAOP 
application.  Access to OAOP requires the establishment of a CTEP IAM account and the 
maintenance of an “active” account stat us, a “current” password and active person registration 
status.  Questions about IB access may be directed to the PMB IB Coordinator via email.  
Useful Links and Contacts  
• CTEP Forms, Templates, Documents:  http://ctep.cancer.gov/forms/  
• NCI CTEP Investigator  Registration:  [EMAIL_088]  
• PMB policies and guidelines: http://ctep.cancer.gov/branches/pmb/agent_management.htm  
PMB Online Agent Order Processing (OAOP) application: 
https://ctepcore.nci.nih.gov /OAOP/  
• CTEP Identity and Access Management (IAM) account: https://ctepcore.nci.nih.gov/iam/  
• CTEP IAM account help:  [EMAIL_089]  
• IB Coordinator:  [EMAIL_413]   
• PMB email:  [EMAIL_087]  
• PMB phone and hours of se rvice: (240) 276 -6575 Monday through Friday between 8:30 am 
and 4:30 pm (ET)  
 
9. GENETIC ANALYSIS  
9.1 Tumor Biopsies  
A mandatory pre -treatment tumor biopsy  (2 cores)  will be obtained from all patients after signing 
the consent and enrolling on the study to determine whether the tumor has a mutation in one of 
the pathways of interest , unless an FFPE block that meets Eligibility Criterion 3.1.[ADDRESS_1005409] week on study for confirmatory screening with 
the Oncominev3 (MATCHv3) assay.  Biopsy samples  will be fixed in formalin and shipped as 
described in Section 9.3.   
 
Additionally, an optional tumor biopsy ( 2-5 cores ) may be taken at or near  the time of disease 
progression to assess for new acquired mutations . 
 
There is increasing awa reness that biopsies lacking tumor of sufficient quantity or quality for 
analysis are a barrier to clinical research in both trials for which genetic sequencing establishes 
eligibility and in trials where paired pre - and post -treatment biopsies are collect ed to quantify 
CTEP #9149 (01 -07-2020 ) 
 
79 
 target modulation.  In a retrospective analysis, we found that only 70% of the 18 -gauge needle 
biopsies collected met pharmacodynamic assay quality control criteria due to necrosis, fibrosis, 
no or insufficient tumor content, and/or poor mor phology; the success rate is only 50% when 
both pre- and post - treatment (paired) biopsies are required (Ferry -Galow et al., manuscript in 
preparation).  The NCI is currently promoting efforts and providing resources to improve 
research biopsy quality give n that insufficient  tumor tissue  samples compromise  the scientific 
value of the study, the patients’ contribution to research, and the staff resources devoted to 
clinical trials .   
 
Based on our experience, immediate and significant improvements in biopsy quality can be 
achieved simply from better communication with the interventional radiologists performing the 
biopsy procedures.  We therefore recommend that participating site PIs invite their site’s 
radiologists to join the research team and to review and  discuss this protocol and the biopsy and 
specimen  handling requirements.   We recognize that these individuals are not always 
compensated for the additional time required to participate nor recognized for their effort, but at 
a minimum, communicating that  research biopsies present requirements beyond those of biopsies 
collected for diagnostic purposes is of considerable value.  Collecting multiple  cores from each 
patient during each biopsy procedure increases the probability of obtaining sufficient samples  for 
analysis , and the radiologist is best placed to determine how many cores are safe and feasible and 
evaluate patient willingness to continue donation.  In the absence of a reliable and rapid method 
for “real -time” tumor content evaluation and given the need to preserve the tissue rapi[INVESTIGATOR_735832], the interventional radiologist’s judgment and experience are 
critical to procuring and preserving quality material .    
 
An adequate tumor biopsy sample will contain at least 50% tumor  cells with minimal necrosis 
and stromal tissue; s amples with less than 50% tumor cells will undergo tumor enrichment using 
a standardized  macrodissection protocol.  In case  of samples with insufficient tumor content or 
DNA yield for analysis, the patient w ill be given the option to undergo a repeat tumor biopsy to 
obtain more tissue.  Patients from whom sufficient tumor DNA material cannot be obt ained for 
targeted analysis  will be  taken off -study.  
9.1.1 Biopsy Procedure  
No more than  three  serial tumor biopsies w ill be obtained through Interventional 
Radiology by a percutaneous approach : one mandatory at screening baselin e; one 
optional repeat biopsy if su fficient tumor DNA cannot be isolated  at baseline ; and one 
optional biopsy at time of disease progression  (this biopsy may instead be collected on 
day 1 (± 2 days) of the cycle following any restaging at which a 10 -19% increase in 
tumor volume is observed, per RECIST criteria, if the patient has been on study for at 
least 4 cycles).    
 
For eligibility determination, it  is preferred that  up to three  core biopsies18 -gauge in 
diameter and at least 1 cm in length are obtained.  Only percutaneous biopsies will be 
performed on patients with solid tumors .  However, excisional biopsy is allowed if 
indicated  and can be used for analysis .  Biopsies will be sent for analyses as defined in 
the protocol .  It is estimated that there will be between 2 -5 million cells from each biopsy.   
If a site is deemed appropriate for biopsy with minimal risk to the participant by 
[CONTACT_472] #9149 (01 -07-2020 ) 
 
80 
 agreement between the investigators and Interventional Radiology, an attempt at biopsy 
will be made .   
 
The biopsy procedure to be used in this protocol is described below; l ocal anesthesia will 
be administered.  Such biopsies can be safely performed as evidenced by [CONTACT_735901] [93] as well as our experience at the Clinical Center.  Risks of the procedure 
include, but are not limited to, bleeding, infection, pain, and scarring.  Each site will 
follow local Interventional Radiology SOPs for coagulant panel and platelets.  
 
• All biopsies will be by [CONTACT_735902] . 
• No biopsy by [CONTACT_735903] (endoscopic, laparoscopic, or surgical) procedure will 
be performed.  
 
The use of imaging to facilitate biopsies will be decided by [CONTACT_684564], CT scan, or MRI.  Should CT scan be 
needed for biopsy, the number of scans for each procedure will be limited to the 
minimum number needed to safely obtain a biopsy.  Tumor biopsies and local anesth esia 
will be administered only if they are considered to be of low risk to the participant as 
determined by [CONTACT_90330].  
 
If an initial attempt at percutaneous biopsy is unsuccessful, the patient will be given an 
option to proceed with a repeated attempt at percutaneous biopsy.  If a pre-treatment 
biopsy sample is unable to be obtained for a given patient, or the patient  choose s not to 
undergo  the pre -treatment tumor biopsy, he/she must be taken off study because t he 
gene tic data from the tumor biopsy are essential to the primary objective of the tria l. 
9.[ADDRESS_1005410] the NCI Phase I/II PK/PD Support Group in NIH 
Building [ADDRESS_1005411] 24 hours prior to sample collection (E -mail: NCIPK -
[EMAIL_12349]; Pager: 102 -[ZIP_CODE]; Phone: 301 -451-1169; Fax: 301 -480-5871).  
The lab staff will be paged for sample pi[INVESTIGATOR_9696] -up.  At the NCI only, 2 -3 additional cores may be 
collected and snap frozen  (see NCI Supplementary Appendix).    
 
Other participating sites should follow the sample collection instructions in Appendix E .  
 
Formalin jars (prefilled 30 mL)  pre-labeled with the participant ID, biopsy date, protocol 
number , and site of tissue biopsy will be used for biopsy collection .  Surgical tumor tissue and 
needle core biopsies (collected  by 16-18-gauge needles)  collected in neutral buffered formalin  
(one core per jar)  will be shipped via overnight  courier at ambient temperature on the day of 
biopsy collection  to [CONTACT_90342]’  laboratory (MoCha) at the Frederick National 
Laboratory for Cancer Research  (FNLCR) as defined in Appendix E .   
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005412]. 
Mickey Williams’  laboratory.  Do NOT  include patient identifiers (e.g., medical 
record number, patient name , or initials) with the samples.   
 
Please e-mail [EMAIL_14049]  if you have any questi ons 
about sample shippin g.  A sample shippi[INVESTIGATOR_735833] E . 
 
Following processing and paraffin embedding, one tissue  section will be stained with 
H&E for histopathological examination  by a designated pathologist.  Tumor cellular 
content must be at least  50% and estimated tumor content will be recorded.  The 
remaining biopsy will be extracted for nucleic acids using the Qiagen FFPET All -Prep 
procedure.   DNA will be assessed for quantity and quality by [CONTACT_735904] (OD 260/280) 
and a PCR -based amplification quality assessment test.   All specimens that meet 
necessary quantity and quality will be sequenced using a targeted sequencing assay.   This 
assay will identify those mutations that are used for treatment  assignment.    
 
If sufficient DNA is available  from the tumor biopsy , whole -exome sequenc ing will be 
performed retrospectively for research purposes  on samples unlinked from patient 
identifiers .   
9.3.2 Blood Samples  for Genetic Analysis  
Whole blood samples will be collected to obtain plasma and mononuclear cells .  All 
sequencing analysis from the plasma and mononuclear cells will be performed only after 
the samples are unlinked and stripped of the patient identifiers for retrospe ctive research 
sequencing.  The nucleic acid extracted from the  unlinked patient’s mononuclear cells 
will be sequenced to compare somatic mutational status to the tumor biopsy specimen.  
Plasma collected in this process will be delinked and used in explora tory research 
protocol to study (but not limited to), circulating tumor DNA.   
 
Two 10-mL cell -free DNA BCT (Streck) tube s should be collected  on the same day as 
the screening  eligibility  biopsy ( collection time can be either pre - or post-biopsy)  and 
shipped at ambient temperature  as described in Appendix E .  The samples should be 
labeled with only the unique patient ID.  Do NOT include patient identifiers (e.g., 
medical record number, patient name , or init ials) with the samples.    
 
Please e -mail [EMAIL_14049]  if you have any questions 
about sample shippin g.  A sam ple shippi[INVESTIGATOR_735834] E.    
 
Upon receipt at the service laboratory, genomic DNA will be extracted for clinical 
targeted sequencing.  
CTEP #9149 (01 -07-2020 ) 
 
82 
 9.4 Sample Handling  and Unlinking Procedures  
Biospecimens will be collected and processed using locked SOPs that will ensure both specimen 
quality and patient confidentiality pursuant to informed consent provisions.  
 
Using a c omputerized inventory system , all specimen collection and processing steps will be 
documented and the specific location of each specimen will be tracked.  Each new specimen 
collecte d will be assigned a unique barcode identifier that can be linked to the original specimen 
collected and other relevant information within the inventory system.  To ensure patient 
confidentiality, only containers used for the initial specimen collections w ill be labeled with 
patient identifiers.  Only the barcode identifier will be applied to all subsequent specimen 
containers.  When specimens are processed and aliquoted, no patient information will be 
included on the new containers.  Original specimen cont ainers will be discarded.  Only barcode -
labeled specimens without patient identifiers will be shipped for analysis and/or storage.  
Specimen labels will indicate: CTEP protocol number  9149 , unique patient accession number, 3 -
digit sample  number (see list b elow) , collection time, and total volume collected, as appropriate.  
Samples from sets of at least three patients will be grouped for scientific analysis.    
 
Standardized 3 -digit sample collection numbers:  
300 series: blood for pharmacodynamics  
500 series : tumor biopsies  
800 series: blood for research (Streck tubes)   
 
The inventory process contains other security provisions sufficient to safeguard patient privacy 
and confidentiality.  Access to the inventory system and associated documents will be restrict ed 
to appropriate individuals.  Requests to use specimens stored in the repository must be approved.  
The only patient information available in the inventory system will be the patient sex, diagnosis, 
and level of informed consent given.  SOPs ensure that any changes in informed consent made 
by a patient and relayed to the PI [INVESTIGATOR_52347].  All laboratory personnel will be trained to adhere to 
SOPs and will be monitored for h igh-quality performance.  
 
Any new use of these samples will require prospective IRB review and approval.  Access to 
these samples will only be granted following IRB approval of an additional protocol, granting 
the rights to use the material.  
   
If at any t ime, a patient withdraws from the study and does not wish for their existing samples to 
be utilized, the individual must provide a written request.  Following receipt of this request, the 
samples will be destroyed (or returned to the patient, if so request ed), and reported as such to the 
IRB.  Samples which are unlinked cannot be traced to the individual patients, and the patient’s 
request cannot be met.   Any samples lost (in transit or by a researcher) or destroyed due t o 
unknown sample integrity (e.g. , broken freezer allows for extensive sample thawing, etc.) will be 
reported as such to the IRB.  
   
CTEP #9149 (01 -07-2020 ) 
 
83 
 9.4.1 Sample Unlinking  
Clinical information linked to the unique patient IDs will be stored in a bioinformatics 
database along with the targeted sequencing panel.  Once patient has completed treatment 
on study and has been taken off study, the unique patient ID will be de leted  and a new 
random ID generated (arbitrary or random alphanumeric code)  in the database by [CONTACT_735905], thereby [CONTACT_735906].  Patient consent to allow research use of his/her samples  will be confirmed at 
this time.  The Bioinformatics team will inform [CONTACT_90342]’  laboratory of the 
new random ID, all samples from a given patient will be transferred to the new ID , and 
[CONTACT_69333]’  lab will also break the link to the unique pat ient ID.  The unique patient 
IDs will be discarded so there is no possibility of linking the samples to the sources.  
[CONTACT_69333]’  lab will proceed with (but not limited to)  whole exome sequencing on de -
identified samples for research purposes only.  Data  reports sent to the clinical site will be 
summary reports with no identifiable patient IDs whatsoever.    
 
When the study was re -opened with a new non -randomized design, a singular patient 
continued to receive randomized first -line study treatment.  As of Amendment Y  
(January 7, 2020 ), sample unlinking  (as described above)  may occur while this patient 
remains on study treatment , if the patient consents to this change,  in order to enable 
research -use analysis  of samples in parallel with the other results fro m the randomized 
phase of the study.  
 
10. STUDY CALENDAR :  
Baseline evaluations are to be conducted within 8 days  prior to start of protocol therapy.  If the 
patient’s condition deteriorates prior to initiation of treatment, evaluations should be repeated 
within [ADDRESS_1005413] be done within 28 days prior 
to the start of therapy .  The start of the next cycl e may be delayed for up to 1 week to 
accommodate scheduling conflicts.  Treatments within a cycle may be delayed up to +/ - 1 day to 
accommodate scheduling conflicts.  Cycles may be continued until a patient meets one of the 
criteria in Section 5. 6.  Additional evaluations will be conducted as clinically indicated at the 
investigator’s discretion.   
CTEP #9149 (01 -07-2020 ) 
 
84 
  Pre-
Study  Cycle 1 
Week 1  Cycle 1 
Week 2  Cycle 1 
Week 3  Cycle 1 
Week 4  Cycle 2 
onwards 
Week 1   
Informed consent   
X      
Tumor biopsy and blood 
sample for genetic analysis  X      
Study Druga  Xa Xa Xa Xa Xa  
Demographics   
X       
Medical historyb  
X X     
Concurrent meds  X         X……………… ...………...……… ………...……... X 
 
Physical examb  
X X    X 
 
Vital signsb  
X X    X  
Height   
X    
   
 
Weightb  
X X    X 
 
Performance status   
X X    X 
 
CBC w/diff, pltsc  
X X X X X X 
 
Serum chemistryc  
X X X X X X 
 
EKGi  
X     X 
Adverse event evaluation  X         X…………… ..……………… …….. ………………X  
Radiologic evaluation  X Tumor measurements are repeated every 2 cycles *  
Documentation (radiologic) must be provided for patients 
removed from study for progressive disease.   
-HCGd  
X    
  X 
Ophthalmologic exame X     X 
ECHO/MUGAf X      
Lipid monitoringg X Lipid monitoring every 2 cycles  
Urinary Proteinh X     X 
a:  Patients  will be assigned  to receive  one of the following study drug s or drug combinations at 
the assigned dose  (cycles +/- 1 day for scheduling) :  
• Veliparib : 40 mg orally BID qd days 1 -7 plus temozolomide 150 mg/m2 orally qd days 1 -
5 (no food restrictions)  in [ADDRESS_1005414] an 
evaluation of their LFTs at the time of coming off -treatment.  
• Everolimus : 10 mg orally each day (no food restrictions)  in 28 -day cycles.  
• Trametinib DMSO :  2 mg orally  each day  either  one hour before or two hours after a 
meal  in 28 -day cycles . 
• AZD1775 :  [ADDRESS_1005415] two hours before or two hours after 
a meal  plus carboplatin (AUC 5) IV on day 1 of every 21-day cycle . 
b:  History and physical, including vital signs and weight at the start of each cycle (up to 3 days 
before start of new cycle) . 
CTEP #9149 (01 -07-2020 ) 
 
85 
 c:  Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN , calcium, creatinine, 
glucose, phosphorus, potassium, SGOT[AST], SGPT[ALT], sodium, magnesium  prior to 
treatment (up to 8 days prior) and as indicated .  CBC w/diff, platelets and serum chemistries 
should be performed prior to cycle 1 treatment (up to 8 days prior),  weekly throughout 
cycle  1, and at the start of each subsequent cycle (up to 3  days before start of new cycle) .  
CBC with differential will be performed more frequently in patients with grade 4 neutro penia 
or thrombocytopenia until resolution to ≤ grade 3.  
d:   Urine  or serum  pregnancy test (women of childbearing potential) pre -study.   Repeat 
pregnancy test at the start of each subsequent cycle (up to 3 days before start of new cycle) for 
patients on AZD 1775 only.  
e:   Complete ophthalmologic examination at baseline for patients on MEK inhibitors only 
(within 6 months  prior to start of  therapy), and at the start of the second cycle .  Additional 
ophthalmologic  exams may be performed as clinically indicated.    
f:  Repeat echocardiograms for patients on trametinib DMSO or everolimus  only, every 3 cycles .  
Additional echocardiograms  may be performed as clinically indicated .  The same modality 
(either ECHO or MUGA) shoul d be used at baseline and at follow -up. 
g: Repeat lipid monitoring for patients on everolimus only (within 1 week prior to enrollment), 
and every 2 cycles . 
h: Repeat urinary protein at baseline for patients on everolimus only (within 1 week prior to 
enroll ment), and at the start of each subsequent cycle (up to 3  days before start of new cycle) . 
i:  Repeat EKGs at the start of each subsequent cycle (up to 3  days before start of new cycle) for 
patients on AZD1775 only.  
* CT scans can be performed every 4 cycles (for  both the 21-day and 28-day cycles) for patients 
on study more than one year; it the patient changes therapy, CT scans will be performed once 
every 2 cycles for 1 year.  
Baseline evaluations are to be conducted within 8 days prior to start of protocol therapy.  If the 
patient’s condition deteriorates prior to initiation of treatment, evaluations should be repeated 
within [ADDRESS_1005416] be done within 28 days prior 
to the start of therapy.  The start of the next cycle may be delayed for up to 1 week to 
accommodate scheduling conflicts.  Treatments within a cycle may be delayed up to +/ - 1 day to 
accommodate scheduling conflicts .  Cycles may be continued until a patient meets one of the 
criteria in Section 5.4 .  
  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005417] – Solid Tumors  
For the purposes of this study, patients should be re -evaluated every 2 cycles  (every 4  cycles for 
patients on study more than one year) .  Response and progression will be evaluated in this study 
using the new international criteria  proposed by [CONTACT_592846] (RECIST) guideline (version 1.1) [94].  Changes  in the largest diameter 
(unidimensional measurement) of the tumor lesions and the shortest diameter in the case of 
malignant lymph nodes are used i n the RECIST criteria.    
11.1.1  Definitions  
Evaluable for toxicity :  All patients will be evaluable for toxicity from the time of their 
first treatment with study drug . 
 
Evaluable for objective response :  Only those patients who have measurable disease 
present at  baseline, have received at least one cycle of therapy, and have had their disease 
re-evaluated will be considered evaluable for response.  These patients will have their 
response classified according to the definitions stated below.  (Note:  Patients who exhibit 
objective disease progression prior to the end of cycle 1 will also be considered 
evaluable.)  
 
Evaluable Non -Target Disease Response :  Patients who have lesions present at baseline 
that are evaluable but do not meet the definitions of measurable di sease, have received at 
least one cycle of therapy, and have had their disease re -evaluated will be considered 
evaluable for non -target disease.  The response assessment is based on the presence, 
absence, or unequivocal progression of the lesions.  
11.1.2  Disease Parameters  
Measurable disease :  Measurable lesions are defined as those that can be accurately 
measured in at least one dimension (longest diameter to be recorded) as > [ADDRESS_1005418] x -ray, as > [ADDRESS_1005419] scan, or > [ADDRESS_1005420] be recorded in millimeters  (or decimal fractions of 
centimeters).  
 
Note:  Tumor lesions that are situated in a previously irradiated area might or might  not 
be considered measurable.  
 
Malignant lymph nodes :  To be considered pathologically enlarged and measurable, a 
lymph node must be > [ADDRESS_1005421] scan (CT scan slice 
thickness recommended to be no greater than 5 mm).  At baseline and in follow -up, only 
the short axis will be meas ured and followed.  
 
Non-measurable disease :  All other lesions (or sites of disease), including small lesions 
(longest diameter <  10 mm or pathologic al lymph nodes with ≥ 10 to <  15 mm short 
axis), are considered non -measurable disease.  Bone lesions, lept omeningeal disease, 
ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast 
CTEP #9149 (01 -07-2020 ) 
 
87 
 disease, and abdominal masses (not followed by [CONTACT_462]), are considered as non -
measurable.  
 
Note:  Cystic lesions that meet the criteria for ra diographically defined simple cysts 
should not be considered as malignant lesions (neither measurable nor non -measurable) 
since they are, by [CONTACT_108], simple cysts.  
 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above.   However, if non -
cystic lesions are present in the same patient, these are preferred for selection as target 
lesions.  
 
Target lesions :  All measurable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representative of all involved organs, should be identified as target 
lesions  and recorded and measured at baseline.  Target lesions should be selected on the 
basis of their size (lesions with the longest diameter), be representative of all involved 
organs, but in addition should be those that lend themselves to reproducible repeated 
measurements.  It may be the case that, on occasion, the largest lesion does not lend it self 
to reproducible measurement in which circumstance the next largest lesion which can be 
measured reproducibly should be selected.  A sum of the diameters (longest for non -
nodal lesions, short axis for nodal lesions) for all target lesions will be calcu lated and 
reported as the baseline sum diameters.  If lymph nodes are to be included in the sum, 
then only the short axis is added into the sum.  The baseline sum diameters will be used 
as reference to further characterize any objective tumor regression in  the measurable 
dimension of the disease.  
 
Non-target lesions :  All other lesions (or sites of disease) including any measurable 
lesions over and above the 5 target lesions should be identified as non-target lesions and 
should also be recorded at baseline.   Measurements of these lesions are not required, but 
the presence, absence, or in rare cases unequivocal progression of each should be noted 
throughout follow -up.  
11.1.3  Methods for Evaluation of Measurable Disease  
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.  
 
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow -up.  Imaging -based 
evaluation is preferred to evaluation by [CONTACT_460](s) being 
followed cannot be imaged but are assessa ble by [CONTACT_461].  
 
Clinical lesions :  Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes) and 10 mm diameter as 
assessed using calipers (e.g., skin nodules).  In the case of skin lesions, documentation by 
[CONTACT_90657] y, including a ruler to estimate the size of the lesion, is recommended.  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005422] x -ray:  Lesions on chest x -ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by [CONTACT_6776].  However, CT is preferable.  
 
Conventional CT  and MRI :  This guideline has defined measurability of lesions on CT 
scan based on the assumption that CT slice thickness is [ADDRESS_1005423] 
slice thickness greater than 5 mm, the minimum size for a measurable lesion should be 
twice the sli ce thickness.  MRI is also acceptable in certain situations (e.g. for body 
scans).   
 
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, wh ich 
greatly impact image quality, lesion conspi[INVESTIGATOR_3934], and measurement.  Furthermore, the 
availability of MRI is variable globally.  As with CT, if an MRI is performed, the 
technical specifications of the scanning sequences used should be optimized for the 
evaluation of the type and site of disease.  Furthermore, as with CT, the modality used at 
follow -up should be the same as was used at baseline and the lesions should be 
measured/assessed on the same pulse sequence.  It is beyond the scope of the RECIST 
guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body 
parts, and diseases.  Ideally, the same type of scanner should be used and the image 
acquisition protocol should be followed as closely as possible to prior scans.  Body  scans 
should be performed with breath -hold scanning techniques, if possible.  
 
PET-CT:  At present, the low dose or attenuation correction CT portion of a combined 
PET-CT is not always of optimal diagnostic CT quality for use with RECIST 
measurements.  Howeve r, if the site can document that the CT performed as part of a 
PET-CT is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast), 
then the CT portion of the PET -CT can be used for RECIST measurements and can be 
used interchangeably w ith conventional CT in accurately measuring cancer lesions over 
time.  Note, however, that the PET portion of the CT introduces additional data which 
may bias an investigator if it is not routinely or serially performed.   
 
Ultrasound :  Ultrasound is not u seful in assessment of lesion size and should not be used 
as a method of measurement.  Ultrasound examinations cannot be reproduced in their 
entirety for independent review at a later date and, because they are operator dependent, it 
cannot be guaranteed t hat the same technique and measurements will be taken from one 
assessment to the next.  If new lesions are identified by [CONTACT_13192], confirmation by [CONTACT_12154].  If there is concern about radiation 
exposure at CT, MRI m ay be used instead of CT in selected instances.  
 
Endoscopy, Laparoscopy :  The utilization of these techniques for objective tumor 
evaluation is not advised.  However, such techniques may be useful to confirm complete 
pathological response when biopsies are  obtained or to determine relapse in trials where 
recurrence following complete response (CR) or surgical resection is an endpoint.  
 
Tumor markers :  Tumor markers alone cannot be used to assess response.  If markers are 
initially above the upper normal lim it, they must normalize for a patient to be considered 
CTEP #9149 (01 -07-2020 ) 
 
89 
 in complete clinical response.  Specific guidelines for both CA -125 response (in recurrent 
ovarian cancer) and PSA response (in recurrent prostate cancer) have been published [95-
97].  In addition, the Gynecologic Cancer Intergroup has developed CA -125 progression 
criteria which are to be integrated with objective tumor assessment for use in firs t-line 
trials in ovarian cancer [98]. 
 
Cytology, Histology :  These techniques can be used to differentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor 
types, such as germ cell tumors, where known residual benign tumors can remain).  
The cytological confi rmation of the neoplastic origin of any effusion that appears or 
worsens during treatment when the measurable tumor has met criteria for response or 
stable disease is mandatory to differentiate between response or stable disease (an 
effusion may be a side effect of the treatment) and progressive disease.  
 
FDG -PET:  While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesions on the basis 
of FDG -PET imaging can be identified according to the following algorithm:  
a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of 
PD based on a new lesion.  
b. No FDG -PET at baseline and a positive FDG -PET at follow -up:  If the positive 
FDG -PET at follow -up corresponds to a new site of disease confirmed by [CONTACT_4654], this 
is PD.  If the positive FDG -PET at follow -up is not confirmed as a new site of 
disease on CT, additional follow -up CT scans are needed to determine if there is 
truly progression o ccurring at that site (if so, the date of PD will be the date of the 
initial abnormal FDG -PET scan).  If the positive FDG -PET at follow -up 
corresponds to a pre -existing site of disease on CT that is not progressing on the 
basis of the anatomic images, this  is not PD.  
c. FDG -PET may be used to upgrade a response to a CR in a manner similar to a 
biopsy in cases where a residual radiographic abnormality is thought to represent 
fibrosis or scarring.  The use of FDG -PET in this circumstance should be 
prospectively described in the protocol and supported by [CONTACT_4623] -specific medical 
literature for the indication.  However, it must be acknowledged that both 
approaches may lead to false positive CR due to limitations of FDG -PET and 
biopsy resolution/sensitivity.  
 
Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake 
greater than twice that of the surrounding tissue on the attenuation corrected image.  
11.1.4  Response Criteria  
[IP_ADDRESS] Evaluation of Target Lesions  
Complete Response (CR) :  Disappearanc e of all target lesions.  Any 
pathological lymph nodes (whether target or 
CTEP #9149 (01 -07-2020 ) 
 
90 
 non-target) must have reduction in short axis to 
<10 mm.  
 
Partial Response (PR) :  At least a 30% decrease in the sum of the 
diameters of target lesions, taking as reference 
the baseline sum of diameters  
 
Progressive Disease (PD) :  At least a 20% increase in the sum of the 
diameters of target lesions, taking as reference 
the smallest su m on study (this includes the 
baseline sum if that is the smallest on study).  In 
addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at 
least 5 mm.  (Note:  the appearance of one or 
more new lesions is also cons idered 
progressions).  
 
Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR 
nor sufficient increase to qualify for PD, taking 
as reference the smallest sum of diameters while 
on study  
[IP_ADDRESS] Evaluation of Non -Target Lesions  
Complete Response (CR) : Disappearance of all non -target le sions and 
normalization of tumor marker level.  All lymph 
nodes must be non -pathological in size (<10 
mm short axis)  
 
         Note:  If tumor markers are initially above the 
upper normal limit, they must normalize for a 
patient to be considered in complet e clinical 
response.  
 
Non-CR/Non -PD:    Persistence of one or more non -target lesion(s) 
and/or maintenance of tumor marker level above 
the normal limits  
 
Progressive Disease (PD) : Appearance of one or more new lesions and/or 
unequivocal progression  of existing non -target 
lesions.  Unequivocal progression  should not 
normally trump target lesion status.  It must be 
representative of overall disease status change, 
not a single lesion i ncrease.     
 
Although a clear progression of “non -target” lesions only is exceptional, the 
opi[INVESTIGATOR_36408], and the 
CTEP #9149 (01 -07-2020 ) 
 
91 
 progression status should be confirmed at a later time by [CONTACT_463] (or 
Principal Investiga tor). 
 
[IP_ADDRESS] Evaluation of Best Overall Response  
The best overall response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for progressive 
disease the smallest measurements recorded  since the treatment started).  The 
patient's best response assignment will depend on the achievement of both 
measurement and confirmation criteria.  
 
For Patients with Measurable Disease (i.e., Target Disease)  
 
Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR > 4 wks.  Confirmation**  
CR Non-CR/Non -PD No PR  
> 4 wks.  Confirmation**  CR Not evaluated  No PR 
PR Non-CR/Non -
PD/not evaluated  No PR 
SD Non-CR/Non -
PD/not evaluated  No SD documented at least once > 4 wks .  
from baseline**  
PD Any Yes or No  PD  
no prior SD, PR or CR  Any PD***  Yes or No  PD 
Any Any Yes PD 
*      See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
**    Only for non -randomized trials with response as primary endpoint.  
***  In exceptional circumstances, unequivocal progression in non -target lesions may be accepted as 
disease progression.  
 
Note : Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration.”   Every effort should be made to document the objective 
progression even after discontinuation of treatment.  
 
 
For Patients with Non -Measurable Disease (i.e., Non -Target Disease)  
 
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
*  ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials so to assign this category 
when no lesions can be measured is not advised  
 
CTEP #9149 (01 -07-2020 ) 
 
92 
 11.1.5  Duration of Response  
Duration of overall response :  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first 
date that recurrent or progressive disease is objectively documented (taking as reference 
for progressive disease the smallest measurements recorded since the treatment started).  
 
The duration of overall CR is measured from the time measurement criteria are first met 
for CR unti l the first date that progressive disease is objectively documented.   
 
Duration of stable disease :  Stable disease is measured from the start of the treatment 
until the criteria for progression are met, taking as reference the smallest measurements 
recorde d since the treatment started, including the baseline measurements.  
 
12. STUDY OVERSIGHT AND D ATA  REPORTING / REGULATORY 
REQUIREMENTS  
Study Oversight  
This protocol is monitored at several levels, as described in this section.  The Protocol Principal 
Investiga tor is responsible for monitoring the conduct and progress of the clinical trial, including 
the ongoing review of accrual, patient -specific clinical and laboratory data, and routine and 
serious adverse events; reporting of expedited adverse events; and acc umulation of reported 
adverse events from other trials testing the same drug(s).  The Protocol Principal Investigator [INVESTIGATOR_25486] -based reporting portal.   
All Study Investigators at participat ing sites who register/enroll patients on a given protocol are 
responsible for timely submission of data via Medidata Rave and timely reporting of adverse 
events for that particular study.  This includes timely review of data collected on the electronic 
CRFs submitted via Medidata Rave.  
All studies are also reviewed in accordance with the enrolling institution’s data safety monitoring 
plan.  
Safety Monitoring Committee  
Because this is a multi -institutional protocol for which the NCI DTC is the coordinating center, it 
will be monitored by [CONTACT_649208] (SMC).  
12.[ADDRESS_1005424] is granted through the iMedidata application  to all persons with the appropriate 
roles assigned in the Regulatory Support System (RSS).  To access Rave via iMedidata, the site 
user must have an active CTEP IAM account (check at https:// ctepcore.nci.nih.gov/iam ) and the 
appropriate Rave role (Rave CRA, Rave Read -Only, Rave CRA (Lab Admin), Rave SLA, or 
Rave Investigator)  on either the LPO or participating organization roster at the enrolling site. To 
hold the Rave CRA role or Rave CRA (Lab Admin)  role, the user must hold a minimum of an 
AP registration type.  To hold the Rave Investigator role, the individual must be registered as an 
NPI[INVESTIGATOR_6735].  Associates can hold read -only roles in Rave.    
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005425] Login (https://login.im edidata.com/selectlogin) 
using their CTEP -IAM user name [CONTACT_2383], and click on the “accept” link in the upper 
right-corner of the iMedidata page.  Please note, site users will not be able to access the study in 
Rave until all required Medidata and stud y specific trainings are completed.  Trainings will be in 
the form of electronic learnings (eLearnings), and can be accessed by [CONTACT_124457].   
 
Users that have not previously activated their iMedidat a/Rave account at the time of initial site 
registration approval for the study in RSS will also receive a separate invitation from iMedidata 
to activate their account.  Account activation instructions are located on the CTSU website, Rave 
tab under the Rav e resource materials (Medidata Account Activation and Study Invitation 
Acceptance).  Additional information on iMedidata/Rave is available on the CTSU members’ 
website under the Rave tab or by [CONTACT_6821] 1 -[PHONE_103] or by e -
mail at  [EMAIL_013].  
12.1.1  Method  
This study will be monitored by [CONTACT_25540] (CTMS).  Data 
will be submitted to CTMS at least once every two weeks via Medidata Rave (or other 
modality if approved by [CONTACT_472]).  Information on CTMS rep orting is available at 
http://www.theradex.com/clinicalTechnologies/?National -Cancer -Institute -NCI-11.  On-
site audits will be conducted three times annually (one annual site visit and two data 
audits).  For CTMS monitored studies, after users have activated their accounts, please 
contact [CONTACT_735907] (609) 619 -7862  or by e -mail at 
CTMSSupport @theradex.com  for additional support with Rave and completion of CRFs.  
 
12.1.2  Responsibility for Data Submission  
For ETCTN trials, it is the responsibility of the PI(s) at the site to ensure that all 
investigators at the ETCTN Sites understand the procedures for  data submission for each 
ETCTN protocol and that protocol specified data are submitted accurately and in a timely 
manner to the CTMS via the electronic data capture system, Medidata Rave.   
 
Data are to be submitted via Medidata Rave to CTMS on a real -time basis, but no less 
than once every [ADDRESS_1005426] for the CRA at the ETCTN to 
resolve.  Monthly web -based reports are posted for review by [CONTACT_34001], CTEP.  Onsite audits will be conducted by [CONTACT_735908] #9149 (01 -07-2020 ) 
 
94 
 regulatory  requirements, GCP, and NCI policies and procedures with the overarching 
goal of ensuring the integrity of data generated from NCI -sponsored clinical trials, as 
described in the ETCTN Program Guidelines, which may be found on the CTEP 
(http://ctep.cancer.g ov/protocolDevelopment/electronic_applications/adverse_events.htm )   
and CTSU websites.  
 
An End of Study CRF is to be completed by [CONTACT_978], and is to include  a summary of study 
endpoints not otherwise captured in the database, such as (for phase 1 trials) , and a 
description of any dose -limiting toxicities (DLTs).  CTMS will utilize a core set of 
eCRFs that are Cancer Data Standards Registry and Repository (caDSR) compliant 
(http://cbiit.nci.nih.gov/ncip/biomedical -informatics -resources/interoperability -and-
semantics/metadata -and-models).  Customized eCRFs will be included when appropriate 
to meet unique study requirements.  The PI [INVESTIGATOR_278583], working 
closely with CTMS to ensure prospectively that all required items are appropriately 
captured in the eCRFs prior to study activation.  CTMS will prepare the eCRFs with 
built-in edit checks to the extent possible to promote data integrity.  
 
CDUS data submissions for ETCTN trials activated after March 1, 2014, will be carried 
out by [CONTACT_735909], Theradex.  CDUS submissions are performed by [CONTACT_34004] a monthly basis.  The trial’s lead institution is responsible for timely submission to 
CTMS via Rave, as above.  
 
Further information on data submission procedures can be found in the ETCTN Program 
Guidelines 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htm).  
 
12.2 Cooperative Research and Development Agreement (CRADA)/Clinical Trials 
Agreement (CTA)  
The agent(s) supplied by [CONTACT_472], DCTD, NCI used in this protocol is/are provided to the NCI 
under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical 
Company(ies) (hereinafter referred to as “Collaborator(s)”) and the NCI Division of Cancer 
Treatment and Diagnosis.  Therefore, the following o bligations/guidelines, in addition to the 
provisions in the “Intellectual Property Option to Collaborator” (http:// ctep.cancer.gov/industry ) 
contained within the terms of award, apply to the use of the Agent(s) in this study:  
 
1. Agent(s) may not be used for any purpose outside the scope of this protocol, nor can 
Agent(s) be transferred or licensed to any party not participating in the clinical study.  
Collaborator(s) data for Agent(s) are confidential and proprietary to Collaborator(s) and 
shall be mainta ined as such by [CONTACT_473].   The protocol documents for studies 
utilizing investigational Agents contain confidential information and should not be shared 
or distributed without the permission of the NCI.  If a copy of this protocol is requested 
by a patient or patient’s family member participating on the study, the individual should 
sign a confidentiality agreement.  A suitable model agreement can be downloaded from: 
http://ctep.cancer.gov . 
 
CTEP #9149 (01 -07-2020 ) 
 
95 
 2. For a clinical protocol where there is an investigation al Agent used in combination with 
(an)other investigational Agent(s), each the subject of dif ferent collaborative agreements , 
the access to and use of data by [CONTACT_474] (data pertaining to 
such combination use shall hereinafter be referred to as “Multi -Party Data.”):  
 
a. NCI will provide all Collaborators with prior written notice regarding the existence 
and nature of any agreements governing their collaboration with NIH, the design of 
the proposed combination protocol, and the e xistence of any obligations that would 
tend to restrict NCI's participation in the proposed combination protocol.  
 
b. Each Collaborator shall agree to permit use of the Multi -Party Data from the clinical 
trial by [CONTACT_735910], obtain regulatory approval or commercialize its own 
investigational Agent.  
 
c. Any Collaborator having the right to use the Multi -Party Data from these trials must 
agree in writing prior to the commen cement of the trials that it will use the Multi -
Party Data solely for development, regulatory approval, and commercialization of its 
own investigational Agent.  
 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement 
will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and 
unless additional disclosure is required by [CONTACT_735911]  (http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ).  
Additionally, all Clinical Data and Results and Raw Data will be collected, used , and 
disclosed consistent with all applicable federal statutes and regulations for the protection 
of human subjects, including, if applicable, the  Standards for Privacy of Individually 
Identifiable Health Information  set forth in [ADDRESS_1005427] be sent to 
the NCI, w ho will then notify the appropriate investigators (Group Chair for Cooperative 
Group studies, or PI [INVESTIGATOR_349]) of Collaborator's wish to contact [CONTACT_476].  
 
5. Any data provided to Collaborator(s) for Phase [ADDRESS_1005428] be in accordance with the 
guide lines and policies of the responsible Data Monitoring Committee (DMC), if there is 
a DMC for this clinical trial.  
 
6. Any manuscripts reporting the results of this clinical trial must be provided to CTEP for 
immediate delivery to Collaborator(s) for adviso ry review and comment prior to 
submission for publication.  Collaborator(s) will have [ADDRESS_1005429] that publication be delayed for up t o 
an additional 30 days to ensure that Coll aborator’s confidential and proprietary data, in 
addition to Collaborator(s)’s intellectual property rights, are protected.  Copi[INVESTIGATOR_36412](s) for courtesy review as soon 
as possible and preferab ly at least three (3) days prior to submission, but in any case, prior 
to presentation at the meeting or publication in the proceedings.   Press releases and other 
media presentations must also be forwarded to CTEP prior to release.   Copi[INVESTIGATOR_735835] #9149 (01 -07-2020 ) 
 
[ADDRESS_1005430] and/or press release/ media presentation should be sent to:  E-mail: 
[EMAIL_001]  
 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No 
publication, manuscript or other form of public disclosure shall conta in any of 
Collaborator’s confidential/ proprietary information.  
 
12.3 Publication Policy  
Recognizing the need to make clinical trial outcomes rapi[INVESTIGATOR_735836] [99], publication of the results from this study wi ll be a priority following 
completion of accrual, follow up, and data analyses.   
 
Authorship of this group -wide study will include the Coordinating Center PI, the study 
statistician, and one representative from each participating institution listed on the cover page of 
the protocol that contributed more than 10% of the eligible, evaluab le cases.  The first author, 
last author, corresponding author(s), and study statistician, will all be NCI investigators.  The 
CTEP medical monitor will also be listed as an author.  Lead investigators from laboratories 
involved in conducting correlative s tudies will be listed as authors if data from their laboratories 
are included in the clinical results manuscript.  
 
If several investigators were responsible for a participating institution’s accrual, the designated 
representative from that institution ord inarily will be the PI.  When an individual other than the 
PI [INVESTIGATOR_735837] a participating institution’s accrual, the PI [INVESTIGATOR_735838]/herself.  The intent is to offer recognition t o the 
individuals who have been most directly involved in the study.  Because the Coordinating Center 
PI [INVESTIGATOR_735839], the PIs 
at participating institutions accruing more than 10% of cases will be solicited routinely to 
determine whether another individual should be substituted for them in authorship.  There will be 
only one author from each of the participating institutions listed on the cover page of the 
protocol.  If the PI [INVESTIGATOR_735840], based on scientific contribution to the study, a second 
person from that PI’s institution will not automatically be accepted for authorship based on 
institutional accrual.   
 
This protocol includes several correlative studies that may be p ublished with the group -wide 
clinical results paper or as separate, stand -alone scientific papers.  The decision to publish 
correlative study papers separately will be made by [CONTACT_735912] [INVESTIGATOR_735841], and wil l be subject to the Collaborative Agreement for study 
publications described in Section 12. 3.  Authorship of the correlative results paper will include 
the Coordinating Center PI, the correlative study lead investigators, and researchers from the 
correlati ve studies laboratories nominated by [CONTACT_735913].  Correlative 
study lead investigators may also nominate authors who have contributed to the feasibility of the 
study and/or the development of assays and procedures that support ed evaluation of study 
samples.  The final decision on the authorship of any manuscripts related to this trial will be 
made by [CONTACT_735912].  
 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005431] initiated treatment will be included in the OR and PFS analyses 
within each agent cohort in which  objective response rate and PF S (as a secondary endpoint) will 
be assessed against the historical standards of 5% response rate and 25% 4-month PFS.  We will 
allow patients to be entered on trial and begin treatment based o n CLIA genetic testing reports 
from MATCH -designated labs  indic ating actionable mutations of interest in study DNA damage 
repair genes.  On -study biopsies will be collected from these patients for study confirmatory 
screening with the Oncominev3 (MATCHv3) assay.  Those whose aMOIs cannot be confirmed 
can choose to rem ain on study and receive study drugs but will not be counted as eligible or 
included in the primary efficacy analysis or the futility analysis.  
 
1. Within each agent cohort , up to 30 eligible patients will be accrued, to discriminate between 
tumor response rates of 20% vs. 5%.   If at least 4 objective responses (at least 13%) are 
observed among the 30 patients, this agent will be conside red promising for this mutation  
category.   If no objective responses are observed among the initial 12 eligible patients, 
beginning, for the veliparib plus temozolomide arm, with Amendment U), the cohort will be 
terminated early.  Accrual to the cohort will be paused after accrual of the initial [ADDRESS_1005432] 88% power 
to detect a true objective response rate of at least 20%.   It yields at least .94 probability of a 
negative result if the true objective response rate is no more than 5% .  As a secondary 
endpoint, [ADDRESS_1005433] 12 instances of 4 -month PFS (at least 
40%) are observed among the 30 patients, 4 -month PFS will be considered promising.   This 
will occur with 90% likelihood if the true 4 -month PFS rate is 50% (median PFS of 
4 months) and with 5% like lihood if the true 4 -month PFS rate is 25% (median PFS of 
2 months).  
 
13.1 Sample Size/Accrual Rate  
Given the re lative frequencies of mutations  it is anticipated that we will need to enroll up to [ADDRESS_1005434] initiated treatment will be included in the toxicity 
assessments.  
 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005435]  Selection  
This study will be open to all individuals regardless of gender, ethnicity, or race provided that the 
aforementioned inclusion and exclusion criteria are met.  For safety reasons, pregnant women 
and children are excluded from this study.  Patien ts for this study will be recruited through 
internal referral, our physician referral base, and through various cancer information hotlines 
(i.e., Clinical Studies Support Center, 1 -800-4Cancer).  Participants should realize that there is 
no guarantee of b enefit to them from participation in this trial.  The results of this trial may 
benefit future cancer patients.  To date, there is no information that suggests that differences in 
drug metabolism or effect on tumor would be expected in one ethnic group com pared to another.  
Efforts will be made to extend accrual to each representative population, but a balance must be 
struck between participant safety considerations and limitations on the number of individuals 
exposed to potentially ineffective treatments o n the one hand and the need to explore 
racial/ethnic aspects of clinical research on the other hand.  If differences in outcome that 
correlate to ethnic identity are noted, a follow -up study may be written to investigate those 
differences more fully.  
14.1.1  Inclu sion of Women and Minorities  
This study will be open to all individuals regardless of gender, ethnicity, or race provided 
that the aforementioned inclusion and exclusion criteria are met.  
 
Accrual Targets  
Ethnic Category  Sex/Gender  
Females   Males   Total  
Hispanic or Latino   18  18  36 
Not Hispanic or Latino  72   72  144 
Ethnic Category: Total of all subjects    90  (A1) + 90 (B1) = 180 (C1) 
Racial Category   
American Indian or Alaskan Native   1  1  2 
Asian   8   8  16 
Black or African American   8   8  16 
Native Hawaiian or other Pacific Islander  1  1  2 
White   72  72  144 
Racial Category: Total of all subjects  90 (A2) + 90 (B2) =  180 (C2) 
 (A1 = A2)   (B1 = B2)   (C1 = C2)  
 
Accrual Rate:  2-3 pts/month  Total Expected Accrual:   45 Min 700 Max 
Projected Start Date of study:  10/20/12       
 
CTEP #9149 (01 -07-2020 ) 
 
99 
 14.2 Justification for Exclusions  
Because the effects of study investigational agents on the developi[INVESTIGATOR_19241], 
pregnant women will be excluded from this trial.  Nursing women are also excluded, as there is 
an unknown but potential risk for adverse events in nursing infants secondary to treatment of the 
mother with study me dications.  
 
Participants with unstable or serious medical conditions (ongoing or active infection, 
symptomatic congestive heart failure [AHA Class II or worse], unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that wo uld limit compliance with study 
requirements) are excluded due to the possibility that the underlying condition may obscure the 
attribution of effect and adverse events with respect to study drugs and may limit study 
compliance.   
14.2.1  Participation of Children    
Because no dosing or adverse event data are currently available on the use of  many of 
these  investigational agents in  patients <18 years of age, children are excluded from this 
study, but may be eligible for future pediatric Phase I /II trials.  
14.3 Evaluation of Benefits and Risks/Discomforts  
There may or may not be any clinical benefit to a patient from participation in this trial.   Their 
participation will benefit future cancer patients .  Potential risks include the possible occurrence 
of any of a  range of side effects that are  listed in the consent document, as well as the risks 
associated with the acquisition and disclosure of information about germline variants  relevant to 
a patient’s hereditary risk of disease.  
 
The procedure for protecting aga inst or minimizing risks will be to medically evaluate patients as 
described in the Study Calendar ( Section 10 ).  To minimize the risk of disclosing information 
about potential nonambiguous germline variants from w hole exome seque ncing, samples will be 
de-identified once the patient has completed treatment and is taken off study.  No genetic data 
will be shared with the patient other than the data from the targeted sequencing panel.   A 
Certificate of Confidentiality has been  obtain ed for this study.   
 
The research component of this study  ([ADDRESS_1005436] 
optional biopsy should a baseline tumor biopsy sample contain insufficient DNA ) confers 
radiation exposure at an effective dose of 1.6 rem at the NIH Clinical Center .  This dose is below 
NIH RSC guidelines for adults of 5.0  rem per year and represents a slightly greater than minimal 
risk to patients.  
14.4 Consent and Assent Process and D ocumentation  
This protocol includes separate informed consent forms for tumor biopsy collection and 
treatment . An associate or principal investigator [INVESTIGATOR_52350], 
alternatives, drug administration plan, research objecti ves, and follow -up of this trial.  The 
patient will be provided IRB-approved consent (s) for review and signature [INVESTIGATOR_43865]/her questions 
will be answered.  After a decision is made to enroll into the study, a signature [CONTACT_735935] #9149 (01 -07-2020 ) 
 
100 
 from the patient.  The  original signed consent (s) go  to Medical Records; a copy is placed in the 
research record.  
 
All patients must have a signed informed consent form and an on -study (confirmation of 
eligibility) form filled out and signed by a participating investigator befo re entering on study.  
14.[ADDRESS_1005437] or Minimizing Any Potential Risks  
All care will be taken to minimize side effects, but they can be unpredictable in nature and 
severity.  This study may involve risks to patients, which are currently u nforeseeable.  All 
patients will be monitored for side effects from taking study medication and from undergoing 
blood sampling procedures.  If patients suffer any physical injury as a result of the participation 
in this study  at the NCI , immediate medical treatment is available at the Clinical Center, National 
Cancer Institute, Bethesda, Maryland.  Although no compensation is available, any injury will be 
evaluated and treated in keepi[INVESTIGATOR_735842].   
CTEP #9149 (01 -07-2020 ) 
 
101 
 15. REFERENCES  
1. Le Tourneau, C., et al., Molecularly targeted therapy based on tumour molecular profiling versus 
conventional therapy for advanced cancer (SHIVA): a multicentre, open -label, proof -of-concept, 
randomised, controlled phase 2 trial.  The Lancet Oncology, 2015. 16(13): p. 1324 -1334.  
2. Jaffe, C.C., Imaging and Genomics: Is There a Synergy?  Radiology, 2012. 264(2): p. 329 -331. 
3. Gevaert, O., et al., Non–Small Cell Lung Cancer: Iden tifying Prognostic Imaging Biomarkers by 
[CONTACT_735914] —Methods and Preliminary Results.  
Radiology, 2012. 264(2): p. 387 -396. 
4. Ding, J., et al., Emerging cancer therapeutic opportunities target DNA -repair systems.  Trend s 
Pharmacol Sci, 2006. 27(6): p. 338 -44. 
5. Pallis, A.G. and M.V. Karamouzis, DNA repair pathways and their implication in cancer 
treatment.  Cancer Metastasis Rev, 2010. 29(4): p. 677 -85. 
6. Schreiber, V., et al., Poly(ADP -ribose) polymerase -2 (PARP -2) is required for efficient base 
excision DNA repair in association with PARP -1 and XRCC1.  J Biol Chem, 2002. 277(25): p. 
[ADDRESS_1005438] and mammals.  Mutat Res, 2000. 
451(1-2): p. 39 -51. 
8. Ruscetti, T., et al., Stimulation of the DNA -dependent protein kinase by [CONTACT_52362](ADP -ribose) 
polymerase.  J Biol Chem, 1998. 273(23): p. [ZIP_CODE] -7. 
9. Galande, S. and T. Kohwi -Shigematsu, Poly(ADP -ribose) polymerase and Ku autoantigen form a 
complex and synergistically bind t o matrix attachment sequences.  J Biol Chem, 1999. 274(29): p. 
[ZIP_CODE] -8. 
10. Fernet, M., et al., Poly(ADP -ribose) polymerase, a major determinant of early cell response to 
ionizing radiation.  Int J Radiat Biol, 2000. 76(12): p. 1621 -9. 
11. Shall, S. and G. d e Murcia, Poly(ADP -ribose) polymerase -1: what have we learned from the 
deficient mouse model?  Mutat Res, 2000. 460(1): p. [ADDRESS_1005439] DNA damaging agents.  Mutat 
Res, 2000. 462(2-3): p. 159-66. 
13. Sulkowski, P.L., et al., 2-Hydroxyglutarate produced by [CONTACT_735915].  Sci Transl Med, 2017. 
9(375).  
14. Watanbe, E., Regulation of the human WEE1 Hu cdk tyro sine 15 -kinase during the cell cycle.  
Embo J, 1995. 14: p. 1878 -1891.  
15. Russell, P. and P. Nurse, Negative regulation of mitosis by [CONTACT_337754]1+, a gene encoding a protein 
kinase homolog.  Cell, 1987. 49(4): p. 559 -567. 
16. Masaki, T., et al., Cyclins and cyclin -dependent kinases: Comparative study of hepatocellular 
carcinoma versus cirrhosis.  Hepatology, 2003. 37(3): p. 534 -543. 
17. Iorns, E., et al., Integrated Functional, Gene Expression and Genomic Analysis for the 
Identification of Cancer Targets.  PLoS ONE, 2009. 4(4): p. e5120.  
18. Mir, S.E., et al., In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against 
Mitotic Catastrophe in Glioblastoma.  Cancer Cell, 2010. 18(3): p. 244 -257. 
19. Marshall, C.J., MAP kinase kinase kinase, MAP kinase  kinase and MAP kinase.  Curr Opin Genet 
Dev, 1994. 4(1): p. 82 -9. 
20. Deramaudt, T. and A.K. Rustgi, Mutant KRAS in the initiation of pancreatic cancer.  Biochim 
Biophys Acta, 2005. 1756 (2): p. 97 -101. 
21. Kohl, N.E., et al., Selective inhibition of ras -dependent transformation by a farnesyltransferase 
inhibitor.  Science, 1993. 260(5116): p. [ADDRESS_1005440], D.A., et al., Mutations in the epi[INVESTIGATOR_735843] -small -cell lung cancer treated with 
chemotherapy alone and in combination with erlotinib.  J Clin Oncol, 2005. 23(25): p. 5900 -9. 
CTEP #9149 (01 -07-2020 ) 
 
102 
 23. Andreyev, H.J., et al., Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' 
study.  Br J Cancer, 2001. 85(5): p. 692 -6. 
24. Davies, H., et al., Mutations of the BRAF gene in human cancer.  Nature, 2002. 417(6892): p. 
949-54. 
25. Hoshino, R., et al., Constitutive activation of the 41 -/43-kDa mitogen -activated protein kinase 
signaling pathw ay in human tumors.  Oncogene, 1999. 18(3): p. [ADDRESS_1005441] suppresses growth of colon 
tumors in vivo.  Nat Med, 1999. 5(7): p. 810 -6. 
27. Milella, M., et al., Therapeutic targeting of the MEK/M APK signal transduction module in acute 
myeloid leukemia.  J Clin Invest, 2001. 108(6): p. 851 -9. 
28. Wee, S., et al., PTEN -deficient cancers depend on PIK3CB.  Proc Natl Acad Sci U S A, 2008. 
105(35): p. [ADDRESS_1005442] in human cancer.  
Oncogene, 2005. 24(50): p. 7455 -64. 
30. Hennessy, B.T., et al., Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery.  Nat Rev 
Drug Discov, 2005. 4(12): p. 988 -1004.  
31. Steelman, L.S., et al., Akt as  a therapeutic target in cancer.  Expert Opi[INVESTIGATOR_735844], 2008. 12(9): p. 1139 -1165.  
32. Samuels, Y., et al., Mutant PIK3CA promotes cell growth and invasion of human cancer cells.  
Cancer Cell, 2005. 7(6): p. 561 -73. 
33. Cantley, L.C. and B.G . Neel, New insights into tumor suppression: PTEN suppresses tumor 
formation by [CONTACT_735916] 3 -kinase/AKT pathway.  Proc Natl Acad Sci U S A, 
1999. 96(8): p. 4240 -5. 
34. Ogita, S. and P. Lorusso, Targeting phosphatidylinositol 3 kinase ( PI3K) -Akt beyond rapalogs.  
Target Oncol, 2011. 6(2): p. 103 -17. 
35. Cejka, D., et al., Everolimus (RAD001) and anti -angiogenic cyclophosphamide show long -term 
control of gastric cancer growth in vivo.  Cancer Biol Ther, 2008. 7(9): p. 1377 -85. 
36. Testa, J. R. and A. Bellacosa, AKT plays a central role in tumorigenesis.  Proc Natl Acad Sci U S 
A, 2001. 98(20): p. [ZIP_CODE] -5. 
37. Han, Z., et al., Akt1/protein Kinase Bα is Involved in Gastric Cancer Progression and Cell 
Proliferation.  Digestive Diseases and Science s, 2008. 53(7): p. [ADDRESS_1005443] cancer: correlation with p53, Hdm2 and 
patient outcome.  Eur J Cancer, 2005. 41(7): p. [ADDRESS_1005444] carcinoma.  Cancer Res, 
2005. 65(7): p. 2554 -9. 
40. Shayesteh, L., et al., PIK3CA is implicated as an oncogene in ovarian cancer.  Nat Genet, 1999. 
21(1): p. 99-102. 
41. Shoman, N., et al., Reduced PTEN expression predicts relapse in patients with breast carcinoma 
treated by [CONTACT_15004].  Mod Pathol, 2005. 18(2): p. 250 -9. 
42. Nakayama, K., et al., Sequence mutations and amplification of PIK3CA and AKT2 genes in 
purified ovarian serous neoplasms.  Cancer Biol Ther, 2006. 5(7): p. 779 -85. 
43. Hu, L., et al., Inhibition of phosphatidylinositol 3' -kinase increases efficacy of paclitaxel in in 
vitro and in vivo ovarian cancer models.  Cancer Res, 2002. 62(4): p. 1087 -92. 
44. MK-2206.  [COMPANY_006] & Co., Inc, 2008.  
45. Barnett, S.F., et al., Identification and characterization of pleckstrin -homology -domain -dependent 
and isoenzyme -specific Akt inhibitors.  Biochem J, 2005. 385(Pt 2): p. 399 -408. 
46. Engelman, J.A., et al., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and 
PIK3CA H1047R murine lung cancers.  Nat Med, 2008. 14(12): p. [ADDRESS_1005445] cancer: how big a role migh t it play?  
Breast Cancer Research, 2001. 3(5): p. 304 -312. 
CTEP #9149 (01 -07-2020 ) 
 
103 
 48. Kawauchi, K., et al., The PI3K/Akt pathway as a target in the treatment of hematologic 
malignancies.  Anti-cancer agents in medicinal chemistry, 2009. 9(5): p. 550.  
49. Kinkade, C.W., et al., Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone -
refractory prostate cancer in a preclinical mouse model.  The Journal of clinical investigation, 
2008. 118(9): p. 3051.  
50. Kirkegaard, T., et al., AKT activation predicts outcome in breast cancer pat ients treated with 
tamoxifen.  The Journal of Pathology, 2005. 207(2): p. 139 -146. 
51. Konecny, G.E., et al., Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER -
2-Overexpressing and Trastuzumab -Treated Breast Cancer Cells.  Cancer Res, 20 06. 66(3): p. 
1630 -1639.  
52. Kornblau, S.M., et al., Simultaneous activation of multiple signal transduction pathways confers 
poor prognosis in acute myelogenous leukemia.  Blood, 2006. 108(7): p. [ADDRESS_1005446] carcinomas and hepatocellular 
carcinomas.  Oncogene, 2004. 24(8): p. 1477 -1480.  
54. Min, Y.H., et al., Constitutive phosphorylation of Akt//PKB protein in acute myeloid leukemia: its 
significance as a prognostic variable.  Leukemia, 2003. 17(5): p. 995 -997. 
55. Nakanishi, K., et al., Akt phosphorylation is a risk factor for early disease recurrence and poor 
prognosis in hepatocellular carcinoma.  Cancer, 2005. 103(2): p. 307 -312. 
56. Oki, E., et al., Akt phosphorylation associates with LOH of  PTEN and leads to chemoresistance 
for gastric cancer.  International Journal of Cancer, 2005. 117(3): p. 376 -380. 
57. Oza, A.M., Molecular correlates associated with a phase II study of temsirolimus (CCI -779) in 
patients with metastatic or recurrent endome trial cancer –NCIC IND 160.  J Clin Oncol, 2006. 24: 
p. A3003.  
58. Rahman, M.A., et al., Impact of PTEN expression on the outcome of hepatitis C virus -positive 
cirrhotic hepatocellular carcinoma patients: Possible relationship with COX II and inducible 
nitric oxide synthase.  International Journal of Cancer, 2002. 100(2): p. 152 -157. 
59. Salvesen, H.B., et al., Integrated genomic profiling of endometrial carcinoma associates 
aggressive tumors with indicators of PI3 kinase activation.  Proceedings of the Nationa l Academy 
of Sciences, 2009. 106(12): p. 4834 -4839.  
60. Sosman, J.A., I. Puzanov, and M.B. Atkins, Opportunities and Obstacles to Combination 
Targeted Therapy in Renal Cell Cancer.  Clin Cancer Res, 2007. 13(2): p. 764s -769. 
61. Staal, S.P., Molecular cloni ng of the akt oncogene and its human homologues AKT1 and AKT2: 
amplification of AKT1 in a primary human gastric adenocarcinoma.  Proceedings of the National 
Academy of Sciences of the [LOCATION_002] of America, 1987. 84(14): p. [ADDRESS_1005447]-Germain, M. -E., et al., Regulation of COX -2 protein expression by [CONTACT_735917] -kappaB/IkappaB pathway.  Molecular Cancer, 2004. 3(1): p. 7.  
63. Tanno, S., et al., AKT activation up -regulates insulin -like growth factor I recepto r expression and 
promotes invasiveness of human pancreatic cancer cells.  Cancer Res, 2001. 61(2): p. 589 -93. 
64. Uddin, S., et al., Role of phosphatidylinositol 3' -kinase/AKT pathway in diffuse large B -cell 
lymphoma survival.  Blood, 2006. 108(13): p. 4178 -4186.  
65. Wolf, J. and B.M. Slomovitz, Novel biologic therapi[INVESTIGATOR_735845].  
International Journal of Gynecological Cancer, 2005. 15(2): p. [ADDRESS_1005448] Malignancies.  Clinical Cancer 
Research, 2011. 17(21): p. 6840 -6846.  
67. Donawho, C.K., et al., ABT-888, an orally active poly(ADP -ribose) polymerase inhibitor that 
potentiates DNA -damagin g agents in preclinical tumor models.  Clin Cancer Res, 2007. 13(9): p. 
2728 -2737.  
68. Motzer, R.J., et al., Efficacy of everolimus in advanced renal cell carcinoma: a double -blind, 
randomised, placebo -controlled phase III trial.  The Lancet. 372(9637): p. 449 -456. 
CTEP #9149 (01 -07-2020 ) 
 
104 
 69. Grunwald, V., et al., An international expanded -access programme of everolimus: Addressing 
safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial 
vascular endothelial growth factor receptor -tyrosine kinase inhibitor therapy.  European Journal 
of Cancer, 2012. 48(3): p. 324 -332. 
70. Kim, D. -H., et al., mTOR Interacts with Raptor to Form a Nutrient -Sensitive Complex that 
Signals to the Cell Growth Machinery.  Cell, 2002. 110(2): p. 163 -175. 
71. Gibbons, J.J., R.T. Abraham, and K. Yu, Mammalian Target of Rapamycin: Discovery of 
Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth.  
Seminars in Oncology, 2009. 36, Supplement 3 (0): p. S3 -S17. 
72. Tabor, H.K., et al., Genomi cs really gets personal: How exome and whole genome sequencing 
challenge the ethical framework of human genetics research.  American Journal of Medical 
Genetics Part A, 2012. 155(12): p. 2916 -2924.  
73. Kass, N.E., et al., Medical privacy and the disclosure of personal medical information: The 
beliefs and experiences of those with genetic and other clinical conditions.  American Journal of 
Medical Genetics Part A, 2004. 128A (3): p. 261 -270. 
74. Dressler, L.G. and S.F. Terry, How Will GINA Influence Participati on in Pharmacogenomics 
Research and Clinical Testing?  Clin Pharmacol Ther, 2009. 86(5): p. 472 -475. 
75. Caulfield, T., et al., Research Ethics Recommendations for Whole -Genome Research: Consensus 
Statement.  PLoS Biol, 2008. 6(3): p. e73.  
76. Berg, J.S., M. J. Khoury, and J.P. Evans, Deploying whole genome sequencing in clinical practice 
and public health: Meeting the challenge one bin at a time.  Genet Med, 2011. 13(6): p. 499 -504. 
77. Hussain, M., et al., Pi[INVESTIGATOR_735846] (ABT -888) with temozolomide (TMZ) in patients (pts) 
with metastatic castration -resistant prostate cancer (mCRPC).  J Clin Oncol 30, 2012. 30(suppl 5; 
abstr 224).  
78. Isakoff, S.J., et al., A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide 
for metastatic breast  cancer.  ASCO Meeting Abstracts, 2010. 28(15_suppl): p. 1019.  
79. Balagula, Y., et al., Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib 
(AZD6244, ARRY -142886).  Investigational New Drugs, 2011. 29(5): p. 1114 -1121.  
80. Lacouture,  M., et al., Clinical practice guidelines for the prevention and treatment of EGFR 
inhibitor -associated dermatologic toxicities.  Supportive Care in Cancer, 2011. 19(8): p. [ADDRESS_1005449], 2011. 16(5): p. 566 -578. 
82. Bruce, D. and P.H. Tan, Blocking the interaction of vascular endothelial growth factor receptors 
with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a 
new look?  Expert Opi[INVESTIGATOR_194444], 2011. 20(10): p. [ADDRESS_1005450]: guidelines for response criteria for use in trials testing 
immunotherapeutics.  The Lancet Oncology, 2017. 18(3): p. e143 -e152.  
84. US Food and Drug Administration,  Clinical Review, September 27, 2011; Drugs@FDA . 
85. Mas-Moruno, C., F. Rechenmacher, and H. Kessler, Cilengitide: the first anti -angiogenic small 
molecule drug candidate design, synthesis and clinical evaluation.  Anticancer Agents Med 
Chem, 2010. 10(10): p. 753 -68. 
86. Kummar, S., et al., Compressing drug development timelines in oncology using phase '0' trials.  
Nat Rev Cancer, 2007. 7(2): p. 131 -139. 
87. Kummar, S., et al., Advances in using PARP inhibitors to tr eat cancer.  BMC Medicine, 2012. 
10(1): p. 25.  
88. Kummar, S., et al., Utilizing targeted cancer therapeutic agents in combination: novel 
approaches and urgent requirements.  Nat Rev Drug Discov, 2010. 9(11): p. 843 -856. 
89. Dudley, J.C., et al., Microsatell ite Instability as a Biomarker for PD -1 Blockade.  Clin Cancer 
Res, 2016. 22(4): p. 813 -20. 
CTEP #9149 (01 -07-2020 ) 
 
105 
 90. Le, D.T., et al., PD-1 Blockade in Tumors with Mismatch -Repair Deficiency.  N Engl J Med, 
2015. 372(26): p. 2509 -20. 
91. Chen, P. -L., et al., Analysis of Immune S ignatures in Longitudinal Tumor Samples Yields Insight 
into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.  
Cancer Discovery, 2016. 6(8): p. 827 -837. 
92. Wallin, J.J., et al., Atezolizumab in combination with bevacizumab enhances antigen -specific T -
cell migration in metastatic renal cell carcinoma.  Nature Communications, 2016. 7: p. [ZIP_CODE].  
93. Dowlati, A., et al., Sequential tumor biopsies in early phase clinical trials of anticancer agents 
for pharmacodynamic evaluation.  Clin Cancer Res, 2001. 7(10): p. 2971 -6. 
94. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST 
guideline (version 1.1).  Eur J Cancer, 2009. 45(2): p. 228 -47. 
95. Bubley, G.J., et al., Eligibility and response guidelines for phase II clinical trials in androgen -
independent prostate cancer: recommendations from the Prostate -Specific Antigen Working 
Group.  J Clin Oncol, 1999. 17(11): p. 3461 -7. 
96. Rustin, G.J., et al., Re: New guidelines to evaluate the response to treatment in solid tumors 
(ovarian cancer).  J Natl Cancer Inst, 2004. 96(6): p. 487 -8. 
97. Scher, H.I., et al., Design and end points of clinical trials for patients with progressive pros tate 
cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical 
Trials Working Group.  J Clin Oncol, 2008. 26(7): p. 1148 -59. 
98. Vergote, I., et al., Re: new guidelines to evaluate the response to treatment in solid tumors 
[ovarian cancer]. Gynecologic Cancer Intergroup.  J Natl Cancer Inst, 2000. 92(18): p. 1534 -5. 
99. Doroshow, J.H., Commentary: Publishing Cancer Clinical Trial Results: A Scientific and Ethical 
Imperative.  Oncologist, 2008. 13(9): p. 930 -932. 
100. Investiga tor's Brochure: Veliparib (ABT -888). No. 5 ed. 2011: Abbott Laboratories.  
101. Yamaguchi, T., et al., Antitumor activities of JTP -[ZIP_CODE] ([COMPANY_004]1120212), a novel MEK1/2 
inhibitor, on colorectal cancer cell lines in vitro and in vivo.  Int J Oncol, 2011. 39(1): p. 23 -31. 
102. Freymann, J., et al., Image Data Sharing for Biomedical Research —Meeting HIPAA 
Requirements for De -identification.  Journal of Digital Imaging, 2012. 25(1): p. 14 -24. 
 
  
CTEP #9149 (01 -07-2020 ) 
 
106 
 APPENDIX A: Performance Status Criteria  
 
 
 
 
Karnofsky Performance Sca le 
Percent  Description  
100 Normal, no complaints, no evidence of disease.  
90 Able to carry on normal activity; minor signs or 
symptoms of disease.  
80 Normal activity with effort; some signs or symptoms of 
disease.  
[ADDRESS_1005451] of his/her needs.  
50 Requires considerable assistance and frequent medical 
care.  
40 Disabled, requires special care and assistance.  
30 Severely disabled, hospi[INVESTIGATOR_374].  Death not 
imminent.  
20 Very sick, hospi[INVESTIGATOR_374].  Death not 
imminent.  
10 Moribund, fatal processes progressing rapi[INVESTIGATOR_375].  
0 Dead.  
 
 
 
 
 
 
 
 
 
 
CTEP #9149 (01 -07-2020 ) 
 
107 
 APPENDIX B: Potential Drug Interactions  and Drug Information Handouts   
 
CYP2C19 Inhibitors  
Amiodarone  
Amitriptyline  
Amprenavir  
Aprepi[INVESTIGATOR_735847]/Vitamin D [ADDRESS_1005452]. John’s wort   
 
CYP2C19 Substrates  
Carisoprodol  
Cilostazol  
Citalopram  
Clobazam  
Clomipramine  
Desogestrel  
Diazepam  Escitalopram  
Esomeprazole  
Fosphenytoin  
Imipramine  
Lansoprazole  
Mephenytoin  
Mephobarbital  Methsuximide  
Moclobemide  
Nelfinavir  
Nilutamide  
Omeprazole  
Pantoprazole  
Pentamidine  Phenobarbital  
Phenytoin  
Progesterone  
Rabeprazole  
Sertraline  
Trimipramine  
Voriconazole  
 
CYP3A4 Inhibitors  
Acetaminophen  
Acetazolamide  
Amiodarone  
Amlodipi[INVESTIGATOR_735848] #9149 (01 -07-2020 ) 
 
[ADDRESS_1005453]. John’s wort  
 
CYP3A4 Substrates  
Albuterol  
Alfentanil  
Alprazolam  
Amlodipi[INVESTIGATOR_735849], conj., synthetic  
Estrogens, conj., equine  
Estrogens, conj., esterified  
Estrone  
Estropi[INVESTIGATOR_735850] #9149 (01 -07-2020 ) 
 
109 
 Dihydroergotamine  
Diltiazem  
Disopyramide  Isradipi[INVESTIGATOR_735851]: Adapted from Cytochrome P450 Enzymes: Substrates, Inhibitors, and Inducers.  In: Lacy CF, 
Armstrong LL, Goldman MP, Lance LL eds. Drug Information Handbook 15TH ed. Hudson, OH; 
LexiComp Inc. 2007: 1899 -1912.   
 
Only major substrates and effective inducers are listed.  Because the lists of these agents are constantly 
changing, it is important to regularly consult a frequently -updated medical reference.  
 
 
PgP substrates, inducers, and inhibitors  
Substrates: colchicine, digoxin, fexofenadine, indinavir, paclitaxel, talinolol, topotecan, 
vincristine, everolimus  
Inducers: rifampin, St John’s wort  
PgP Inhibitors and PgP/CYP3A Dual Inhibitors: amiodarone, azithromycin, captopril, 
carvedilol, clarithromycin, conivaptan, diltiazem, dronedarone, elacridar, erythromycin, 
felodipi[INVESTIGATOR_050], fexofenadine, fluvoxamine, ginkgo (ginkgo biloba), indinavir, itraconazole, 
lopi[INVESTIGATOR_054], mibefradil, milk thistle (silybum marianum), nelfinavir, nifedipi[INVESTIGATOR_050], nitrendipin e, 
paroxetine, quercetin, quinidine, ranolazine, rifampin, ritonavir, saquinavir, Schisandra 
chinensis, St John’s wort, talinolol, Telaprevir, telmisartan, ticagrelor, tipranavir, tolvaptan, 
valspodar, verapamil  
Reference: Internal Clinical Pharmacology D rug-drug interaction (DDI) memo, updated [ADDRESS_1005454]-
2012 which summarizes DDI data from three sources including the FDA’s “Guidance for 
Industry, Drug Interaction Studies”, the University of Washington’s Drug Interaction Database, 
and Indiana University School  of Medicine's Drug Interaction Table.  
 
  
CTEP #9149 (01 -07-2020 ) 
 
110 
 Information for Patients, Their Caregivers, and Non -Study Healthcare Team on Possible 
Interactions with Veliparib and Other Drugs and Herbal Supplements  
 
The patient ______________________________________ is enrol led on a clinical trial using 
the experimental study drug Veliparib .  This clinical trial is sponsored by [CONTACT_6808].  This form is addressed to the patient, but includes important information for others 
who care for this patient.  
 
Thes e are the things that you as a prescriber need to know:  
 
Veliparib  interacts with certain specific enzymes in the liver.  
• The enzymes in question are  CYP1A1, CYP2D6, CYP2C19, and CYP3A4.  Veliparib is 
metabolized by [CONTACT_735918].  
 
To the patient:  Take this paper with you to your medical appointments and keep the 
attached information card in your wallet .   
 
Veliparib may interact with other drugs which can cause side effects.  For this reason, it is very 
important to tell your study doctors of any medicines you are taking before you enroll onto this 
clinical trial.  It is also very important to tell your doctors if you  stop taking any regular 
medicines, or if you start taking a new medicine while you take part in this study.  When you talk 
about your current medications with your doctors, include medicine you buy without a 
prescription (over -the-counter remedy), or herb al supplements such as St. John’s Wort.  It is 
helpful to bring your medication bottles or an updated medication list with you.  
 
Many health care providers can write prescriptions.  You must tell all of your health care 
providers (doctors, physician assist ants, nurse practitioners, or pharmacists) you are taking part 
in a clinical trial.  
 
These are the things that you and they need to know:  
 
Veliparib must be used very carefully with other medicines that need certain liver enzymes to be 
effective or to be  cleared from your system.  Before you enroll onto the clinical trial, your 
study doctor will work with your regular health care providers to review any medicines and 
herbal supplements that are considered “strong inducers/inhibitors of CYP 1A1, CYP2D6, 
CYP2C19, and CYP3A4.” 
 
•  Please be very careful!  Over -the-counter drugs (including herbal supplements) may 
contain ingredients that could interact with your study drug.  Speak to your doctors or 
pharmacist to determine if there could be any side effects.  
•  Your regular health care provider should check a frequently updated medical reference or 
call your study doctor before prescribing any new medicine or discontinuing any 
medicine.   
Your study doctor’s name [CONTACT_832] ________________________________ _____________ _  
and he or she can be contact[CONTACT_6811]  _____________________________________.             
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005455] with drugs that are 
processed by [CONTACT_6813] .  Because of this, it is very 
important to:  
➢ Tell your doctors if you stop taking any medicines or if 
you start taking any new medicines  
➢ Tell all of your health care providers (doctors, 
physician assistants, nurse prac titioners, or 
pharmacists) that you are taking part in a clinical trial  
➢ Check with your doctor or pharmacist whenever you 
need to use an over -the-counter medicine or herbal 
supplement s such as St. John’s Wort  
➢ Avoid grapefruit, grapefruit juice, Seville oranges, and 
starfruit while taking this drug  
 Veliparib  interacts with CYP 1A1, 2D6, 2C19, and 3A4, 
and must be used very carefully with other medicines that 
interact with these enzymes and proteins.  
• Before you enroll onto the clinical trial, your study doctor 
will work with your regular health care providers to 
review any medicines and herbal supplements that are 
considered “strong inducers/inhibitors of CYP  1A1, 
CYP2D6, CYP2C19, and CYP3A4” 
• Before prescribing new medicines, your regular 
prescribers should go to a frequently -updated medical 
reference for a list of drugs to avoid, or contact [CONTACT_297478].   
• Your study doctor’s name [CONTACT_832]:  
and can be contact[CONTACT_6811]:  
CTEP #9149 (01 -07-2020 ) 
 
112 
 Information for Patients, Their Caregivers , and Non -Study Healthcare Team on Possible 
Interactions with AZD1775  and Other Drugs and Herbal Supplements  
 
The patient ______________________ _________ ______ is enrolled on a clinical trial using the 
experimental study drug AZD177 5.  This clinical trial is sponsored by [CONTACT_6808].  This form is addressed to the patient, but includes important information for others 
who care for this patient.  
 
These are the things that you as a prescriber need to know:  
 
AZD1775  interacts with certain specific enzymes in the liver and certain transport proteins that 
help move drugs in and out of cells.  
 
• The enzyme in question  is CYP 3A4 .  AZD1775  is metabolized by [CONTACT_097]3A4 and may be 
affected by [CONTACT_735919] .  AZD1775  is an inhibitor of 
CYP 3A4 and may affect the metabolism of other drugs.  
 
• The proteins in question are OATP1B1, OATP1B3, MATE1, MATE2K, P -gp, and BCRP .  
AZD1775  is a substrate of P -gp and BCRP and may be affected by [CONTACT_735920].  AZD1775 is an inhibitor of OATP1B1, OATP1B3, MATE1, 
MATE2K, P -gp, and BCRP and may affect transport of oth er drugs in and out of cells.  
 
 
To the patient:  Take this paper with you to your medical appointments and keep the 
attached information card in your wallet .   
 
AZD1775  may interact with other drugs which can cause side effects.   For this reason, it is very  
important to tell your study doctors of any medicines you are taking before you enroll onto this 
clinical trial.  It is also very important to tell your doctors if you stop taking any regular 
medicines, or if you start taking a new medicine while you take  part in this study.  When you talk 
about your current medications with your doctors, include medicine you buy without a 
prescription (over -the-counter remedy), or herbal supplements such as St. John’s Wort.  It is 
helpful to bring your medication bottles or an updated medication list with you.  
 
Many health care providers can write prescriptions.  You must tell all of your health care 
providers (doctors, physician assistants, nurse practitioners, or pharmacists) you are taking part 
in a clinical trial.  
 
These are the things that you and they need to know:  
 
AZD1775  must be used very carefully with other medicines that need certain liver enzymes or 
transport proteins to be effective or to be cleared from your system.  Before you enroll onto 
the clinical tria l, your study doctor will work with your regular health care providers to review 
any medicines and herbal supplements that are considered “strong inducers/inhibitors or 
substrates of CYP 3A4, OATP1B1, OATP1B3, MATE1, MATE2K, P -gp, and BCRP.”  
 
 
CTEP #9149 (01 -07-2020 ) 
 
113 
 •  Please be very careful!  Over -the-counter drugs (including herbal supplements) may 
contain ingredients that could interact with your study drug.  Speak to your doctors or 
pharmacist to determine if there could be any side effects.  
•  Your regular health care provider should check a frequently updated medical reference or 
call your study doctor before prescribing any new medicine or discontinuing any 
medicine.   
Your study doctor’s name [CONTACT_832] _______________________________________________ _  
 
and he or she can be contact[CONTACT_6811] _____________________________________                                  
                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Study Drug Information Wallet Card   
You are enrolled on a clinical trial using the experimental 
study drug  AZD1775 .  This clinical trial is sponsored by 
[CONTACT_6812] .  AZD1775 may interact with drugs that are  
processed by [CONTACT_6813], or use certain transport 
proteins in your body .  Because of this, it is very 
important to:  
➢ Tell your doctors if you stop taking any medicines or if 
you start taking any new medicines  
➢ Tell all of your health care providers (doctors, 
physician assistants, nurse practitioners, or 
pharmacists) that you are taking part in a clinical trial  
➢ Check with your doctor or pharmacist whenever you 
need to use an over -the-counter medicine or herbal 
supplement s such as St. John’s Wort  
➢ Avoid grapefruit, grapefruit juice, Seville oranges, and 
starfruit while taking this drug  
 
 
 AZD1775  interacts with CYP 3A4, OATP1B1, OATP1B3, 
MATE1, MATE2K, P -gp, and BCRP , and must be use d 
very carefully with other medicines that interact with these 
enzymes and proteins.  
• Before you enroll onto the clinical trial, your study doctor 
will work with your regular health care providers to review 
any medicines and herbal supplements that are 
considered “strong inducers/inhibitors of  CYP 3A4, 
PgP and BCRP, and sensitive substrates  of 
OATP1B1, OATP1B3, MATE1 and MATE2K"  
• Before prescribing new medicines, your regular 
prescribers should go to a frequently -updated medical 
reference  for a list of drugs to avoid, or contact [CONTACT_297478].   
• Your study doctor’s name [CONTACT_832]:  
and can be contact[CONTACT_6811]:  
CTEP #9149 (01 -07-2020 ) 
 
114 
 Information for Patients, Their Caregivers , and Non -Study Healthcare Team on Possible 
Interactions with Everolimus and Other Drugs and Herbal Supplements  
 
The patient ______________________________________ is enrolled on a clinical trial using 
the experimental study drug Everolimus .  This clinica l trial is sponsored by [CONTACT_6808].  This form is addressed to the patient, but includes important information for others 
who care for this patient.  
 
These are the things that you as a prescriber need to know:  
 
Everolimus interacts with certain specific enzymes in the liver.  
• The enzyme in question is  CYP3A4.  Everolimus is metabolized by [CONTACT_735921].  
 
To the patient:  Take this paper with you to your medic al appointments and keep the 
attached information card in your wallet .   
 
Everolimus  may interact with other drugs which can cause side effects.  For this reason, it is very 
important to tell your study doctors of any medicines you are taking before you en roll onto this 
clinical trial.  It is also very important to tell your doctors if you stop taking any regular 
medicines, or if you start taking a new medicine while you take part in this study.  When you talk 
about your current medications with your doctor s, include medicine you buy without a 
prescription (over -the-counter remedy), or herbal supplements such as St. John’s Wort.  It is 
helpful to bring your medication bottles or an updated medication list with you.  
 
Many health care providers can write presc riptions.  You must tell all of your health care 
providers (doctors, physician assistants, nurse practitioners, or pharmacists) you are taking part 
in a clinical trial.  
 
These are the things that you and they need to know:  
 
Everolimus  must be used very c arefully with other medicines that need certain liver enzymes to 
be effective or to be cleared from your system.  Before you enroll onto the clinical trial, your 
study doctor will work with your regular health care providers to review any medicines and 
herbal supplements that are considered “strong inducers/inhibitors of CYP3A4.” 
 
•  Please be very careful!  Over -the-counter drugs (including herbal supplements) may 
contain ingredients that could interact with your study drug.  Speak to your doctors or 
pharmacist to determine if there could be any side effects.  
•  Your regular health car e provider should check a frequently updated medical reference or 
call your study doctor before prescribing any new medicine or discontinuing any 
medicine.   
Your study doctor’s name [CONTACT_832] ______________________________________________  
and he or she can be c ontacted at _____________________________________.                                           
  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005456] with drugs that are 
processed by [CONTACT_6813] .  Because of this, it is very 
important to:  
➢ Tell your doctors if you stop taking any medicines or if 
you start taking any new medicines  
➢ Tell all of your health care providers (doctors, 
physician assistants, nurse practitioners, or 
pharmacists) that you are taking part in a clin ical trial  
➢ Check with your doctor or pharmacist whenever you 
need to use an over -the-counter medicine or herbal 
supplements such as St. John’s Wort  
➢ Avoid grapefruit, grapefruit juice, Seville oranges, and 
starfruit while taking this drug  
 
 
 Everolimus interacts  with CYP 3A4, and must be used 
very carefully with other medicines that interact with these 
enzymes and proteins.  
• Before you enroll onto the clinical trial, your study doctor 
will work with your regular health care providers to 
review any medicines and herbal supplements that are 
considered “strong inducers/inhibitors of CYP 3A4” 
• Before prescribing new medicines, your regular 
prescribers should go to a frequently -updated medical 
reference for a list of drugs to avoid, or contact [CONTACT_297478].   
• Your study doctor’s name [CONTACT_832]:  
and can be contact[CONTACT_6811]:  
CTEP #9149 (01 -07-2020 ) 
 
116 
 APPENDIX C: Medications  That May  Cause  QTc P rolongation  
 
The following table presents a list of drugs that prolong, may prolong, or are unlikely to prolong the 
QTc.  Please note that this list is frequently updated.  For the most current list of medications, users 
should be directed to the following website : http://crediblemeds.org/  
 
Drugs that are generally 
accepted  to have a risk of 
causing Torsades de Pointes  Drugs that in some reports have been 
associated  with Torsades de Pointes 
and/or QTc pr olongation but at this 
time lack substantial evidence for 
causing Torsades de Pointes  Drugs that, in some reports, have been 
weakly associated  with Torsades de 
Pointes and/or QTc prolongation but that 
are unlikely to be a risk for Torsades de 
Pointes when used in usual recommended 
dosages and in subjects without other risk 
factors (e.g., concomitant QTc prolonging 
drugs, bradycardia, electrolyte 
disturbances, congenital long QTc 
syndrome, concomitant drugs that inhibit 
metabolism)  
      
Generic/Brand Name  [CONTACT_107518]/Brand Name  [CONTACT_107518]/Brand Name  
[CONTACT_107519] /Cordarone®  Alfuzosin /Uroxatral®  Amitriptyline /Elavil®  
Amiodarone /Pacerone®  Amantadine /Symmetrel®  Ciprofloxacin /Cipro®  
Arsenic trioxide /Trisenox®  Atazanavir /Reyataz®  Citalopram /Celexa®  
Astemizole /Hismanal®  Azithromycin /Zithromax®  Clomipramine /Anafranil®  
Bepridil /Vascor®  Chloral hydrate /Noctec®  Desipramine /Pertofrane®  
Chloroquine /Aralen®  Clozapi[INVESTIGATOR_050] /Clozaril®  Diphenhydramine /Benadryl®  
Chlorpromazine /Thorazine®  Dolasetron /Anzemet®  Diphenhydramine /Nytol®  
Cisapride /Propulsid®  Dronedarone /Multaq®  Doxepin /Sinequan®  
Clarithromycin /Biaxin®  Felbamate /Felbatrol®  Fluconazole /Diflucan®  
Disopyramide /Norpace®  Flecainide /Tambocor®  Fluoxetine /Sarafem®  
Dofetilide /Tikosyn®  Foscarnet /Foscavir®  Fluoxetine /Prozac®  
Domperidone /Motilium®  Fosphenytoin /Cerebyx®  Galantamine /Reminyl®  
Droperidol /Inapsine®  Gatifloxacin /Tequin®  Imipramine /Norfranil®  
Erythromycin /Erythrocin®  Gemifloxacin /Factive®  Itraconazole /Sporanox®  
Erythromycin /E.E.S.®  Granisetron /Kytril®  Ketoconazole /Nizoral®  
Halofantrine /Halfan®  Indapamide /Lozol®  Mexiletine /Mexitil®  
Haloperidol /Haldol®  Isradipi[INVESTIGATOR_050] /Dynacirc®  Nortriptyline /Pamelor®  
Ibutilide /Corvert®  Lapatinib /Tykerb®  Paroxetine /Paxil®  
Levomethadyl /Orlaam®  Lapatinib /Tyverb®  Protriptyline /Vivactil®  
Mesoridazine /Serentil®  Levofloxacin /Levaquin®  Sertraline /Zoloft®  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005457] been 
associated  with Torsades de Pointes 
and/or QTc prolongation but at this 
time lack substantial evidence for 
causing Torsades de Pointes   
Drugs that, in some reports , have been 
weakly associated  with Torsades de 
Pointes and/or QTc prolongation but that 
are unlikely to be a risk for Torsades de 
Pointes when used in usual recommended 
dosages and in subjects without other risk 
factors (e.g., concomitant QTc prolonging 
drugs, bradycardia, electrolyte 
disturbances, congenital long QTc 
syndrome, concomitant drugs that inhibit 
metabolism)  
Generic/Brand Name  [CONTACT_107518]/Brand Name  [CONTACT_107518]/Brand Name  
[CONTACT_675323] /Dolophine®  Lithium /Lithobid®  Solifenacin /VESIcare®  
Methadone /Methadose®  Lithium /Eskalith®  Trimethoprim -Sulfa /Sulfa®  
Pentamidine /Pentam®  Moexipril/HCTZ /Uniretic®  Trimethoprim -Sulfa /Bactrim®  
Pentamidine /NebuPent®  Moxifloxacin /Avelox®  Trimipramine /Surmontil®  
Pi[INVESTIGATOR_3924] /Orap®  Nicardipi[INVESTIGATOR_050] /Cardene®    
Probucol /Lorelco®  Nilotinib /Tasigna®    
Procainamide /Pronestyl®  Octreotide /Sandostatin®    
Procainamide /Procan®  Ofloxacin /Floxin®    
Quinidine /Cardioquin®  Ondansetron /Zofran®    
Quinidine /Quinaglute®  Oxytocin /Pi[INVESTIGATOR_31933]®    
Sotalol / Betapace®  Paliperidone /Invega®    
Sparfloxacin /Zagam®  Perflutren lipid microspheres 
/Definity®    
Terfenadine /Seldane®  Quetiapi[INVESTIGATOR_050] /Seroquel®    
Thioridazine /Mellaril®  Ranolazine /Ranexa®    
  Risperidone /Risperdal®    
  Roxithromycin* /Rulide®    
  Sertindole /Serlect®    
  Sertindole /Serdolect®    
  Sunitinib /Sutent®    
  Tacrolimus /Prograf®    
  Tamoxifen /Nolvadex®    
  Telithromycin /Ketek®    
  Tizanidine /Zanaflex®    
  Vardenafil /Levitra®    
  Venlafaxine /Effexor®    
  Voriconazole /VFend®    
  Ziprasidone /Geodon®    
References:  
Physician’s Desk Reference 2002  
Facts and Comparisons (update to June 2005)  
The Pharmacological Basis of Therapeutics 9th Edition, 1996   
CTEP #9149 (01 -07-2020 ) 
 
118 
 APPENDIX D: Patient Study Diar ies 
 
Study Name: [CONTACT_735936] -based Assignment of Cancer Therapy for Patients With 
Advanced Solid Tumors  
 
CTEP Study ID: 9149  
 
 
Patient Name :  __________________ _______________________________________  
 
Instructions to the patient:  
Please complete this form and return to the research nurse or doctor every cycle  (28 days)  
 
You will take :         Veliparib  and Temozolomide   
Medication dose :   Take Veliparib  capsules twice each day (morning and evening) on  
days [ADDRESS_1005458]. 
John’s Wort while taking this drug .  
 
Do not open, crush, or chew Veliparib capsules . 
 
Cycle number:      _________  
Start date:  _________  
 
 
Patient Signature:  _____________________________________  
 
 
 
  
CTEP #9149 (01 -07-2020 ) 
 
119 
 DATE  DAY  Time taken  
Veliparib   Time taken  
Temozolomide  COMMENTS:  
Side effects/missed dose  
AM PM 
 
1     
 
2     
 
3     
 
4     
 
5     
 
6   
No drug taken today   
 
7   
No drug taken today   
 
8 No drug taken today  No drug taken today   
 
9 No drug taken today  No drug taken today   
 
10 No drug taken today  No drug taken today   
 
11 No drug taken today  No drug taken today   
 
12 No drug taken today  No drug taken today   
 
13 No drug taken today  No drug taken today   
 
14 No drug taken today  No drug taken today   
 
15 No drug taken today  No drug taken today   
CTEP #9149 (01 -07-2020 ) 
 
120 
  
16 No drug taken today  No drug taken today   
 
17 No drug taken today  No drug taken today   
 
18 No drug taken today  No drug taken today   
 
19 No drug taken today  No drug taken today   
 
20 No drug taken today  No drug taken today   
 
21 No drug taken today  No drug taken today   
 
22 No drug taken today  No drug taken today   
 
23 No drug taken today  No drug taken today   
 
24 No drug taken today  No drug taken today   
 
25 No drug taken today  No drug taken today   
 
26 No drug taken today  No drug taken today   
 
27 No drug taken today  No drug taken today   
 
28 No drug taken today  No drug taken today   
 
  
CTEP #9149 (01 -07-2020 ) 
 
121 
 Patient Study Diary  
 
Study Name: [CONTACT_735936] -based Assignment of Cancer Therapy for Patients With 
Advanced Solid Tumors  
 
CTEP Study ID: 9149  
 
 
Patient Name :  ________________________ ______________________________  
 
Instructions to the patient: Please complete this form and return t o the research nurse or doctor 
every cycle  (21 days)  
 
You will take :       AZD1775 and c arboplatin  
Medication dose :   Take AZD1775 capsules  twice  each day on days 1 and 2 (morning and 
evening) and once on day 3 (either in the morning or evening) at least two 
hours  before or t wo hours after a meal .  Do not open, crush, or chew the 
capsules.   Avoid grapefruit, grapefruit juice, Seville oranges, starfruit, and the 
herbal supplement St. John’s Wort while taking this drug.    
Carboplatin will be given by [CONTACT_735922][INVESTIGATOR_735852] 1  only of each 2 1-day cycle .  
 
Cycle number:      _________  
Start date:  _________  
 
Patient Signature:  _____________________________________  
 
 
  
CTEP #9149 (01 -07-2020 ) 
 
122 
 DATE  DAY  Time taken  
AZD1775  COMMENTS:  
Side effects/missed dose  
 
1 AZD1775 and carboplatin 
will be given in clinic today.  
Take one dose of AZD1775 
in the evening  
Time evening:  ________   
 
2 Take 2 doses of AZD1775 
today.  Take one dose of 
AZD1775 in the morning 
and one in the evening.  
Time morning: ________  
Time evening: ________   
 
3 Take only one dose of 
AZD1775 today  
Time:  _________   
 
4 No drug taken today   
 
5 No drug taken today   
 
6 No drug taken today   
 
7 No drug taken today   
 
8 No drug taken today   
 
9 No drug taken today   
 
10 No drug taken today   
CTEP #9149 (01 -07-2020 ) 
 
123 
 DATE  DAY  Time taken  
AZD1775  COMMENTS:  
Side effects/missed dose  
 
11 No drug taken today   
 
12 No drug taken today   
 
13 No drug taken today   
 
14 No drug taken today   
 
15 No drug taken today   
 
16 No drug taken today   
 
17 No drug taken today   
 
18 No drug taken today   
 
19 No drug taken today   
 
20 No drug taken today   
 
21 No drug taken today   
  
CTEP #9149 (01 -07-2020 ) 
 
124 
 Patient Study Diary  
 
 
Study Name: [CONTACT_735936] -based Assignment of Cancer Therapy for Patients With 
Advanced Solid Tumors  
 
CTEP Study ID: 9149  
 
 
Patient Name:   _________ ___________________ ________________________________  
 
Instructions to the patient: Please complete this form and return to the research nurse or doctor 
every cycle  (28 days)  
 
You will take :       Everolimus        
Medication dose :  Take everolimus tablets once a day every day for [ADDRESS_1005459]. John’s Wort  while taking this  drug.  Caregivers should wash their hands 
with soap and water after touching the tablets.    
 
Cycle number:      _________  
Start date:  _________  
 
Patient Signature:  _____________________________________  
 
 
 
  
CTEP #9149 (01 -07-2020 ) 
 
125 
 DATE  DAY  Time taken  
Everolimus  COMMENTS:  
Side effects/missed dose  
 
1   
 
2   
 
3   
 
4   
 
5   
 
6   
 
7   
 
8   
 
9   
 
10   
 
11   
 
12   
 
13   
 
14   
CTEP #9149 (01 -07-2020 ) 
 
126 
 DATE  DAY  Time taken  
Everolimus  COMMENTS:  
Side effects/missed dose  
 
15   
 
16   
 
17   
 
18   
 
19   
 
20   
 
21   
 
22   
 
23   
 
24   
 
25   
 
26   
 
27   
 
28   
  
CTEP #9149 (01 -07-2020 ) 
 
127 
 Patient Study Diary  
 
 
Study Name: [CONTACT_735936] -based Assignment of Cancer Therapy for Patients With 
Advanced Solid Tumors  
 
CTEP Study ID: 9149  
 
 
Patient Name:   __________________________________ ___________________________  
 
Instructions to the patient: Please complete the form on the next page a nd return  it to the 
research nurse or doctor every cycle  (28 days) .  Store trametinib DMSO tablets in the 
refrigerator.   Keep the tablets in the bottle they come in and do not move to a pi[INVESTIGATOR_735853].  Do not 
take out the anti -moisture cube or packet.  
 
You will take :      Trametinib DMSO  
Medication dose :  Take Trametinib DMSO  tablets once a day for 2 8 days with a full glass of 
water  either 1 hour before or 2 hours after a meal.   If you vomit the tablets, do 
not take a n additional  dose.   If you miss a dose, take it as soon as you 
remember.  If it is less than 12 hours until your next dose, skip the dose.  
 
Cycle number:      _________  
Start date:  _________  
 
Patient Signature:  _____________________________________  
 
  
CTEP #9149 (01 -07-2020 ) 
 
128 
 DATE  DAY  Time taken  
Trametinib DMSO  COMMENTS:  
Side effects/missed dose  
 1   
 2   
 3   
 4   
 5   
 6   
 7   
 8   
 9   
 10   
 11   
 12   
 13   
 14   
CTEP #9149 (01 -07-2020 ) 
 
129 
 DATE  DAY  Time taken  
Trametinib DMSO  COMMENTS:  
Side effects/missed dose  
 15   
 16   
 17   
 18   
 19   
 20   
 21   
 22   
 23   
 24   
 25   
 26   
 27   
 28   
 
  
CTEP #9149 (01 -07-2020 ) 
 
130 
 Study Chart : 
 
Treatment cycles will be repeated as long as you are tolerating the study drug and your cancer is 
either stable or getting better.  Each cycle is numbered in consecutive order.  The chart below 
shows what will happen during Cycle 1 and future cycles.  The left-hand column shows the day 
in the cycle, and the right -hand column tells you what will happen on that day.  This schedule 
shows what will happen to you after you sign the consent and start the study.  
 
Day What to do and what will happen to you  
Before 
starting 
study 
drugs  • Check in at the Outpatient Clinic  
• Get routine blood tests  
• EKG  
• Eye exam (depending on the study treatment)  
• Pregnancy test  
• Have a history taken of how you feel and undergo a physical examination by a 
Health Care Provider  
• CT scan will be done  
Day 1  • Check in at the Outpatient Clinic  
• Based on analysis of gene variations in your tumor, you may be given one of 
the following drugs: Trametinib DMSO, or everolimus, or Veliparib  and 
temozolomide, or AZD1775  and carboplatin  
• Have a history taken of how you feel and undergo a physical examinati on by a 
Health Care Provider  
• Get routine blood tests   
• During the first week, have a tumor biopsy to confirm your genetic testing 
report (no biopsy if you already had one for screening on this study)  
Day 8  • Continue taking your study drug by [CONTACT_249734] (if taking everolimus or 
Trametinib DMSO ) according to the instructions in your study medication 
diary   
• Get routine blood tests (Cycle 1 only)  
Cycle 2  
Day 1  • For patients getting AZD1775  plus carboplatin only, check in at the Outpatient 
Clinic (first day of every cycle only).  
• Continue taking your study drug by [CONTACT_249734]  
• Eye exam (depending on the study treatment)  
Cycle 3 
onwards  • CT scans to determine how your tumor is responding to the treatment will be 
done every 2  cycles  (less often if you have been on study for more than one 
year. 
• Echocardiogram (depending on the study treatment) to check for po ssible 
damage to your heart may  be done every [ADDRESS_1005460] had.   
 
  
CTEP #9149 (01 -07-2020 ) 
 
131 
 APPENDIX E : MPACT  (9149)  Sample Shippi[INVESTIGATOR_735854] -fixed tumor s amples (2 cores) from the initial screening biopsy procedure .  Please consult with the study PI 
[INVESTIGATOR_735855] .   
 
 
Sample collection and shippi[INVESTIGATOR_735856]:  
Biopsy collection *:  
• Pre-filled 10% neutral -buffered formalin specimen jar, 30 mL ( e.g., Leica 3800770 ), one jar per core  sample  
 
Blood collection:  
• [ADDRESS_1005461] tubes, 10 mL (e.g., Streck  218961 )  
 
Shippi[INVESTIGATOR_735857] :  
• Specimen bags (zip -lock)  
• Absorbent pa per for packing  
• Controlled room temperature (CRT) gel packs  (e.g.,  STT-521-500 Saf -T-Temp CRT PCM Paks ) 
• Small thermo -shipper boxes  (e.g., Thermo -safe [ZIP_CODE] -434)  
 
Notes:  
Follow manufacturer’s instructions for specimen collection and handling.   
Put shippi[INVESTIGATOR_735858] a plastic zip-lock bag in case of sample leakage.  Include the Clinical Center number,  study number (9149), patient 
ID, site of biopsy , patient diagnosis, b iopsy/blood collection date , and fixation time (i.e., initial/date/time placed into 10% NBF)  on the 
manifest.  Do not include patient identifiers . 
 
Please do not collect samples on Fridays for overnight delivery  as FNLCR cannot accept weekend courier delivery.  If Friday collection  is 
unavoid able, ship the samples via overnight delivery but contact [EMAIL_14049]  and include  two CRT gel 
packs  in the shipper boxes .  The samples will be sta ble until Monday delivery.   
 
*Archival FFPE tumor blocks may be acceptable if collected within 6 months of registration and if the patient has not receive d targeted or 
investigational therapy since collection; check with study investigator for details   
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005462]  
Protocol 9149  Shippi[INVESTIGATOR_107278]:  Carrier:  
SHIP FROM:  
Ordering 
Physician/PI:   [INVESTIGATOR_735859]:  MoCha Histology Laboratory (K. Benauer)  
   Address:      Address:  
    Leidos Biomedical Research Inc. (FNLCR)  
 [ADDRESS_1005463]. Bldg 321, Room #[ADDRESS_1005464] Name:    
   [CONTACT_10880]:   Telephone:  [PHONE_15296]/301 -846-1535  
   Email:   Email:  [EMAIL_14049]  
Item  Unique GeneMed ID*  
(Sample ID)  Biopsy Site  Diagnosis  Date 
Collected  No. Containers/Tubes  Fixation Time  
Biopsy  Blood  FFPE  block  Into 10%NBF -Site  
(Initial/Date/Time)  
1         
2         
3         
4         
5         
6         
7         
8         
  TOTAL No. ITEMS      
COMMENTS:  
*DO NOT include patient identifiers  
 
 
 
 
 
 
CTEP #9149 (01 -07-2020 ) 
 
133 
 APPENDIX F: Biopsy Sequencing Results and Analysis Form  
 
Form begins on the next page.  
 
 
134 
 
 
Molecular Characterization Laboratory                                                                                
Frederick National Laboratory for Cancer Research                                                                                  
(Leidos Biomedical Research, Inc.)                                                                                                           
[ADDRESS_1005465], Frederick, MD [ZIP_CODE]                                                                                     
[PHONE_15297]  
CLIA Laboratory ID 21D2097127  
 
 
  
CTEP -9149 TUMOR SPECIMEN REPORT  
Patient ID:   
Report Date:   
 
Patient ID:   MoCha ID:  HIS- 
Principal Investigator:  [INVESTIGATOR_649188], MD  
Diagnosis:    
Biopsy Site:   Date 
Collected:   DNA/cDNA 
Block Source:   Tumor Content 
(%)1:  
 
This report identifies only actionable MOIs (aMOIs ) relevant to the genes currently validated for clinical application.  
aMOIs not detected are not otherwise identified.  
 
DNA Repair :   None identified (delete this text if variants are reported)  
aMOIs Detected  
Gene  Chr. Position  REF (hg19)  ALT (Tumor)  Transcript 
ID Amino Acid 
Change  VAF Variant ID  
         
         
         
         
1Preanalytical preparation was performed by [CONTACT_735923], [ADDRESS_1005466], Frederick, MD [ZIP_CODE] [CLIA ID 21D2137521].  Reported 
assay characteristics cannot be guaranteed for specimens that present a tumor content below 20%.  
KEY: NA=Not Applicable; Chr=Chromosome;  REF (HG19)=Reference base, Human Reference Genome hg19); ALT (Tumor)=Variant base  
  Comments:   
   
SIGNATURE [CONTACT_70822]:    
The signature [CONTACT_735937] s. 
 
 
 
DISCLAIMER:   This assay is considered a Laboratory Developed Test (LDT).  Its performance characteristics have been determined through extensiv e 
testing although it has not been cleared by [CONTACT_735924] l implementation. Furthermore, 
any Comments included in this report are strictly interpretive and the opi[INVESTIGATOR_560533]. This laboratory  is certified under the Clinical Laboratory 
Improvement Amendments (CLIA) for the performance of high -complexity molec ular testing for clinical purposes.   
 
 
135 
 
 
Molecular Characterization Laboratory                                                                                
Frederick National Laboratory for Cancer Research                                                                                  
(Leidos Biomedical Research, Inc.)                                                                                                           
[ADDRESS_1005467], Frederick, MD [ZIP_CODE]                                                                                     
[PHONE_15297]  
CLIA Laboratory ID 21D2097127  
 
 
  
Methodology, Scope, and Application:  The sequencing test utilizes the Thermo Fisher Scientific Oncomine® Comprehensive Assay v3.0 (OCAv3), a nex t -
generation sequencing (NGS) assay that utilizes a multiplex polymerase chain reaction (PCR) with  DNA extracted from formalin -fixed tissue for sequencing 
on the Ion S5 XL platform . The OCv3 NGS Assay can reliably id entify the presence or absence of known (reported in COSMIC or ClinVar databases) aMOIs in 
15 DNA repair genes, with results compared to Human Reference Genome hg19. The table below lists these genes with the aMOIs t hat can be identified. The 
remainder of the genes included in the Oncomine panel include no relevant hotspots.  Novel deleterious calls and truncating mutations (fra meshift indels 
and/or nonsense mutations) will also be considered actionable.  The OCAV3 NGS Assay is a laboratory developed test d esigned to find gene mutations 
within tumors (somatic mutations). It was not designed to find hereditary mutations.  
Analytical Sensitivity and Specificity:  The OCAV3 NGS Assay has been determined to be suitably analytically sensitive and specific for the various types of 
abnormalities within its reportable range, demonstrating 97.18% sensitivity compared with orthogonal assay results and 100% s pecificity for the mutation types 
reported.  99.99% or greater reproducibility has been demonstrated. All quality measures for this assay were within defined assay parameters.  
 
Gene  Pathway  Identifiable aMOIs (defined as Coding Sequence Change)  Functionality  
 
ATM   
DNA repair  c.1009C>T, c.1009C>A, c.1010G>C, c.1010G>A, c.5558A>T, c.6490G>C, c.6490G>A, c.7325A>C, 
c.7325A>G, c.7327C>G, c.7328G>A, c.8083G>T, c.8083G>A, c.8084G>C, c.8494C>T, c.8494C>A, 
c.8624A>G, c.8624A>C, c.8625T>A, c.8668C>G, c.8669T>G, c.8860T>A, c.8861A>G, c.9022C>A,  
c.9022C>T, c.9023G>T, c.9023G>A   
Loss 
NBN  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
RAD51  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
RAD51B  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
RAD51C  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
RAD51D  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
PALB2  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
 
 
 
BRCA1   
 
 
DNA repair  c.5363G>T, c.5277+1G>A, c.441+2T>G, c.5468 -40T>A, c.5467G>A, c.5359T>A, c.5332+1G>A, 
c.5331_5332+1delinsCAACAT, c.5324T>G, c.5324T>A, c.5297T>G, c.5291T>C, c.5278 -2del, c.5212G>A, 
c.5194 -12G>A, c.5153 -1G>C, c.5152+3A>C, c.5152+1G>T, c.5143A>C, c.5123C>A,  
c.5117G>A, c.5095C>T, c.5 074+1G>A, c.5074G>A, c.5074G>C, c.5074G>T, c.5054C>T, c.5053A>G, 
c.4987 -1G>A, c.4986+6T>C, c.4986+6T>G, c.4986+4A>G, c.4986+4A>C, c.4986+4A>T, c.4675+3A> T, 
c.4675+1G>A, c.4675G>A, c.4675G>C, c.4484G>T, c.4357+1G>A, c.4185G>A, c.4097 -1G>A, 
c.547+2T>A, c.302 -1G>C, c.302 -3C>G, c.213 -3C>G, c.213 -11T>G, c.213 -12A>G, c.212+3A>G, 
c.212G>A, c.211A>G, c.191G>A, c.181T>G, c.131G>A, c.130T>A, c.122A>G, c.115T>C, c.110C>A,  
c.65T>C, c.3G>T, c.2T>C, c.2T>G, c.1A>G, c.5513T>A   
 
 
Loss 
 
BRCA2   
DNA repair  c.2T>G, c.3G>T, c.475G>A, c.475+1G>A, c.476 -2A>G, c.631G>C, c.631G>A, c.682 -2A>G, c.7007G> C 
c.7007G>T, c.7008 -2A>T, c.7617+1G>A, c.7618 -1G>A, c.7878G>C, c.7879A>T, c.7976G>C, c.7988A>T,  
c.8009C>T, c.8165C>G, c.8167G>C, c.8168A>G, c.8243G>A, c.8487+1G>A, c.8953+1G> T,  
c.8954 - 3C>G, c.9154C>T   
Loss 
CHEK1  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
CHEK2  DNA repair  c.1556G>A, c.1169A>G, c.1141A>G  Loss 
FANCA  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
MRE11A  DNA repair  Novel loss of function frameshift or nonsense mutation  Loss 
IDH1  DNA repair  c.394C>A, c.395_396GT>AC, c.394_395CG>GT, c.394_395CG>TC, c.395G>A, c.395G>T, c.394C>G, 
c.394C>T  Altered  
IDH2  DNA repair  c.515_516GG>AT, c.516G>C, c.516G>T, c.515G>A, c.515G>C, c.515G>T, c.514A>T, 
c.514A>G, c.419G>A, c.419G>T, c.418C>G, c.418C>T  Altered  
aMOI COSMIC ID may be found at: Catalog of Somatic Mutations in Cancer, https://cancer.sanger.ac. uk/cosmic   
 
 
 
 
CTEP #9149 (01 -07-2020 ) 
 
136 
 APPENDIX G: Molecular Tumor Board Members  
 
The Molecular Tumor Board is a multidisciplinary group with expertise in molecular and clinical 
genetics, gene analysis, pharmacogenomics, pharmacodynamics, statistics, and bioinformatics  
assembled to review and select the genetic variants being assessed  on this study .  The Board will 
meet on an ad hoc basis to review and  discuss findings and results  but will not influence initial 
treatment assignment s.   
 
Name  [CONTACT_735938], MD  CTEP/DCTD/NCI  Clinical oncology  
James H. Doroshow, MD  DCTD/NCI  Molecular and clinical oncology  
Jeff Hildesheim, PhD  CCBB/NCI  Molecular oncology  
Robert Kinders, PhD  Leidos Biomed.,  FNLCR  Molecular oncology and pharmacodynamics  
Chris Karlovich, PhD  Leidos Biomed ., FNLCR  Molecular oncology and genetic analysis  
Paul Meltzer, MD, PhD  GB/CCR/NCI  Molecular oncology  and genetic analysis  
Eric Polley, PhD  Mayo  Statistics  
Yves Pommier, MD, PhD  LMP/ CCR/NCI  Molecular oncology  
Larry Rubinstein, PhD  DCTD/NCI  Statistics  
Jim Tricoli, PhD  Leidos Biomed ., FNLCR  Molecular oncology and genetic analysis  
Mickey Williams, PhD  Leidos Biomed ., FNLCR  Molecular oncology and genetic analysis  
 
   
 
CTEP #9149 (01 -07-2020 ) 
 
137 
 APPENDIX H: Example Tumor Variant Patient Report    

CTEP #9149 (01 -07-2020 ) 
 
138 
 APPENDIX I: Veliparib  plus Temozolomide  (Proprietary Information)  
 
Veliparib  is an orally available, small molecule inhibitor of PARP.  Preclinical and clinical data 
show that inhibition of PARP potentiates the effects of DNA -damaging chemotherapeutic drugs 
such as th e alkylating agent temozolomide [67].  In thi s study, Veliparib  and temozolomide will be 
administered to patients with defects in DNA repair pathways.   
 
Nonclinical Studies  
One of the most studied alkylating agents in combination with PARP inhibition is temozolomide, 
which is used in the treatment of CNS tumors and melanoma.  In vitro, potentiation of 
temozolomide -induced cytotoxicity was observed in the MMR -deficient HCT -116 cell line.  In 
nonclinical models of murine melanoma, dose -dependent potentiation of temozolomide was 
demonstrated with 12.5 mg/kg BID of orally administered Veliparib  that was identified as the 
maxim ally efficacious dose (AUC , 3 µg•hr/mL) [100].  Preliminary human pharmacokinetic (PK) 
results indicate that an oral dose of 40  mg Veliparib  BID achieves the exposure (AUC) that was 
maximally effective in murine efficacy models.  The predicted efficacious exposures are below 
Veliparib  concentrations that resulted in a NOAEL in repeated -dose toxicity studies in rats and 
dogs.  
 
The PK profile of Veliparib  was evaluated in tumor -bearing rats by [CONTACT_735925].  After multiple doses of Veliparib  (50 mg/kg/day), the 
concentration of the compound 2 hours after dosing (near  Cmax) was 1.36 ± 0.16 μg/mL in 
plasma, 0.72 ± 0.12 μg/g in brain, and 3.00 ± 0.16 μg/g in tumor tissue.  Co -administration with 
temozolomide did not alter the plasma pharmacokinetic profile of Veliparib . 
 
Ataxia, tremors, seizures/convulsions, and other behaviors consistent with CNS effects were 
observed after repeated oral doses in dogs during multiple studies.  In the aggregate of studies in 
which convulsions were observed in dogs, the lowest plasma conce ntration of Veliparib  measured 
at time of convulsion was 1.16 µg/mL, and the lowest calculated AUC 0-24 corresponding to 
convulsion was 16.7 µg•hr/mL.  The lowest observed exposure values correspond to an exposure 
of approximately 5.[ADDRESS_1005468] ed clinical maximum plasma concentration ( Cmax) of 
0.210 µg /mL, and approximately 6 -fold above the predicted clinical AUC 0-24 of 3 µg•hr/mL.   
Convulsions were either self -resolving or resolved after treatment with diazepam.  There was no 
evidence of abnormal cortical activity or seizures occurring at a dose of 20 mg/kg BID in an EEG 
study in the conscious dog.  There is no proposed pathophysio logic mechanism for the observed 
seizures.  No seizures have been reported in clinical trials with Veliparib  to date.  
 
In a separate study in rats in which Veliparib  was combined with temozolomide, observed 
toxicities were consistent with exacerbation of k nown temozolomide toxicity.  Co -administration 
of temozolomide at 16 mg/kg/day and Veliparib  at doses of 12.5 and 25  mg/kg/day (divided BID) 
resulted in increased toxicity over that observed with temozolomide administration alone, 
effecting bone marrow, ly mphoid tissues, testes, and ovaries.  Most toxicological findings 
resolved at the end of a 22 -day recovery period, with the exception of the testes.  In this study, the 
combination of Veliparib  (50 mg/kg/day) in combination with temozolomide significantly reduced 
tumor volume by 63%, which was more effective than temozolomide alone (44%) [100].   
 
CTEP #9149 (01 -07-2020 ) 
 
139 
 The reversible and nonlethal exacerbation of temozolomide hematologic to xicity in the rat 
occurred at doses of Veliparib  that, in previous studies, resulted in exposures that were similar to 
or greater than anticipated clinically efficacious exposure (AUC).   
 
Veliparib  can produce fetal toxicities, including decreased fetal w eights, increased post -
implantation loss, fetal malformation and variations (external, visceral, and skeletal), and delayed 
skeletal ossification.  The rat is the most sensitive species for fetal toxicity, with the C max at the 
NOEL for rat and rabbit of 0. 02 and 2.4 µg/mL, respectively.  There are no data regarding the 
effects of Veliparib  on pregnancy in humans.  
 
Clinical Studies  
Pharmacokinetic results from a Phase I study of Veliparib  in combination with temozolomide 
(Study M06 -862) were consistent with those seen in the Phase 0 study [100].  Similar to results 
from CTEP Study 7675 (A06 -161), Velip arib absorption and elimination were relatively rapid 
after administration of Veliparib  alone on Day 7.  Across Study M06 -862 subjects, the time to the 
maximum concentration (Tmax) averaged 1.2 hours and the predose concentration averaged 27% 
of the maximu m concentration (C max).  The coefficients of variation in dose -normalized Cmax and 
area under the curve (AUC) over a dosing interval (AUC0 -12) on Day 7 were 40% and 50%, 
respectively.  Veliparib  40 mg twice daily (BID) produced an average steady -state AUC0 -24 of 
4.81 µg•hr/mL, assuming equivalent AUCs following the morning and evening doses.  This 
clinical regimen exposure is comparable to that associated with the maximally effective Veliparib  
regimens in murine efficacy models (3.0 µg•hr/mL).  Across the d ose range studied, Veliparib  
Cmax and AUC were approximately dose -proportional with minimal accumulation of plasma 
Veliparib  concentrations following BID dosing.  Additionally in Study M06 -862, the potential 
pharmacokinetic interaction between Veliparib  and temozolomide is being assessed by 
[CONTACT_735926] [ADDRESS_1005469] . 
 
Preliminary safety and/or efficacy results are available from 5 Phase 1, 1 Phase 1/2, and 4 Phase 2 
Abbott -sponsored studies of Veliparib  in combination with a DNA -damaging agent [100].  In the 
Phase 1 Study M06 -862, doses in the dose -escalation portion of the study ranged from 10 mg 
Veliparib  BID/150 mg/m2 temozolomide once daily (QD) to 80 mg Veliparib  BID/200 mg/m2 
temozolomide QD.  No DLTs were reported for the first 3 dose -escalation cohorts (10 , 20, and 40 
mg Veliparib  BID).  In cohorts receiving 60 and 80 mg BID, events of grade 4 neutropenia or 
thrombocytopenia were reported.  The MTD combination dose was defin ed as 40 mg Veliparib  
BID/200 mg/m2 temozolomide QD.  In addition to defining the MTD, a second dose, lower than 
the MTD but also predicted to be biologically active, was defined as 20 mg Veliparib  BID/200 
mg/m2 temozolomide QD.  
 
Although no DLTs were repo rted in Study M06 -862 subjects in the 40 mg Veliparib  BID 200 
mg/m2 temozolomide QD dose -escalation cohort, 2 subjects enrolled at the same dose in the 
expanded MTD safety cohort experienced serious adverse events of grade 4 neutropenia and/or 
thrombocytop enia, and 8 of all 12 subjects receiving 40 mg Veliparib  BID 200 mg/m2 experienced 
CTEP #9149 (01 -07-2020 ) 
 
140 
 grade 3 or 4 adverse events of neutropenia and/or thrombocytopenia.  In general, subjects with 
these events recovered after dose reduction of Veliparib  and/or temozolomide, and all subjects 
remained on study.  
 
To minimize these hematologic toxicities, Study M06 -862 protocol was modified to treat new 
subjects with 40 mg Veliparib  BID in combination with 150 mg/m2 temozolomide QD in the first 
cycle.  If a subject did not experi ence grade 3 or 4 neutropenia or thrombocytopenia or other 
clinically significant NCI CTCAE  greater than grade 3, the temozolomide dose was escalated to 
200 mg/m2 QD.  In addition to neutropenia and thrombocytopenia, the other most commonly 
reported advers e events in Study M06 -862 occurring in ≥ 30% of subjects were nausea, fatigue, 
vomiting, constipation, decreased appetite, and headache.  All of the most commonly reported 
adverse events have previously been reported in subjects receiving temozolomide.   
 
For Study M06 -862, preliminary data on tumor assessment was available for 42 subjects.  
Two of 42 subjects (4.76%) experienced an objective partial response.  Of these, one subject, a 
BRCA -deficient ovarian cancer patient, experienced an objective partial r esponse in Cycle [ADDRESS_1005470] with hepatocellular 
carcinoma (HCC), experienced a partial response in  Cycle 4 that was confirmed in Cycles 6, 8, 
10, and the Final Visit.  
 
In the Phase 1/ 2 Study M10 -190, Veliparib  was administered in combination with radiation 
therapy with concurrent and adjuvant temozolomide (75 mg/m2 for 6 weeks).  
Preliminary safety data were available for [ADDRESS_1005471] commonly reported adverse 
events occurring  in ≥ 30% of subjects were nausea, fatigue, headache, insomnia, and 
thrombocytopenia.   Study M10 -440 is a Phase 2 randomized, double blind, placebo -controlled 
study of Veliparib  (20 or 40 mg BID) in combination with temozolomide (150 mg/m2/day with 
possibl e escalation to 200 mg/m2).  This study is fully enrolled and ongoing.  Preliminary blinded 
safety data are available for [ADDRESS_1005472] common AEs (reported in ≥ 30%  of subjects 
receiving Veliparib  plus temozolomide) were nausea, fatigue, constip ation, thrombocytopenia, and 
vomiting.  
 
In the Phase [ADDRESS_1005473] 
common treatment -emergent AEs (reported for ≥ 30% of subjects receiving Veliparib  plus 
temozolomide at any point) reported in  subjects with recurrent high -grade serous ovarian cancer 
treated with Veliparib  plus with temozolomide versus PLD alone, were nausea, fatigue, 
thrombocytopenia, vomiting, constipation, neutropenia, and decreased appe tite.  Preliminary 
efficacy data are not yet available.   Preliminary safety data are available for [ADDRESS_1005474] 
common treatment -emergent AEs (≥ 30% of all subjects) reported in  Study M11 -070, a trial 
evaluating subjects with metastatic castratio n-resistant prostate  cancer treated with Veliparib  plus 
temozolomide, were fatigue, nausea, and platelet count decreased.  Preliminary data on maximum 
percentage reduction from baseline in PSA values are available for [ADDRESS_1005475] been observed in 2 subjects.  The mean (SD) for the largest observed decrease 
from baseline in PSA values was 11.7% (48.3%).   In an extens ion study of Study M11 -846, 
preliminary safety data available are for [ADDRESS_1005476] common treatment -emergent AEs 
(≥ 30% of all subjects) reported in Study M12 -273, a trial evaluating subjects with solid  tumors 
treated with Veliparib  plus temozolomide, were nausea, fatigue, vomiting, abdominal pain, 
decreased appetite, and thrombocytopenia.  No preliminary e fficacy data are available.    
CTEP #9149 (01 -07-2020 ) 
 
141 
 APPENDIX J: AZD1775  (Proprietary Information)  
 
AZD1775  with Carboplatin (Investigators Brochure)  
AZD1775  is a selective, adenosine -triphosphate (ATP) competitive, small molecule inhibitor of 
Wee1 kinase (IC 50 = 5.18  nM), that directly inhibits phosphorylation of CDC2 at Tyr15.  The 
antitumor effect of AZD1775  in combination with carboplatin was investigated in the HeLa -luc 
(human cervical adenocarcinoma) nude rat xenograft model.  AZD1775  was administered orally 
to the animals 24 hr after carboplatin (50 mg/kg: MTD) at doses of 10, 20 and 30 mg/kg; single 
IV bolus treatments of carboplatin showed significant antitumor efficacy with %T/C = 70%.  
Tumor growth was not inhibited by [CONTACT_99213]1775  monotherapy at a dose of 30 mg/kg, with %T/C = 
96%.  AZD1775  dose-dependently enhanced the anti -tumor effect of carboplatin in HeLa -luc 
tumors with %T/C = 85, 39 and 28% at doses of 10, 20 and 30 mg/kg, respectively.  AZD1775  did 
not cause significant enhancement of carboplatin -induced redu ction of WBC (38 - 45% control) 
and platelets (15 - 26% control), and these parameters returned to normal by [CONTACT_2006] 20 and 10 in the 
combination arms.  AZD1775  alone did not show severe blood cell toxicity.  No severe body 
weight loss ( -2 to -5% delta change vs. control), abnormal physical signs or mortality were 
observed in any treatment group.  These results suggest that the combination of AZD1775  with 
carboplatin has anti -tumor efficacy and is well tolerated.  
 
An additional tolerability study was conducted in non -tumor bearing nude rats dosed with 
carboplatin alone or in combination with AZD1775  over multiple cycles.  Doses of carboplatin 
(50 mg/kg IV), alone and in combination with AZD1775  (20 mg/kg orally, 24 hrs after 
carboplatin dosing), wer e administere d once during a 28 -day cycle for 3 consecutive cycles.  
Body weight and blood cell counts were monitored during the study period.  There were no 
significant changes in toxicity parameters between the carboplatin alone and the carboplatin + 
AZD1775  treatmen t arms.  Thus, AZD1775  did not significantly enhance the toxicity parameters 
of carboplatin when used in the multi -cycle dosing schedule.  
 
Non-clinical Toxicology  
The toxicology profile of AZD1775  in rats involved the lymphoid and hematopoietic organs and 
gastrointestinal tract, and included decreased food consumption, body weight loss, hematologic 
and serum chemistry changes, decreased urine volume and soft feces.  AZD1775  had no effect on 
CNS function in mice.  The cardiovascular effects of AZD1775  were e xamined in 5 isoflurane -
anesthetized and mechanically vented dogs.  At doses of 3 and 10 mg/kg, QTc was marginally 
prolonged by [CONTACT_5554] 5% and 7%, respectively.  No QTc changes were observed in the 
intact dog studies or human studies.  Evidence of re versibility of all toxicity changes was 
generally demonstrated by [CONTACT_2671] 2 -week recovery period.  In a single dose oral toxicity 
study, severe irreversible toxicity (mortality) was seen in 1 female out of 10 female rats after a 
single dose at 300 m g/kg (1800 mg/m2).  
 
Based on the preliminary safety data available, the most frequent AEs observed were blood and 
lymphatic disorders (thrombocytopenia, neutropenia, anemia, febrile neutropenia), gastrointestinal 
disorders (diarrhea, vomiting, nausea, abdominal pain, constipa tion), and investigation findings 
(hematology and serum chemistry).  The single -dose TD for both the gemcitabine and cisplatin 
combination therapi[INVESTIGATOR_26615] 200 mg of AZD1775 .  DLTs tended to be hematological in nature in 
the gemcitabine group and constitution al in the cisplatin group.  The single -dose MTD for the 
CTEP #9149 (01 -07-2020 ) 
 
142 
 combination with carboplatin was 325 mg of AZD1775 .  DLTs in this group were related to 
serum chemistry.  
 
Clinical Studies  
AZD1775 has been administered to patients in 12 [COMPANY_008] -sponsored or Merc k-sponsored 
clinical studies, 6 of which are ongoing.  
Completed or terminated early:  
• PN001 ([STUDY_ID_REMOVED]): a first -time-in-patients (FTIP), Phase I, dose -escalation study 
evaluating AZD1775 both as monotherapy and combination therapy with gemcitabine, 
cisplatin, or carboplatin in adult patients with advanced solid tumours   
• PN004 ([STUDY_ID_REMOVED]): a Phase II study evaluating AZD1775 combined with carboplatin 
and paclitaxel in patients with platinum -sensitive p53 -mutant ovarian cancer  
• PN005 ([STUDY_ID_REMOVED]): a P hase I, dose -escalation study evaluating AZD1775 as 
monotherapy (Part 1), combination therapy with 5 -FU (Part 2), and combination therapy 
with 5 -FU plus cisplatin (Part 3) in adult Japanese patients with advanced solid tumours 
was terminated early due to p ortfolio prioritisation in oncology at [COMPANY_006] after 3 patients 
had been enrolled in Part 1 and 8 patients had been enrolled in Part 2. Part 3 was not 
initiated.  
• PN008 ([STUDY_ID_REMOVED]): a Phase I/IIa, dose -escalation study evaluating AZD1775 in 
combination wit h topotecan plus cisplatin in adult patients with cervical cancer was 
terminated early due to portfolio prioritisation in oncology at [COMPANY_006] after 7 patients had 
been enrolled in the dose -escalation part of the study. The Phase IIa part was not initiated.  
• D6011C00001 ([STUDY_ID_REMOVED]; SCRI LUN 262): a lead -in Phase II multicentre, 
randomised, double -blind study comparing AZD1775 plus docetaxel with placebo plus 
docetaxel in previously treated patients with non -small -cell lung cancer (NSCLC)  
• D6011C00002 (NCT020 [ZIP_CODE]; SCRI LUN 261): a Phase II study of AZD1775  plus 
pemetrexed and carboplatin followed by a randomised comparison of pemetrexed and 
carboplatin with or without AZD1775 in patients with previously untreated stage IV non -
squamous NSCLC.  
Ongoing:  
• D6010C0000 4 ([STUDY_ID_REMOVED]; SCRI GYN 49): multicentre Phase II study of AZD1775 
plus either paclitaxel, gemcitabine, carboplatin, or pegylated liposomal doxorubicin in 
patients with platinum -resistant epi[INVESTIGATOR_12253], fallopi[INVESTIGATOR_8916], or primary peritoneal 
cancer  
• D6010C00005 (N CT02511795; SCRI REFMAL 384): Phase I study evaluating AZD1775 
in combination with olaparib in refractory solid tumours.  
• D6011C00003 ([STUDY_ID_REMOVED]): Phase Ib dose -finding study evaluating AZD1775 as 
monotherapy and in combi nation with carboplatin and paclitaxel in adult Asian patients 
with advanced solid tumours  
• D6015C00001 (N CT02482311; SCRI REFMAL 383): Phase I, dose escalation, safety and 
pharmacokinetic study of AZD1775 monotherapy (Schedule 1) in patients with advanced  
or metastatic solid tumours  
• D6015C00002 ([STUDY_ID_REMOVED]; SCRI REFMAL 412): Phase I study assessing the safety, 
tolerability, and pharmacokinetics of AZD1775 in combination with MEDI4736 in 
patients with advanced solid tumours  
• D6015C00003 (N CT02610075; SCRI  REFMAL 398): Phase Ib study to determine the 
CTEP #9149 (01 -07-2020 ) 
 
143 
 maximum -tolerated dose (MTD) of AZD1775 monotherapy (Schedule 2) in patients with 
locally advanced or metastatic solid tumours.  
• In addition, Phase I and II studies are being conducted and sponsored by [CONTACT_735927]’s (NCI) Cancer Therapy Evaluation Program, and by [CONTACT_735928] -sponsored studies.  
 
As of [ADDRESS_1005477] 
received single doses per cycle as high as 1300 mg of AZD1775 as monotherapy, 325  mg of 
AZD1 775 in a single -dose in combination with chemotherapy, and 325 mg twice a day (BID) in a 
multiple -dose regimen in combination with chemotherapy.  
 
The PK data of AZD1775 following a single oral administration showed a moderate rate of  
absorption with a Tmax occurring at [ADDRESS_1005478]-peak plasma concentrations declined  
essentially in a mono -exponential manner with a t1/2 in the region of 10 h ours.  Exposure as  
measured by [CONTACT_173347] (Cmax) and AUC0 -∞ increased in a 
dose -proportional manner over the dose range of 325 to 1300 mg.  Following single (100 to 325 
mg) and multiple dose administrations of AZD1775 (25 t o 325 mg BID and 100 to 200 mg once 
daily [QD]) with carboplatin, cisplatin, and gemcitabine, plasma exposure of AZD1775 was 
consistent with predictions based on the single -dose regime.  Preliminary investigation of drug -
drug interactions in Study PN001 su ggest a 40% to 60% increase in the exposure of AZD1775 in 
the presence of aprepi[INVESTIGATOR_053] (moderate CYP3A4 inhibitor), but no effect with the concomitant 
administration of various different corticosteroids (moderate CYP3A4 inducers). Preliminary 
studies also su ggested that the PMF of AZD1775 was similar to that of the FFP formulation.  
 
Based on the safety data from the [ADDRESS_1005479] frequent adverse events (AEs) observed were blood and ly mphatic 
disorders (leukopenia, lymphopenia, neutropenia, thrombocytopenia, anaemia, febrile 
neutropenia, pancytopenia), gastrointestinal disorders (diarrhoea, vomiting, nausea, abdominal 
pain, constipation), general disorders and administration site condit ions (fatigue, fever, chills), and 
investigation findings (haematology and serum chemistry). Cardiac disorders (tachycardia, 
palpi[INVESTIGATOR_814], QTc prolongation) were not observed frequently, but are considered to be important 
identified risks. Gastrointestinal  haemorrhage is considered an important potential risk to be 
monitored closely as the programme progresses.  
 
Based on the safety data from the completed AZD1775 clinical studies and preliminary data from 
ongoing studies adverse drug reactions to AZD1775 mo notherapy include: anaemia, neutropenia, 
thrombocytopenia, QTc prolongation, gastrointestinal events such as dyspepsia, diarrhoea, nausea 
and vomiting (with or without dehydration or serum electrolyte decreases), as well as decreased 
appetite. In addition,  the following events are also considered expected during treatment with 
AZD1775 in combination with cytotoxic chemotherapy: febrile neutropenia, leukopenia, 
stomatitis, asthenia, fatigue, mucosal inflammation and myalgia.  
 
CTEP #9149 (01 -07-2020 ) 
 
144 
 Based on information emerging du ring the clinical development programme of AZD1775, 
potential risks with AZD1775 monotherapy include asthenia/fatigue, febrile neutropenia, 
gastrointestinal haemorrhage, lymphopenia/lymphocyte count decreased, leukopenia/WBC count 
decreased, myalgia, stoma titis, sepsis and transaminases elevation.  
 
In addition, the following events are also considered potential risks for AZD1775 in combination 
with cytotoxic chemotherapy: tachycardia and pancytopenia.  Refer to the IB for AZD1775 for 
information on the pote ntial benefits and assessment of potential and known risks.  
 
In Study PN001, of 176 evaluable patients who received AZD1775 (either single or multiple  
doses) as monotherapy or in combination with gemcitabine, cisplatin, or carboplatin, a partial 
response (PR) (confirmed and unconfirmed) was observed in 17 (9.7%) patients, and stable 
disease (SD) was observed in 94 (53.4%) patients.  No complete responses (CRs) or PRs were 
observed in either of Studies PN005 or PN008 at the time that they were terminated.  
In Study PN004, all patients were treated at the [ADDRESS_1005480] v1.1 in  
Part 1, there were 11 PRs (6 confirmed and 5 unconfirmed), and 3 SDs; 7  patients were  
evaluable by [CONTACT_28474] -125 with 3 CRs and 4 PRs.   Final data for Part 2 was not available as of the  
cut-off date for this brochure.  
In Study D6011C00001, 32 patients with NSCLC were treated with 225 mg AZD1775 BID  
over 2.5 days in combination with docetaxel (75 mg/m2 IV) administered on Day 1 followed  
by [CONTACT_735929] 4 of each 21 -day cycle.  The 3 patients (9.4%) that achieve d PR by  
[CONTACT_393] v1.1 had TP53 mutations.  Twenty -one patients (65.6%) had SD and 10 (47.6%) of  
these patients had TP53 mutations.  The planned Interim Analysis of 32 patients in the single  
cohort lead -in (Part A) suggested that toxicities associated with AZD1775 given in  
combination with docetaxel were greater in frequency and severity than with docetaxel alone.  
Additionally, the analysis revealed that it was very unlikely the target response rate would be 
reached in this study and a decision was made to  terminate enrolment.  
 
In Study D6011C00002, 14 patients with NSCLC were treated with 225 mg AZD1775 BID  
over 2.5 days in combination with pemetrexed 500 mg/m2 IV and carboplatin AUC [ADDRESS_1005481] of AZD1775  in human liver preparations is oxidative metabolism.  
Oxidative metabolism of AZD1775  is mediated predominantly by [CONTACT_9058] P450 (CYP) 3A4 
and FMO3.  AZD1775  is also a weak reversible inhibitor of CYP2C8, CYP2C9, CYP2C19 and 
CYP3A4.  In addition, AZD177 5 is a time -dependent inhibitor of CYP3A4 in in vitro human liver  
microsomes.  
 
  
CTEP #9149 (01 -07-2020 ) 
 
145 
 APPENDIX K: Trametinib DMSO  (Proprietary Information)  
 
Trametinib DMSO  is a reversible, highly selective allosteric inhibitor of MEK1/MEK2  activation 
and kinase activity.  Th e safety, pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and 
activity of trametinib DMSO  are currently being evaluated in 13 ongoing monotherapy and 
combination therapy clinical trials involving subjects with a variety of cancers.  
 
In May 2013, th e FDA approved trametinib DMSO for the treatment of patients with unresectable 
or metastatic melanoma with BRAFV600E or BRAFV600K  mutations.  In January 2014, the FDA also 
granted accelerated approval to the combination of trametinib DMSO and dabrafenib to treat 
patients with unresectable or metastatic melanoma with BRAF V600E or V600K  mutations.  
 
Nonclinical Pharmacology  
MEK protei ns are critical  components of the extracellular signal -related kinase (ERK) pathway 
which is commonly  hyperactivated in tumor cells.  Oncogenic mutations in both B -RAF and RAS 
signal  through MEK1 and MEK2.  Trametinib DMSO  is non -competitive towards ATP an d 
inhibits  activation of MEK by [CONTACT_735930].  The specificity of  
trametinib DMSO  to MEK1 and MEK2 was confirmed against a panel of [ADDRESS_1005482] kinase homolog to MEK1 and MEK2, and no significant  inhibitory activity 
was measured  [101].  In vitro, 8 0% of cell lines carrying  activating mutations of B -Raf and 72% 
of Ras mutant cancer cell lines were sensitive to  trametinib DMSO  in cell proliferation assays, 
and a majority (83%) of hematopoietic cancers  from acute or chronic myeloid leukemia (AML or 
CML , respectively) origins were also  very sensitive.  
 
Antitumor Activity in vitro  
Cancer cells expressing high constitutive levels of activated ERK (pERK) tended to be  more 
sensitive to trametinib DMSO  than those with lower levels of pERK, suggesting that  tumors with 
B-RAF or RAS mutations and/or high levels of pERK may respond to  trametinib DMSO  
treatment.  In all cell lines, pERK was strongly inhibited following  treatment with trametinib 
DMSO  and was i ndependent of their proliferative response,  suggesting that pERK inhibition is 
necessary but not sufficient to inhibit cell  proliferation.  In cell lines that were sensitive to the 
anti-proliferative activity of  the agent , the response was associated with arrest in G1 phase of the 
cell cycle,  accumulation of p27, reduction of cyclin D1 and phospho -retinoblastoma protein.   
Induction of apoptosis was demonstrated in some cell lines.   Inhibition of pERK and  inhibition of 
cancer cell proliferation were fully re versible following compound removal,  suggesting that 
sustained exposure to trametinib DMSO , or potential combination with other  drugs, may be 
required for full activity.  
 
When trametinib DMSO  was combined with standard of care drugs against human cancer cell  
lines in vitro, an additive effect was observed for pancreatic cancer with gemcitabine or  erlotinib 
and for colon cancer with [ADDRESS_1005483]  AML cell 
lines tested.  In addition, combination of agent with an investigational  phosphoinositide 3 -kinase 
(PI3K) inhibitor, as well as with a Centromer Protein -E (CENP -E) inhibitor, was synergistic on 
inhibition of cell growth i n various cancer  (pancreas, colon, lung) cells.  Additionally, the 
combination of trametinib DMSO  and a  CENP -E inhibitor increased caspase activity, indicating 
enhanced apoptosis in colon  cancer cell lines.  
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005484] non -dividing normal cells and did not completely inhibit  bone marrow progenitor cells at 
concentrations demonstrating anti -proliferative activity  on very sensitive cancer cell lines.   
 
Antitumor Activity in vivo  
Trametinib DMSO  was orally bioavailable in mice, and doses as low as 1 mg/kg reached  blood 
concentrations that caused sustained reductions of pERK, an accumulation of p27,  and a decrease 
of Ki67 in tumor xenografts; brain exposure le vels were ~10% of those in  blood, and no 
significant pERK inhibition was measured in brain tissue.   In mice,  exposure to trametinib DMSO  
produced dose - and schedule -dependent anti -tumor responses  correlating with blood levels.  
Typi[INVESTIGATOR_897], B -RAF --mutant xen ografts responded with  tumor regression while K -RAS -mutant 
xenografts responded with tumor growth  inhibition.   In vivo combination studies testing 
trametinib DMSO  together with various other anticancer  drugs showed good potential for 
synergistic effects.  
 
Safety Pharmacology  
In a rat neurobehavioral screen, following a single oral dose of trametinib DMSO  at 650 mg/m2 to 
male rats, diarrhea, prone position, blepharoptosis, pi[INVESTIGATOR_2657], reduced  spontaneous locomotion 
and mydriasis were observed between [ADDRESS_1005485] dose.   In a respi[INVESTIGATOR_735860], an oral dose of 1 mg/m2 produced a  mild, transient decrease in body 
temperature (up to 0.8 °C) at [ADDRESS_1005486] resistance or body temperature.   Trametinib DMSO  inhibited hERG channel 
repolarization in HEK293 with an IC 50 of 1.54 μM (950 ng/mL).  In a rabbit left ventricular 
wedge assay, trametinib DMSO  had no significant  effect on QT interval at concentrations up to 30 
μM ([ZIP_CODE] ng/mL; limit of solubility).   However, significant decreases in isometric contractile 
force occurred at concentrations  of 10 (6150 ng/mL) and 30 μM.  Trametinib DMSO  also 
decreased the Tp -e interval at a  concentration of 30 μM.  A single intravenous infusion of drug in 
dogs at 20 mg/m2 over 10 minutes  (Cmax of 2.5 μM or 1500 ng/mL) produced no changes in 
electrocardiogram (ECG)  parameters, blood pressure , or heart rate during the 30 minute 
measurement period.  In addition, single oral doses up to 1.5 mg/m2 in dogs produced no changes 
in arterial blood  pressure, heart rate, body temperature,  or ECG intervals, including QTc.   While 
trametinib DMSO  affected cardiac electrophysiology in vitro, no effects were observed  in vivo at 
doses that were maximally tolerated in dogs.  This difference in responses is  likely related to the 
very low Cmax (~10  ng/mL total drug) at tolerated doses in dogs and  the high protein binding 
(97% in dogs)  of agent .  The concentrations at which  effects were seen in these in vitro studies are 
significantly higher than the free fraction  observed in nonclinical toxicology s tudies or the clinical 
dose (2 mg).  These results  suggest a low risk for cardiovascular effects in the clinic.  
 
Pharmacokinetics and Product Metabolism in Animals  
Trametinib DMSO  exhibited low plasma clearance among nonclinical species (mouse, rat, dog  
and monkey) with varied but generally long half -lives.  Oral bioavailability ranged  between 42% 
and 100%.  Since trametinib DMSO  is a low solubility, high permeability  molecule, its absorption 
is likely limited by [CONTACT_735931].   Plasma protei n binding was high in nonclinical 
species and human (>95%) and blood cell  association was low.  Consistent with high 
permeability, trametinib DMSO  had moderate to  high volume of distribution among the 
nonclinical species  studied and DRM was widely  distribu ted into rat tissues.  The low 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005487] dose was observed.   Although 
studies showed protracted elimination of  DRM (consistent with high volume and long half -life), 
DRM in tissues was not  detectable by [ADDRESS_1005488] dose.   In rats and dogs after repeat oral dosing 
up to 13 weeks, systemic exposure increased  approximately dose -proportionally at higher doses or 
when steady state was reached at  Week 3.  Upon repeat dosing, increases in systemic exposure 
after Day 1 were observed  up to Week 3 ; however, between Weeks 4 and 13, there was no marked 
increase in  systemic exposure for either pre -clinical species.  A tendency for higher exposure in  
females than in males was observed in some studies in both rats and dog s. 
 
No apparent human -specific metabolite was observed in the in vitro cross -species  [14C]  
trametinib DMSO  metabolism study.   [14C] trametinib DMSO  was also found to metabolize  
predominantly via a non -cytochrome P450 (CYP) mediated deacetylation with secondary  
oxidation or glucuronidation biotransformation pathways.  CYP3A4 was implicated in  the in -vitro 
formation of M7, a metabolite mediated by [CONTACT_735932] -CYP and CYP  pathways.  The relative 
contribution of CYP3A4 to the total metaboli c clearance of  trametinib DMSO  in human in vivo is 
not currently understood and, therefore, the possibility  of a metabolic drug interaction cannot be 
eliminated.   Elimination of DRM in rat and dog after oral administration occurred predominantly 
via the fe ces (>60% of dose), with urinary excretion (<7% of dose) representing a minor  route.  
 
Trametinib DMSO is metabolized predominantly via deacetylation (non -cytochrome P450 
[CYP450] -mediated) with secondary oxidation or in combination with glucuronidation 
biotransformation pathways (Investigator’s Brochure, 2012).  Deacetylation is likely mediated by 
[CONTACT_190759], such as carboxylesterases, or amidases.  Based on in vitro  studies, trametinib 
is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2D6, and CY P3A4.  Trametinib DMSO 
has an overall low potential for drug -drug interactions.  There was no evidence  of time -dependent 
inhibition with any of the CYP enzymes investigated.   
 
Toxicology  
Systemic toxicity of trametinib DMSO  has been evaluated following oral dosing in rats and  dogs 
for up to [ADDRESS_1005489] sensitive nonclinical species, rat, the principal  adverse effects 
seen in oral toxicity studies of up to 13 weeks with daily dosing were skin  and stomach erosions, 
skin ulcerations, wh ich were secondary to reduced proliferation,  altered phosphate homeostasis 
that resulted in soft tissue mineralization, hepatocellular  necrosis, bone marrow 
degeneration/necrosis and ovarian perturbations.  The skin and  stomach findings and 
phosphatemia de monstrated reversibility with 4 weeks of recovery.   MTD  in rats in the definitive 
13 week study with daily  dosing was 0.25 mg/m2/day (AUC0 -t of 126 ng.h/mL, end of study).  
Reversible acute  effects (diarrhea, decreased body weight gain, prone position, ble pharoptosis,  
pi[INVESTIGATOR_2657], reduced spontaneous locomotion and mydriasis) were observed following a  single 
high dose of 650  mg/m2 to rats.  In dogs, the principal dose -limiting toxicities seen  oral toxicity 
studies of up to 13 weeks with daily dosing were r elated to gastrointestinal  and hematopoietic 
perturbations.  Inflammatory responses to gastrointestinal erosions  were observed in dogs  and 
were reversible following a recovery period.  In the definitive  13 week daily oral dosing study in 
dogs, the NOAEL  was 0.45 mg/m2/day (AUC0 -t of 139 ng.h/mL, end of study).  Principal adverse  
effects were consistent with inhibition of cell proliferation and were monitorable and  generally 
reversible.  Trametinib DMSO  was negative in both in vitro and in vivo genotoxicity  assays.  
 
 
CTEP #9149 (01 -07-2020 ) 
 
[ADDRESS_1005490] o ne dose of trametinib DMSO  in the ongoing Phase I/II/III clinical  studies.  There are no 
completed clinical trials to date.   Preliminary trametinib DMSO  pharmacokinetics were 
determined after single - and repeat  dose oral administration of tablets in subjects with solid 
tumors.   Trametinib DMSO  is absorbed rapi[INVESTIGATOR_735861]  1-3 
hours after oral administration under fasting conditions.  Following  repeat -dosing the mean area 
under the cu rve (AUC0 -τ) and maximum concentrations  (Cmax) increased in an approximately 
dose proportional manner.  Trametinib DMSO  accumulates with repeat dosing with a mean 
effective half-life of approximately 5 days.   The MTD was established at  3.0 mg once daily (Q D), 
and the r ecommended Phase II dose was identified as 2.0 mg QD.  
 
Phase   Study #  Treatment Regimen  Study Population  
Monotherapy Studies  
I  MEK111054  Single agent (First -time-in-human)  Solid tumors and BRAF -
mutant melanoma  
I/II  MEK111759  Single Agent  Leukemia  
II  MEK113583  Single agent  BRAF -mutant Melanoma  
III  MEK114267  Randomized comparison [COMPANY_004]1120212 vs. 
chemotherapy (dacarbazine, or paclitaxel)  BRAF -mutant melanoma  
MEK113708  Phase I ADME study  Solid tumors  
MEK113709  Phase I Food -Effect study   
Combination Therapy Studies  
IB/II  MEK112110  Combination with everolimus (mTOR -
inhibitor)  Solid tumors  
I/IB  MEK112111  Combination with gemcitabine  Solid tumors and pancreatic 
cancer  
I/IB MEK113486  Multi -arm combination with docetaxel, 
pemetrexed, pemetrexed/carboplatin, nab -
paclitaxel, or erlotinib  Solid tumors  
I  MEK114784  Single agent and combination with 
gemcitabine  Japanese subjects with solid 
tumors  
I/II  BRF113220  Combination with [COMPANY_004]2118436 (BRAF -
inhibitor)  BRAF -mutant melanoma  
I  TAC113886  Combination with [COMPANY_004]214795 (AKT -
inhibitor)  Solid tumors  
I  P3K113794  Combination with [COMPANY_004]2126458 (PI3 
Kinase -inhibitor)  Advanced solid tumors  
II  MEK113487  Randomized combination [COMPANY_004]1120212 with 
gemcitabine vs. gemcitabine  Pancreatic cancer  
 
 
 
CTEP #9149 (01 -07-2020 ) 
 
149 
 Safety/Tolerability Profile  
The maximum tolerated dose was established at [ADDRESS_1005491] increased, ALT 
increased, and  dry skin.   
 
Other clinically important adverse reactions observed in ≤10% of patients (n=329) treated with 
trametinib were: nervous system disorders (dizziness, dysgeusia), ocular disorders (blurred vision, 
dry eye), infections and infestations (folliculitis, rash pustular, cellulitis), cardiac disorde rs 
(bradycardia), gastrointestinal disorders (xerostomia), and musculoskeletal and connective tissue 
disorders (rhabdomyolysis).   
 
  
CTEP #9149 (01 -07-2020 ) 
 
150 
 APPENDIX L: NCI Correlative Imaging Studies  
 
Patients  at the NCI  will be asked to sign a separate consent to allow collection and use of the 
standard -of-care images (CT or MRI) that qualified the patient for inclusion in this trial, along with 
the images taken during image -guided biopsy and any follow up imaging studie s showing 
progression, to allow research into correlation of the image phenotypic features with genomic 
analyses.  Research analysis of these images will only be done once the images have been de -
identified; no research data generated from any image will b e reported back to the patient, and no 
clinical decisions will be made based on research data generated from any image collected under 
this protocol.   
 
To accomplish delinking, the NCI’s secure GeneMed bioinformatics database will assign  an 
imaging ID tha t, initially, will be coupled with the MPACT protocol ID in the GeneMed database.  
When a patient is off -study, GeneMed will provide the limited clinical information from that 
patient to the Cancer Imaging Archive (TCIA), linked through the imaging ID (not  the patient 
protocol ID).   GeneMed will assign a new ID that will trigger permanent recoding of the physical 
tissue, which will undergo whole exome sequencing.  Following recoding, all samples and images 
will be completely unlinked from the clinical datab ase.  
 
Patient images will be de -identified of PHI at the CCR Molecular Imaging Program before leaving 
the NIH Clinical Center site and stored in an NIH policy compliant internet -accessible collection, 
The Cancer Imaging Archive (TCIA), with controlled acc ess.   
 
Images for TCIA are processed at the clinical site through a program developed by [CONTACT_735933] (CTP) 
[102].  Images are di rectly sent to the TCIA where they are sequestered pending, as needed,  further 
QC/QA and appropriate sponsor access approvals.  
 
The individual responsible for this process is Justin Kirby ([EMAIL_14050]).   
 
The CTP is the primary means for uploading  images into TCIA.  CTP is a client -server software 
package with the server installed on a special intake system at TCIA.  The CTP client, containing 
de-identification scripts customized for the trial site and specific trial data collection, will be 
instal led in the Molecular Imaging Program in CCR.    
 
The Digital Imaging and Communications in Medicine (DICOM) image is sequestered in TCIA 
pending review, QC/QA, and sponsor permission to link to genomic and limited clinical data after 
it has been delinked fr om the patient identifiable data.  
 
The de -identification process follows the DICOM WG18 Supplement [ADDRESS_1005492].   The following 
are examples of the changes made:  
• Patient Names – Real patient names and initials are removed.  
• Patient IDs - Institutionally created patient identifiers that can be traced back to individual 
patients are replaced with another unique identifier that cannot be traced back to the patient.  
• Patient Demographics – Although patient date of birth is removed, patient age and gender 
are retained.  
CTEP #9149 (01 -07-2020 ) 
 
151 
 • Dates related to the examination – For a given collection/site, dates are offset by a fixed 
number of days, preserving time intervals between exams for ea ch subject.  
• Exam Identifiers – Codes assigned to exams and images are altered to prohibit the 
possibility of tracing an exam back to an institution and individual patient.  
 
As part of the QC/QA process TCIA will also review submitted images for vendor spe cific 
DICOM tags.  Vendor DICOM Conformance Statements are reviewed to learn which tags might 
contain PHI.  These tags are reviewed and PHI removed if found.   
 
 
CTEP #9149 (01 -07-2020 ) 
 
152 
 APPENDIX M: Treatment Assignment  Flow Chart  
 
 
